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Abstract 
Half-sandwich complexes of ruthenium, iridium, and more recently osmium, have 
shown promise as anticancer agents. Many of these ‘piano-stool’ complexes appear to 
target the redox balance in cells. Separately, similar complexes have been investigated 
for the catalysis of hydrogenation reactions, with many examples achieving high 
turnover frequencies and enantioselectivities. This thesis is concerned with achieving 
in cell catalysis to increase drug potency and generate selectivity for cancer cells. 
A series of eighteen Os(II) and Ir(III) complexes, of the type [M(ηx-arene)(diamine)] 
(Os-arene: p-cymene, biphenyl, or m-terphenyl; Ir-arene: Cp*, CpxPh, or CpxBip), were 
synthesised and fully characterised. The structures were derived from a Ru(II) transfer 
hydrogenation catalyst [Ru(η6-p-cymene)(TsDPEN)], TsDPEN = N-tosyl-diphenyl-
ethylenediamine. The complexes were isolated as 16-electron amido catalysts, which 
were highly stable in solution and upon storage, unlike their 16-electron Ru(II) 
counterparts, and were highly active for asymmetric transfer hydrogenation of 
ketones. Os complexes afforded enantiomerically-pure alcohols with high conversion 
and enantioselectivity (> 99%) at rates exceeding those of the existing Ru catalyst.  
Two Os and Ir complexes were explored for the conversion of NADH to its oxidised 
form (NAD+) under physiologically-relevant conditions. Antiproliferative activities 
determined in 14 human cell lines correlated with experimentally-determined 
hydrophobicities. Typically, Os catalysts were found to be more active than their Ir 
counterparts, though were internalised by cancer cells to a lesser degree, suggestive of 
a more potent in-cell mechanism of action. Structural modifications identified an 
apparent inert site of substitution on the sulfonamide substituent. Furthermore, their 
potency towards cancer cells was increased in combination with L-buthionine 
sulfoximine, an inhibitor of glutathione synthesis.  
 iv 
Acute in vivo toxicities were determined in zebrafish, and all compounds investigated 
exhibited lower toxicities than the Pt anticancer drug, cisplatin. The complexes were 
shown to generate reactive oxygen species (ROS) in cancer cells, and similarly 
generated ROS in zebrafish.  
Transfer hydrogenation catalysis was explored under physiologically-relevant 
conditions using sodium formate as a biologically-compatible hydride source. 
Osmium complexes catalysed the reduction of pyruvate, a key metabolite in cells, to 
either L-lactate or D-lactate, selectively (ca. 83% ee). Upon co-administration of the 
catalyst and sodium formate, cancer cell proliferation was decreased by up to 13× 
(relative to cells treated with the catalyst alone), while no sodium formate effect was 
determined in non-cancerous cells. Importantly, the treatment of cells with a particular 
enantiomer of the Os catalyst and sodium formate facilitated the in cell reduction of 
pyruvate to D-lactate, providing, to the best of my knowledge, the first example of a 
synthetic catalyst carrying out asymmetric transfer hydrogenation chemistry in cells.  
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1. Introduction 
This thesis is concerned with the synthesis of novel Os(II) organometallic complexes 
of the general structure [Os(η6-arene)(diamine)] which are active asymmetric transfer 
hydrogenation (ATH) catalysts. For comparison, structurally-similar Ir(III) η5-Cp* 
complexes (Cp* = 1,2,3,4,5-cyclopentamethyl) were also synthesised. The complexes 
are derived from the reputable ruthenium(II) chemistry pioneered by Professor Ryoji 
Noyori. The catalytic cycle begins with the transference of hydride from a sacrificial 
donor molecule (such as formic acid) to the catalyst, forming a metal-hydride complex 
which can then go on to donate the hydride to a substrate acceptor molecule, affording 
the product in a highly enantioselective manner and with high conversion (Figure 
1.3).1, 2 Ruthenium(II) arene chlorido pre-catalysts of the general structure [Ru(η6-
arene)Cl(diamine)] are well-established,1 however the apparent inertness of Os(II) 
allows the active 16-electron catalytic species [Os(η6-arene)(diamine)] to be directly 
obtained, rather than isolation of a pre-catalyst which must first dissociate chloride. It 
is envisaged that the greater stability of osmium(II) transfer hydrogenation catalysts 
compared to ruthenium(II) will reduce catalyst degradation (trace Ru(0) is known to 
contaminate reduction products), while direct use of the active catalyst may be 
advantageous, achieving higher catalytic rates.  
Highly potent Os(II) half-sandwich anticancer complexes have previously been 
identified, achieving nanomolar antiproliferative activities towards cancer cells in a 
non-catalytic manner.3 Conversely, a catalytic metallodrug may be obtained by 
combining structural components from a known asymmetric hydrogenation catalyst 
and a potent anticancer complex in a single structure (Figure 1.1). In vitro catalysis 
may specifically target unique biochemical traits of a particular disease (e.g. the 
increased rate of glycolysis in cancer cells).4  
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The osmium(II) catalysts designed in this thesis are explored initially for the catalysis 
of simple aromatic ATH substrates (based on acetophenone) under forcing conditions 
in organic solvents (formic acid : triethylamine azeotrope), before exploring both the 
catalytic oxidation (NADH to NAD+) and reduction (pyruvate to lactate) of important 
biomolecules under physiologically-relevant conditions (aqueous-phase reduction, 
bio-compatible hydride source). Ultimately, the catalysts are employed to carry out in 
cell reductions with high enantioselectivity, making use of new bio-orthogonal 
chemistry as a new strategy for inducing cell death.  
 
 
Figure 1.1. Rational design of Os(II) transfer hydrogenation catalysts for the treatment of cancer, based 
on existing catalyst technologies of Ru (red) and Os (pink), combined with the high potency of Os(II) 
arene anticancer complexes (blue). R = 4-methylphenyl, 4-methoxyphenyl, phenyl, 4-fluorophenyl, 
methyl; R2 = phenyl or 4-methoxyphenyl.   
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1.1 Asymmetric transfer hydrogenation 
Transfer hydrogenation reactions are a relatively recent advance in hydrogenation 
chemistry. This involves the relocation of hydrogen from a sacrificial donor molecule 
to an acceptor (target) transition metal complex, thereby providing a controlled route 
to reduce organic targets, and safer alternative to reactions involving the use of 
hydrogen gas under high pressure conditions.1, 5 In the mid-20th century, iridium 
hydride complexes were shown to catalyse the reduction of unsaturated ketones to 
alcohols, using isopropanol as a sacrificial hydride donor.6  
 
1.1.1 The Noyori ruthenium bifunctional catalyst 
Prof. Noyori is often considered to be the pioneer of asymmetric transfer 
hydrogenation. His work, concerning catalysts capable of affording enantiomerically-
pure alcohols (and later, imines) with high conversion, won the 2001 Nobel Prize in 
Chemistry. First-generation catalysts [Ru(BINAP)Cl2(diamine)] (BINAP = 2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl) demonstrated high turnover frequency and 
enantioselectivity (> 99%) for the reduction of ketones (Figure 1.2a).7 Studies 
demonstrated that the mechanism of hydrogenation was non-classical and occurred in 
an outer-sphere process, rather than the traditional [2+2] mechanism (Figure 1.2).8  
 
(a) 
 
  
(b) 
 
 
 
 
 
Figure 1.2. (a) First and second-generation Ru transfer hydrogenation catalysts, developed by Noyori 
and co-workers. (b) The Noyori bifunctional catalyst transfers H2 to an acceptor (ketone) via a non-
classical 6-membered transition state, rather than via a traditional [2+2] mechanism.8  
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The second-generation bifunctional half-sandwich complexes improved catalytic 
efficiency,7 even though they share structural similarity with the first-generation 
catalysts in the chiral diamine (Figure 1.2a).1, 2, 9-20 The catalytic mechanism for 
Noyori-type bifunctional catalysts has been studied in great depth, both 
experimentally and computationally.9, 20-22 The complexes must first dissociate the 
chloride ligand, and are deprotonated by a base, forming the 16-electron complex 
[M(arene)(TsDPEN)], the active catalytic species. Note that the M2+ complex is still 
neutral overall due to the formation of two anionic nitrogen atoms on the bidentate 
ligand, which is reflected by the shorter metal-nitrogen bond length in the x-ray 
crystallographic structures. Upon addition of a sacrificial hydride donor (commonly 
formic acid or 2-propanol)2, 15 the basic nitrogen atom is re-protonated, and a metal-
hydride bond is formed, along with the elimination of the oxidised sacrificial molecule 
(carbon dioxide, if the donor was formic acid).2, 15-26 The reverse process can then 
occur with the target hydrogen acceptor, transferring hydrogen from the hydride 
catalyst to the target via a 6-membered transition state (Figure 1.3). The entire catalytic 
process is considered outer sphere,21-26 since neither the acceptor or donor molecules 
have any direct interaction with the metal centre. The system is reversible, and will 
carry out the thermodynamically favourable reduction. This can be influenced by the 
selection of formic acid as a hydride source, since after donation of hydrogen, carbon 
dioxide gas is released, effectively making the reaction irreversible. 
The success of the Noyori transfer hydrogenation catalysts is down to the reaction 
achieving high enantiomeric excess when prochiral acceptor molecules are used. The 
geometry of the transition state, and subsequent enantioselectivity, is directed by the 
chirality of the bidentate diamine17 and stabilised by favourable -interactions with 
the η6-arene of the catalyst (Figure 1.3).2, 15-26  
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Figure 1.3. General mechanism for the asymmetric transfer hydrogenation of ketones using the Noyori 
2nd generation bifunctional catalyst (hydrogen donor: formic acid; hydrogen acceptor: acetophenone). 
 
Wills et al. modified the diamine component of the Noyori catalyst by alkylation of 
either nitrogen atom, forming a covalent “tether” between the diamine and the η6-arene 
of the catalyst.27, 28 This modification stabilised the catalyst further by constraining the 
pseudo-octahedral geometry of the chlorido pre-catalyst to be retained in the 16-
electron active catalyst, resulting in higher reaction turnover frequencies and high 
conversions, whilst retaining the high enantioselectivity of the original Noyori 
catalyst.28-30 Electron-rich amino-substituted ketones were readily reduced under 
aqueous conditions using the tethered ruthenium catalysts, however methoxy-
substituted substrates proved more challenging.31  
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The analogous iridium(III) and rhodium(III) TsDPEN bifunctional catalysts were soon 
reported, from which other structurally-derived transfer hydrogenation catalysts were 
developed.5, 32-38 In particular, the Rh(III) catalyst was found to be the most efficient 
catalyst for aqueous reduction of ketones using sodium formate as a hydride source.32 
Transfer hydrogenation catalysts using the bidentate ligand TsCYDN (N-tosyl-1,2-
cyclohexadiamine) have been developed, and some out-perform the catalytic rate of 
TsDPEN analogues.35 TsCYDN catalysts have also been used to carry out asymmetric 
reductions in water with sodium formate without the need for an inert atmosphere.39 
Noyori-type catalysts have also been immobilised on supports and polymers for both 
continuous-flow systems and ease of recyclability. The supported catalyst retained 
high catalytic activity with no loss of enantioselectivity.39-42 
 
1.1.2 Osmium transfer hydrogenation catalysts 
More recently, osmium transfer hydrogenation catalysts have been explored, despite 
osmium often being considered catalytically-inferior to other platinum group metals 
(Figure 1.4).43 Osmium catalysts were largely pioneered by Baratta et al. who have 
worked extensively in the field of pincer complexes,6 achieving extraordinarily high 
rates of reduction (up to 106 h-1 TOF) at very low catalyst loadings (0.005 mol%).44-48 
Other osmium catalysts containing a ferrocene moiety were found to out-perform 
ruthenium analogues, achieving up to 3 × 105 h-1 TOF (Figure 1.4).49  
Various bidentate ligands have been explored to produce both chiral and achiral 
osmium catalysts.50-52 Complexes with N,O-chelating ligands achieved high 
enantioselectivities, including cis-aminoindanol53, 54 and L-α-amino carboxylate55 
complexes. Other N,N-ligands, including iminopyridine,56 and pybox (pybox = 2,6-
bis[4′-(S)-isopropyloxazolin-2′-yl]pyridine) have been explored.57  
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Os-pincer 
 
Os-ferrocene 
 
Os-pybox 
 
Figure 1.4. Various osmium transfer hydrogenation catalysts. Pincer complexes,44, 47 complexes 
conjugated to ferrocene,49 and pybox ligands57 all demonstrated high activity and enantioselectivity for 
the transfer hydrogenation of ketones. 
 
Osmium derivatives of the Noyori first-generation ATH catalyst were explored, and 
were demonstrated to be more robust. [OsCl2(diphosphine)(2-aminomethylpyridine)] 
catalysed the rapid transfer hydrogenation of acetophenone (TOF 5.7 × 105 h-1), an 
order of magnitude greater than the ruthenium analogues.47 Hydride complexes  of 
osmium formed in situ have also been investigated for the transfer hydrogenation of 
acetophenone, showing high catalytic activity but low enantioselectivity.43 Hydride 
complex mer-[OsHCl(CO)(PR3)3] achieved 70% conversion with 3.5% ee in 
isopropanol (356 K).58 As well as the reduction of ketones to alcohols, osmium 
complexes have been used to catalyse the reduction of imines to amines,43, 59 
hydrogenation of olefins,60 and the hydrogenation of esters to their corresponding 
alcohols, though were typically out-performed by their ruthenium analogues.61  
Osmium catalysts have also been investigated for hydrogen-borrowing reactions.62 
Such reactions are highly similar to transfer hydrogenation chemistry, however the 
reagent itself acts as the hydrogen donor. A molecule (typically an alcohol) donates 
hydrogen to the catalyst molecule and is oxidised to the corresponding ketone, which 
can undergo a subsequent reaction (e.g. with an amine to form an imine). Hydrogen is 
then transferred back from the catalyst to reduce the final product (e.g. to an amine).  
Chapter 1. Introduction 
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1.2 Metals in medicine 
Inorganic chemistry provides a wealth of novel solutions to pharmaceutical 
challenges. Where organic compounds are typically restricted to linear, trigonal or 
tetrahedral coordination, the introduction of a metal centre allows access to new 
geometries, such as square planar, trigonal bipyramidal and octahedral. The central 
cobalt ion in cobalamin (Vitamin B12) provides structure and functionality unmatched 
by an organic molecule. Inorganic metal ions can also access a vast range of oxidation 
states. For example, osmium may exist from -2 to +8. Since redox processes are key 
to many cellular pathways,63 the tuneable redox potential of a metal-based drug may 
be advantageous to clinical success.  
 
1.2.1 Historical use of metallodrugs 
Metals have played an important role in treatments of diseases and illnesses over the 
ages. Gold has been used in medicine since ancient times, and may be traced back as 
early as 2500 BC. Preparations were particularly common in ancient China and India, 
and were used to treat a range of illnesses, ranging from diabetes mellitus to memory 
loss and asthma.64 Since the 1920s, gold thiolates such as sodium 2-(auriosulfanyl)-3-
carboxypropanoate (sodium aurothiomalate) and tetraacetyl-β-d-thioglucose gold(I) 
triethylphosphine (Auranofin) have been used for the treatment of rheumatoid 
arthritis, and are currently being explored for their anticancer activities.65 Gold(I) N-
heterocyclic carbene (NHC) metallodrugs have also earned popularity as potential 
anticancer agents. Many Au complexes have been shown to be potent TrxR 
(Thioredoxin reductase) inhibitors. An example is the di-carbene gold complex MC-
3, which possess nanomolar IC50 values (21-67 nM) against pancreatic cancer cells 
(Figure 1.5).66 
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Sodium aurothiomalate       Auranofin MC-3 
 
Figure 1.5. Gold thiolates used for the treatment of rheumatoid arthritis (sodium aurothiomalate and 
Auranofin) alongside MC3, a potent apoptosis-inducing gold(I) N-heterocyclic carbene complex.66 
 
Silver has also been used medicinally for thousands of years.67 The ancient Romans 
and Greeks were known to have stored water in silver vessels, and made use of the 
antimicrobial properties of silver nitrate, which continues to be used during the modern 
day treatment of severe skin burns.68 The antibacterial activity of silver ions is now 
well established,67 and commonly feature in personal hygiene products. Recently, 
alkyl phosphine complexes of group 11 metals (copper, silver and gold) have been 
investigated for their in vitro antitumor activity, with mechanistic studies identifying 
interactions of the gold and silver complexes with thioredoxin reductase, while the 
copper complexes lead to proteasome inhibition.69 
In 1907, a compound of arsenic was first synthesised and subsequently tested for 
activity against spirochaetes, a group of organisms found to cause syphilis, infections 
from which were highly prevalent in the early 20th century.70 The compound, named 
“606” after its preparation number (also known as Arsphenamine or Salvarsan) 
continued to be widely used until penicillin became readily available after World War 
II.70 In fact, a study conducted in 2005 reported the structure of “606” as a mixture of 
two structural isoforms, both of which led to the formation of the active compound 
RAs(OH)2, where R = 3-amino-4-hydroxyphenyl.
71 
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1.2.2 The discovery of cisplatin 
In 1965, physicist Barnett Rosenberg (Michigan State University) observed inhibition 
of cell division as well as filamentous growth, up to 300× the usual length, in E. coli.72 
Electrolysis products formed from his platinum mesh electrodes and salt solution were 
found to be Peyrone’s compound, cis-[PtCl2(NH3)2], first synthesised in 1845.73 The 
compounds molecular structure was elucidated in 1893 by Werner,73, 74 and almost a 
century later, was found by Rosenberg to exhibit potential as an anticancer agent in 
rats, as reported in his 1969 publication: “Platinum compounds: a new class of potent 
anti-tumor agents”.72 Peyrone’s compound (cis-diaminedichloroplatinum(II) / 
cisplatin) was first administered to a human patient in 1971, and became clinically 
available in 1978 under the brand name Platinol®.73 The discovery of a 
pharmaceutically active metal-containing compound was so significant in that an 
entirely new area of bio-inorganic research emerged, involving the development of 
other novel metallodrugs. Cisplatin is also commonly found in combination therapies, 
such as administration with the anticancer drug paclitaxel (for the treatment of ovarian, 
breast, lung, head and neck cancers), fluorouracil (5FU, for the treatment of oral 
cancers)75 and metformin (for the treatment of lung adenocarcinoma).74, 76 
Cisplatin has since been used in the successful treatment of various cancers, including 
testicular, lung, breast, cervical and prostate cancers.74 It is the mainline treatment for 
ovarian cancer, a highly prominent female gynaecological cancer with high mortality 
rates, often associated with late-stage diagnosis and poor detection.76 However, 
platinum-resistant ovarian cancers are common, through either intrinsic or acquired 
resistance.77-79  For this reason, this thesis will largely focus on a human ovarian 
carcinoma cell line (A2780) allowing for direct comparison between novel catalytic 
metallodrugs of osmium, and existing platinum-based treatments.   
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The DNA-targeting mechanism of action of cisplatin is commonly accepted. Cellular 
Pt uptake occurs via copper transporter proteins as well as a contribution from passive 
diffusion. The chloride ligands are labile, and once inside the cell, the lower 
intracellular chloride concentration favours chloride dissociation, allowing stepwise 
hydrolysis to afford the di-aqua complex [Pt(NH3)2(OH2)2]
2+ which can form 1,2-
intra-strand cross-links with purine bases; typically, N7 of guanine (Figure 1.6). If the 
DNA cannot be successfully repaired, high-mobility group (HMG) proteins recognise 
and bind platinated DNA,80 causing either apoptotic or necrotic cell death, depending 
on the cisplatin exposure time.76, 81 The cis geometry of cisplatin is important, since 
its trans isomer is inactive as intra-strand adducts cannot form. While DNA adduct 
formation lacks specificity for cancer cells, metal complexes are commonly multi-
targeting, which may increase cancer cell selectivity.82, 83 Though only ca. 1% of 
cisplatin reaches the nucleus, the complex is also known to interact with many other 
biomolecules. The tripeptide GSH (Glu-Cys-Gly) is present at millimolar (1-10 mM) 
concentrations in mammalian cells, and has been shown to highly influence the 
efficacy of cisplatin.84 GSH also chelates Cu2+ causing up-regulation of the copper 
transporter Ctr1, increasing Pt uptake. Conversely, GSH-Pt adducts may also facilitate 
Pt efflux via the multidrug resistance protein 2 (MRP2) efflux pump.84, 85  
 
 
Figure 1.6. Cisplatin undergoes step-wise hydrolysis inside cells due to the lower cytosolic chloride 
concentration, forming aqua adducts (hydroxido complexes are also known). Protein and DNA adducts 
can then form (nucleus [Cl-] = 4 mM), causing apoptotic and necrotic cell death.  
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Despite the widespread use of cisplatin, dosage is limited due to the side effects in 
normal tissue; causing nausea, vomiting, hair loss, nephrotoxicity, neurotoxicity, and 
hearing loss.74 Cisplatin resistance is also of clinical concern, which may be either 
intrinsic or acquired. Resistance mechanisms may include decreased cellular uptake, 
or increased efflux by membrane-bound transport ATPases such as MDR-1/2.74, 86  To 
reduce off-target effects, Carboplatin was introduced in the 1980s, and possesses a 
bidentate carboxylate in the place of the two chlorido ligands.73 Carboplatin is used 
for the treatment of lung, head and neck cancers, and does not exhibit the nephrotoxic 
effects of cisplatin, which may be associated with the lower reactivity and subsequent 
slower rate of DNA binding. The longer retention half-life of 30 hours (compared to 
1.5-3.6 h for cisplatin) means that effects are longer-lasting. Other cisplatin-derived 
compounds (Figure 1.7) that have reached the clinic or clinical trials include 
Oxaliplatin (1999),87 Heptaplatin (2005), Nedaplatin (1996) and Lobaplatin (2004).88 
 
 
 
  
Cisplatin 
 
Carboplatin 
 
Oxaliplatin 
 
 
 
 
 
 
Heptaplatin Nedaplatin Lobaplatin 
 
Figure 1.7. Six platinum(II) anticancer drugs. Cisplatin, carboplatin and oxaliplatin are established 
world-wide. Heptaplatin is approved for the treatment of gastric cancers in South Korea, Nedaplatin for 
the treatment of head and neck, testicular, lung, ovarian, cervical, and non-small-cell lung cancers in 
Japan, and Lobaplatin for the treatment of chronic myelogenous leukaemia in China.88 
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1.2.3 Platinum group metals in medicine 
The six elements of the platinum group (Ru, Os, Rh, Ir, Pt, Pd) are chemically very 
similar. It is perhaps unsurprising that after the successes of Pt therapies, interests into 
the design of Ru complexes have grown exponentially over the last few decades. A 
Ru(III) complex, NKP-1339 (sodium trans-[tetrachloridobis(1H-indazole)ruthenate]), 
the sodium salt of KP1019 (Figure 1.8), is currently in phase II clinical trials.89 The 
planar arrangement of chloride ligands around the octahedral Ru centre shows 
structural similarity to the square planar geometry of cisplatin. NKP-1339, like 
cisplatin, induces G2/M arrest and apoptosis in cancer cells.
90 However unlike 
cisplatin, NKP-1339 disrupts the redox balance of the cell by generation of reactive 
oxygen species (ROS),91 and also appears to target the endoplasmic reticulum.90 In 
fact, the generation of ROS by metal complexes in cells is well documented, providing 
an alternative mechanism of action to DNA binding.92-95 The contrasting mechanism 
provides evidence that both the chemical and biological properties of the complex may 
be modified by careful selection of suitable ligands, paired with a particular metal.  
The analogous cis-osmium(III) complexes, derived from KP1019, have been prepared 
by the 1-electron reduction of precursor Os(IV) complexes.96 The osmium complexes 
were found to not interact with amino acids or model nucleotides (such as 5’-
guanosine monophosphate). While the Os(III) complexes exhibited lower 
antiproliferative activities than those of the parent Ru(III) compound, they showed 
selectivity for human melanoma cells (FemX), while the antiproliferative activities 
determined using KP1019 were comparable between all cell lines investigated.97 
Interestingly, though trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) and 
its trans-Os(III) isomer are known, at the time of writing, the cis-Ru(III) isomer is not 
isolable, while cis-osmium(III) isomer has recently been fully characterised.96 
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KP-1019 NAMI-A 
 
 
Figure 1.8. Anticancer Ru(III) complexes in clinic trials: (a) KP-1019,91 (b) NAMI-A.98 
 
A structurally similar ruthenium complex, NAMI-A (Figure 1.8) has been extensively 
studied.89, 99, 100 The complex entered a phase I/II clinical study, in combination with 
gemcitabine, for the treatment of non-small cell lung cancers, however was only 
moderately tolerated in patients.98 Similarly to KP1019, the osmium analogues of 
NAMI-A have also been investigated, prepared stepwise from osmium tetroxide.101 
As a third-row transition metal with slower exchange kinetics, osmium was previously 
discounted as a useful metal centre for a metallodrug. The osmium complexes did not 
undergo hydrolysis of the chloride ligands, unlike the ruthenium centre in NAMI-A, 
yet showed approximately an order of magnitude greater activity than the ruthenium 
counterparts.101 In contrast, replacement of Ru for Os in KP1019 decreased 
antiproliferative activity, indicating that trends anticancer activity cannot be predicted 
upon metal exchange.  
While NAMI-A and KP1019 were synthesised by selection of small-molecule ligands 
with properties that would benefit the overall complex, ruthenium complexes of 
natural products have also been explored, where the role of the metal centre allows 
access to unique structural architectures. Ruthenium protein kinase inhibitors based 
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on staurosporine have been synthesised (Figure 1.9).102 These complexes exhibit high 
selectivity for particular tyrosine-protein kinases, specifically for the Abelson tyrosine 
kinase (Abl) which is known to be highly involved with cell growth processes. In fact, 
the complex was found to be inactive against a range of other kinases (e.g. PKCα).
102 
Interestingly, the IC50 (half-maximal inhibitory concentration) of the Ru complex was 
found to be ca. 10× lower than that of the free ligand (2 nM compared to 25 nM) 
towards the Abl, reinforcing the importance of the metal centre. 
In recent years, “sandwich” structures have gained substantial interest. Such 
complexes are identified by the coordination of one (or many) η5 or η6- arene(s) to a 
central metal, which can act to stabilise the overall complex as well as providing a 
lipophilic region. Since the synthesis of the organo-iron compound, Ferrocene [Fe(η5-
C5H5)2] in 1951,
103 structurally-derived sandwich complexes of ruthenium, osmium 
and iron have been conjugated to the anticancer compound Tamoxifen, increasing the 
potency towards breast cancer cells (Figure 1.9). Iron-conjugates of ferrocene were 
found to be more active than Os and Ru counterparts, demonstrating that the role of 
the ferrocene moiety was not purely structural.104  
 
  
 
 
Protein kinase inhibitors 
(M = Ru) 
 
Tamoxifen derivatives 
(M = Fe / Ru / Os) 
 
Figure 1.9. Organometallic “sandwich” complexes derived from established anticancer compound 
Tamoxifen, and a ruthenium protein kinase inhibitor based on a natural product, staurosporine. 
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Half-sandwich “piano-stool” complexes [M(ɳ6-arene)(bidentate)(monodentate)] only 
possess one metal-coordinated arene, and typically adopt pseudo-octahedral geometry. 
Early examples of half-sandwich complexes with anticancer properties are the Ru 
compound RM-175 and its Os analogue, AFAP-51, with the general structure [M(ɳ6-
biphenyl)(ethylenediamine)Cl]+ (Figure 1.10).105 Though the chemistry of Ru(II) and 
Os(II) ions is often considered similar, the Os complex was found to be 6 more potent 
than the Ru analogue. RM-175 (Ru) however showed high in vivo activity, leading to 
a reduction in metastases which was not found in the Os case.105 In this example, there 
are meaningful biological implications resulting from the fine-tuning of the redox and 
kinetics by of the different metal centres. Sadler et al. developed a series of osmium 
and ruthenium azo/imino-pyridine complexes of the general formula [M(ɳ6-
arene)(azo/imino-pyridine)(X)]+ where X = Cl or I, that show high activity against 
cancer cells,106 which were found to be higher for iodido complexes than their chloride 
analogues.3 The complexes were shown to exhibit a new mechanism of action that 
differed from that of existing platinum therapies, since these complexes did not appear 
to undergo aquation nor bind to DNA.3 The complexes also retained activity in Pt-
resistant cells.107 One Os complex in particular (FY26; Figure 1.10), has been shown 
to delay growth of human colon cancer xenografts in mice, with negligible toxicity.108  
 
 
 
 
 
 
RM-175 AFAP-51 FY-26 
 
Figure 1.10. Anticancer Ru(II) and Os(II) complexes: (a) FY26, (b) RM-175, (c) AFAP-51. 
Hexafluorophosphate (PF6-) counter-ions not shown.  
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1.3 Cancer 
In the UK, someone dies from cancer every two minutes.109 Cancer is one of the most 
significant cause of death around the world,110 and is particularly prevalent in 
developed countries. In Britain, cancer is now expected to affect around 1 in 2 people, 
with the lifetime risk for men slightly exceeding that for women.109, 111 Cancers may 
result from inherited genetic traits, but it is estimated that up to 80% are caused by 
external factors such as radiation, carcinogenic chemicals or viruses.112  Many cancers 
that were previously considered highly lethal (such as testicular cancer, Hodgkin's 
lymphoma, and some leukemias) are now effectively treatable with anticancer drugs.86 
However, while highly sensitive screening methods are detecting many cancers before 
they have metastasized, the battle against malignant cancers is expected to remain a 
key part of modern medicine.86 
 
1.3.1 The origin of cancer 
The six hallmarks of cancer, according to Hanahan and Weinberg, are growth-
suppressor evasion, growth signaling self-sufficiency, becoming active for invasion 
and metastasis, enabling replicative immortality, the induction of angiogenesis and 
resisting cell death.113  
In normal cells, proto-oncogenes code for proteins that play an important role in many 
cellular processes such as cell division, cell differentiation, and cell death. Over-
production of these proteins leads to a loss of control over such cellular processes. 
Proto-oncogenes may become activated by mutations that either increase the 
expression level or activity to become oncogenes,114 which may result in causing 
cancer.112 Cells also possess anti-oncogenes, known as tumor suppressor genes. 
Inactivation of a tumor suppressor gene removes restrictions that regulate normal and 
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controlled cell proliferation. A key tumor suppressor gene (P53) encodes the 
transcriptional regulator protein p53, the absence of which greatly increases the 
occurrence of tumors.112 After exposure to DNA-damaging agents, expression of p53 
is increased, resulting in cell cycle arrest and apoptosis. Both the activity of the p53 
protein and transcription of the P53 gene are negatively regulated by the E3 ubiquitin 
ligase, Mdm2 (Figure 1.11). Mutations in P53 are in fact the most common genetic 
alteration in human cancers.115 Such mutations include: (a) deletion of  the carboxyl-
terminal domain, preventing p53 tetramer formation, (b) amino acid alteration in the 
DNA binding domain, preventing downstream gene activation, (c) overexpression of 
MDM2, stimulating the degradation of p53.116 
 
 
Figure 1.11. Simplified p53 pathway (adapted from A. J. Levine and M. Oren, 2009).117 P53 is 
expressed after oncogene activation, DNA replication stress, hypoxia and oxidative stress; resulting in 
metabolic homeostasis, antioxidant defense and DNA repair; or in severe cases, growth arrest, 
senescence and apoptotic cell death.  
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Differences in the physiology and biochemistry of cancer cells compared to normal 
cells may facilitate selective targeting by novel anticancer agents. Physiologically, 
tumors typically are commonly hypoxic,118 and have low extracellular pH as a result 
of lactate secretion.119 These traits are commonly observed as microenvironments 
which are chemically-distinct from healthy tissue, and have led to interest in 
developing inactive pro-drugs that become activated by tumor physiology.120 Such 
compounds typically contain N-oxides, quinones or transition metals, which are 
activated under hypoxic conditions. Tirapazamine, a di-N-oxide compound, 
demonstrated up to 200× more cytotoxicity in hypoxic cells.121  
Biochemically, the metabolism of glucose in cancer cells differs from that in healthy 
cells.122 Rapidly-proliferating cells require more ATP, a cellular energy source. While 
healthy cells metabolize glucose to pyruvate (via glycolysis) and subsequently oxidize 
pyruvate to carbon dioxide by oxidative phosphorylation, the ‘Warburg Effect’ 
summarises the observation that cancer cells display a preference for the reduction of 
pyruvate to lactate, rather than oxidation to carbon dioxide.123 Only in the absence of 
oxygen would healthy cells utilise lactate production as a means of acquiring energy, 
since ATP production by glycolysis is far less efficient than by oxidative 
phosphorylation (2 molecules of ATP, compared to 36 molecules per glucose 
molecule).4 For this reason, the consumption of glucose is significantly higher in 
cancer cells.124 This glucose-dependence makes glycolysis a target for anticancer drug 
design, and in fact, many glycolytic inhibitors (2-deoxyglucose, lonidamine, 3-
bromopyruvate, Imatinib) have been explored for use as anticancer agents.124 
Furthermore, the availability of cellular reducing agents (e.g. NADH or NADPH) has 
been associated with the rate of proliferation,125 making redox-based strategies an 
attractive method of selectively targeting cancer cells.63, 126, 127  
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1.3.2 Current treatment of cancer 
Three treatment options are well established in the clinic, and are usually used in 
combination to achieve the best outcome for the patient. Surgical excision of a tumour 
is most commonly employed after size-reduction using radiotherapy or chemotherapy. 
Many existing chemotherapy agents target cellular replication processes, by damaging 
DNA or affecting key pathways involved with cell growth. Many of these targets are 
not unique to cancer cells, and drugs have little selectivity for cancerous cells over 
healthy cells that also have rapid rates of proliferation, such as the hair follicles, bone 
marrow and gastrointestinal tract cells;128 resulting in a range of side-effects.  
New targeted approaches to chemotherapy are required that exploit the unique 
biochemical properties of cancer cells. While cancer-specific drug delivery strategies 
can reduce off-target effects, research into future novel anticancer compounds may 
identify other chemotherapeutic targets, such as the previously discussed hypoxic 
environment,120, 121 high rate of glycolysis,124 and increased levels of oxidative 
stress129 in cancer cells. By combining targeting monoclonal antibodies with an 
anticancer drug, antibody-drug conjugates increase the selectivity of existing 
therapies. Trastuzumab emtansine is the first FDA-approved conjugate, for use against 
human epidermal growth factor receptor 2 positive (HER2+) breast cancers.130 Recent 
studies have also explored the potential of kinase inhibitors. Kinases are known to be 
crucial in many cell signalling pathways, including those associated with cancer (such 
as proliferation and cell survival mechanisms).131 While highly potent (nanomolar 
IC50), many of the inhibitors investigated lacked specificity for a particular kinase.
132 
In addition, drug carriers; for example nanoparticles, liposomes and polymeric 
conjugates, have also been explored to improve delivery of cytotoxic agents 
specifically to cancer cells, while protecting the drug from deactivation.128, 133 
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1.4 Catalytic therapies 
Though absorption, metabolism and excretion mechanisms of current pharmaceuticals 
have been thoroughly studied, the damage that may occur at high concentrations is a 
common clinical concern. By designing catalytic therapies, dosage could be 
dramatically reduced while achieving the same efficacy. For many diseases, including 
cancer, the redox balance in cells is known to differ from normal levels.63, 134 Cellular 
redox homeostasis is mainly regulated by two co-factors; nicotine adenine 
dinucleotide (NAD), and flavin adenine dinucleotide (FAD), which catalytically 
transport hydride. Chemical mimics that can catalytically generate and transfer redox-
active molecules may play a crucial role in future pharmaceuticals.  
Catalysts are well-established in chemical synthesis to achieve reaction rates that 
would not be possible in their absence. Inorganic catalysts allow access to a range of 
redox potentials and coordination numbers. Ligands may be stabilising, substrate-
directing, or participate in the catalytic cycle, and allow for the fine-tuning of the 
properties. However, many inorganic catalysts require inert atmospheres (to prevent 
metal oxidation) and particular solvents to circumvent catalyst deactivation. Advances 
are being made in the development of water-compatible catalysts,5 which are 
advantageous when considering the development of catalytic medicines, which would 
be required to maintain activity in an aqueous cellular environment, and indeed many 
successful examples have been reported. Artificial protease complexes of cobalt(III) 
and copper(II) have been shown to catalytically cleave bovine serum albumin and 
myoglobin.135 Suzuki-Miyaura cross-couplings and allylcarbamate cleavages have 
been carried out inside cells using palladium(0) nanoparticles.136 Ruthenium  catalysts 
have been used to uncage an active anticancer drug in HeLa cells,137 and to uncouple 
the mitochondrial electron transport chain by in situ generation of 2,4-dinitrophenol.138 
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1.4.1 Oxidative catalytic therapies 
The catalytic generation of reactive oxygen species (ROS), such as hydroxyl radicals 
OH• and superoxide O2•
- has been frequently identified for cells exposed to metal 
complexes.56, 139 This is particularly important for the treatment of many conditions, 
including cancer, Alzheimer’s disease and Parkinson’s disease; where abnormal 
cellular redox balance is observed, offering a promising therapeutic target.140 
Methodical design and modification of ligands around the metal centre allows for fine 
tuning of the metal centre chemistry, to access physiologically-relevant redox couples.  
Inhibition of thioredoxin reductase (TrxR), an enzyme known to be important in the 
regulation of cellular redox levels, has been demonstrated using ruthenium(II) arene 
complexes.141 Ruthenium azopyridine complexes have been shown to catalytically 
oxidise glutathione (GSH), an important anti-oxidant molecule in cells, to glutathione 
disulphide (GSSG).93 Iridium(III) catalysts have been successfully used catalytically 
oxide NADH,142 and shown to increase the NAD+/NADH ratio inside cancer cells 
(Figure 1.12).143 While osmium(II) iminopyridine and azopyridine complexes have 
been also shown to generate reactive oxygen species in cells, the oxidation was not 
catalytic, and only iminopyridine complexes were capable of NADH oxidation 
(forming NAD+) by abstraction of hydride, while azopyridine complexes could not.106  
Superoxide dismutase (SOD) mimics have also been studied to catalyse the conversion 
of the superoxide radical to dioxygen and hydride peroxide, since SOD is considered 
one of the cell’s primary defence mechanisms against oxidative stress.144-146 Many 
transition metal-catalysed examples have been described, including OsO4,
144 while 
more recent reports have explored the high activity of manganese(II) complexes. In 
particular, Mn(II) salen complexes and Mn(II) peptide complexes have been found to 
significantly reduce superoxide levels inside cells.147, 148  
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1.4.2 Reductive catalytic therapies 
Transfer hydrogenation of NAD+ to its reduced form (NADH) have been extensively 
studied using inorganic catalysts of ruthenium and iridium, in combination with 
sodium formate (or hydrogen gas).149, 150 NADH mimics have also been used for 
reduction reactions in aqueous solution, and hydrogenation (regeneration) of the 
coenzyme mimics, using sodium formate, has been successfully described.151 Non-
asymmetric ruthenium N,N-bidentate piano-stool complexes [Ru(arene)Cl(tosyl-
diamine)] have been used to reduce NAD+ using sodium formate in an aqueous 
model,152 and later inside cancer cells using a non-toxic concentration of sodium 
formate (Figure 1.12).129  
 
 
 
Figure 1.12. Modulation of the NAD+/NADH ratio inside cancer cells by: (a) transfer hydrogenation 
(reduction) of NAD+ to NADH using Ru ATH catalysts with sodium formate as a hydride source;129 
(b) catalytic oxidation of NADH (abstraction of hydride) by Ir(III) complexes.143 
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Stereoselective ruthenium(II) complexes have been assessed for both catalytic 
efficiency and antiproliferative activity in cells. Interestingly, highly potent complexes 
were found to be poor transfer hydrogenation catalysts, while promising catalysts were 
less effective against cancer cells.153 Half-sandwich rhodium(III) Cp* complexes have 
been shown to reduce NAD+ to NADH by 1H-NMR in a model system, and can also 
rapidly convert pyruvate to lactate, using sodium formate as a hydride source, though 
the reduction is not enantioselective. In competition experiments, the rhodium 
complexes preferentially reduced NAD+ over pyruvate.154 Pyruvate reduction using 
ruthenium(II) bipyrimidine and iridium(III) phenanthroline complexes has also been 
studied by 1H-NMR,143 however no previous examples have demonstrated reduction 
of pyruvate by an osmium catalyst. Furthermore, at the time of writing, no examples 
have reported the selective reduction of pyruvate to L- or D-lactate with high 
enantioselectivity, nor the reduction of pyruvate inside cells. 
The work in this thesis builds on the aforementioned examples to explore the 
antiproliferative activities of Os(II) and Ir(III) transfer hydrogenation catalysts against 
cancer cells, which are compared to current non-catalytic Pt therapies. Utilising the 
enantioselective properties of the catalyst, modulation of intracellular L- or D-lactate 
concentrations by asymmetric reduction of pyruvate inside cells are carried out using 
novel Os(II) complexes, generating selectivity for cancer cells over healthy cells. Such 
complexes are based on racemic Ru(II) catalysts previously described to carry out the 
reduction of NAD+ to 1,4-NADH inside cells (using sodium formate as a hydride 
source). Furthermore, the reverse osmium(II)-catalysed reaction is explored by 
catalysing the oxidation of the co-enzyme and cellular hydride source 1,4-NADH to 
NAD+ in a model system under biologically-relevant conditions (pH 7.4, aqueous-
phase reduction). 
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1.5 Aims 
This thesis aims to explore the novel catalytic and anticancer properties of 16-electron 
osmium(II) sulfonamide complexes of the general formula [Os(ɳ6-arene)(diamine)], 
where the ɳ6-arene is para-cymene, biphenyl or meta-terphenyl, and the diamine 
substituent contains a sulfonamide with various R group substituents. 
 
• Asymmetric transfer hydrogenation of ketones by an Os(II) catalyst 
Structurally similar ruthenium 16-electron complexes of the general form [Ru(ɳ6-
arene)(diamine)] have previously been identified as the active species in the catalytic 
cycle for the transfer hydrogenation of ketones. In Chapter 3, the osmium complexes 
are assessed for their activity, including degree of enantioselectivity, for the transfer 
hydrogenation of asymmetric ketones (derived from acetophenone) to assess primary 
catalytic activity in organic solvent systems.  
 
• Conversion of the co-enzyme NADH to NAD+ by an Os(II) catalyst 
In Chapter 4, the osmium(II) (and structurally-similar iridium(III)) sulfonamide 
catalysts are explored as catalysts for the oxidation of NADH, an important biological 
source of hydride. Furthermore, the primary anticancer activities are investigated in 
range of human cell lines to examine activity trends. As the compounds contain a 
xenobiotic element, cellular metal accumulation mechanisms and pathways, and 
cellular distribution patterns are reported, using representative compounds from the 
osmium(II) and iridium(III) series. The oxidation of NADH is known to generate 
downstream reactive oxygen species, which can be detected in cells. 
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• Asymmetric reduction of pyruvate in cancer cells by an Os(II) catalyst 
Chapter 5 further explores the catalytic potential of the complexes in vitro by co-
administering the catalyst with a source of hydride (sodium formate) to enhance 
antiproliferative potency. This effect is examined in both cancer cells and healthy cells 
(primary fibroblasts). Both enantiomers of Os(II) sulfonamide complex [Os(p-
cymene)(TsDPEN)] are explored for their ability to catalyse the asymmetric reduction 
of pyruvate to L- or D-lactate in cells and in model systems, which are studied using 
time-dependent 1H-NMR and enzymatic assays. Enzymes that are known to be over-
expressed in certain cancer cells are also explored to selectively generate hydride in 
situ, further increasing the selectivity of the compounds for cancer cells. 
  
• Exploring the toxicity and mechanism of Os(II) complexes in zebrafish  
Lead osmium(II) anticancer complexes are explored in Chapter 6 for the first time in 
vivo using the zebrafish model (Danio rerio) to evaluate both acute aquatic toxicity as 
described in OECD guideline 236. Data are compared to results obtained with 
currently available anticancer drugs and other osmium(II) complexes which have 
shown clinical promise. Additionally, since production of reactive oxygen species was 
observed in cells, generation of ROS was investigated in whole-mount zebrafish to 
determine whether the observation is maintained in a whole live animal. ROS were 
visualised using confocal microscopy and a green-fluorescent ROS probe. To confirm 
the specific role of the metal complex, a red-fluorescent Os(II) complex derived from 
the sulfonamide series was designed, synthesised, fully characterised, and its 
biological activities assessed before co-imaging Os(II) complex (red) and ROS 
generation (green) in zebrafish. 
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2. Materials, methods and instrumentation 
 
2.1 Materials 
Osmium trichloride hydrate was purchased from Heraeus. Iridium trichloride hydrate 
was purchased from Precious Metals Online. Potassium hydroxide, magnesium 
sulphate and all non-dried solvents were obtained from Fischer Scientific. (1R,2R) and 
(1S,2S)-1,2-diphenylethylenediamine were purchased as optically pure compounds 
from Arran Chemical Company Ltd (Ireland). Reduced precursors (1,4-dihydro-
biphenyl and 1,4-dihydro-m-terphenyl) were kindly provided by Khatija Bhayat, Dr. 
Russell Needham and Dr. Abraha Habtemariam (University of Warwick, UK). 
Deuterated solvents were purchased from Goss Scientific.  
Reagents for biological experiments: acetic acid, CDDP (cisplatin), DMSO, 
sulforhodamine B and trichloroacetic acid were purchased from Sigma Aldrich as 
biological-grade reagents.  
ICP standards for Os (hexachlorodiammonium osmate, 1000 ± 10 µg/mL in 15% v/v 
hydrochloric acid), Ru (ruthenium chloride, 1004 ± 5 µg/mL in 10% v/v hydrochloric 
acid), Ir (iridium chloride, 995 ± 4 µg/mL in 10% v/v hydrochloric acid) and Pt 
(TraceCERT® platinum, 1001 ± 2 mg/L in 5% w/w hydrochloric acid) were purchased 
from Inorganic Ventures and stored at 276 K. Sodium chloride (TraceSELECT®), 
thiourea (puriss) and ascorbic acid (BioXtra) were used for ICP experiments. Nitric 
acid (72% v/v) was freshly distilled and diluted with doubly deionized milliQ water 
(18.2 MΩ·cm at 298 K) to achieve a working concentration of 3.6% v/v. 
All other reagents and solvents were purchased from Sigma Aldrich and used as 
received, unless specified otherwise. 
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2.1.1 Metal salt aquation analysis 
A standard solutions of osmium trichloride was prepared (1 mM) assuming an 
anhydrous molecular weight, in 3.6% v/v nitric acid containing thiourea (10 mM) and 
ascorbic acid (100 mg/L). The stock solution was diluted in triplicate to achieve final 
working concentrations appropriate for ICP-OES analysis (ca. 300 ppb Os). The 
determined concentration of the solution was used to solve for n (the water of 
crystallisation), determined to be n = 2.71 (≈ 3).  
 
2.1.2 Synthesis of dimer precursors 
Osmium dimer precursors were synthesised following an adapted literature procedure 
for microwave synthesis of similar (Ru / Ir / Rh) metal dimer complexes.1 All dimers 
were characterised by NMR and ESI-MS, and data matches previously reported 
results. Chain-extended iridium dimer compounds [Ir(CpxPh)Cl2]2 and 
[Ir(CpxBip)Cl2]2 (Figure 2.1) were kindly provided by Dr. Abraha Habtemariam.  
 
 
 
Figure 2.1. Chain-extended iridium dimer compounds [Ir(CpxPh)Cl2]2 and [Ir(CpxBip)Cl2]2. 
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[Os(ƞ6-p-cymene)Cl2]2.2 Osmium trichloride trihydrate (1.00 g, 2.8 mmol) was 
dissolved in degassed methanol (10 mL). To this was added α-phellandrene (3.8 g, 28 
mmol) with stirring. The reaction vessel was placed in a CEM Discovery-SP 
microwave reactor for 10 min (413 K, 150 W, 250 psi). An orange solid precipitate 
was observed, which was washed with n-pentane (3 × 10 mL). The solid was washed 
with diethyl ether yielding a bright orange crystalline solid (863 mg, 1.1 mmol, 79%). 
1H NMR (300 MHz, CDCl3, 25°C, TMS): δ=6.18 (d, 4H, 3J(H,H)=5.0 Hz; Os-ArH), 
6.02 (d, 4H, 3J(H,H)=5.0 Hz; Os-ArH), 2.78 (sept, 2H, 3J(H,H)=6.8 Hz; CH(CH3)2), 
2.21 (s, 6H; Ar-CH3), 1.29 (d, 12H, 
3J(H,H)=6.8 Hz; CH(CH3)2).  
 
 
[Os(ƞ6-biphenyl)Cl2]2. The synthesis was carried out as described for the osmium p-
cymene dimer using 3-phenyl-cyclohexa-1,4-diene (1.56 g, 10 mmol) in place of α-
phellandrene. The solid was washed with n-pentane followed by diethyl ether to obtain 
the product as a dark orange amorphous solid (936 mg, 1.3 mmol, 81%). 1H NMR 
(400 MHz, CDCl3, 25°C, TMS): δ=7.69 (m, 4H; ArH), 7.47 (m, 6H; ArH), 7.29 (m, 
2H; ArH) 6.65 (m, 2H; ArH), 6.32 (m, 6H; ArH). 
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[Os(ƞ6-m-terphenyl)Cl2]2. To a solution of osmium trichloride trihydrate (287 mg, 
0.82 mmol) in freshly distilled ethanol (20 mL) was added 1,5-dihydroterphenyl (dh-
m-terp, 570 mg, kindly prepared by Dr. Abraha Habtemariam by Birch reduction of 
m-terphenyl).  The reaction mixture was heated under reflux for 24 h under a nitrogen 
atmosphere. A  brown precipitate was observed upon cooling. The solid was collected 
by filtration, before washing with ethanol (25 mL) and diethyl ether (5 × 25 mL). The 
product was obtained by Buchner filtration as a light brown amorphous solid (173 mg, 
0.18 mmol, 22%). 1H NMR (400 MHz, CDCl3, 25°C, TMS): δ=7.11-7.49 (m, 20H; 
ArH), 6.16 (m, 2H; Os-ArH), 5.97 (m, 2H; Os-ArH), 5.82 (m, 2H; Os-ArH), 4.16 (m, 
2H; Os-ArH). 
 
 
[Ir(Cp*)Cl2]2. This compound was synthesised following a known literature 
procedure.1 Iridium trichloride trihydrate (0.5 g, 1.38 mmol) was dissolved in 
methanol (10 mL) that had been sonicated and de-gassed. The solution was stirred 
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vigorously to ensure the solid had fully dissolved. To this was then added 1,2,3,4,5-
pentamethylcyclopentadiene (0.67 mL, 4.27 mmol) with stirring. The reaction vessel 
was placed in a CEM Discovery-SP microwave reactor for 5 min (413 K, 150 W, 250 
psi) after which a precipitate of a crystalline red solid was observed. The reaction 
solution was cooled to ambient temperature (298 K) before washing with n-pentane 
(3 × 10 mL). The precipitated solid was collected and washed further with diethyl 
ether to yield the product as a crystalline red solid. 1H NMR (300 MHz, CDCl3, 25°C, 
TMS): δ=1.59 (s, 30H; CH3). 
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2.2 Instrumentation 
 
2.2.1 Nuclear magnetic resonance spectroscopy (NMR) 
Samples were prepared in CDCl3 (0.05% v/v TMS) unless stated otherwise. 5 mm 
NMR tubes were used to record spectra at 298 K (unless specified) on Bruker DPX-
400, HD-500, or AV-600 spectrometers. Data were acquired using standard pulse 
sequences, and chemical shifts referenced to residual solvent(s): CHCl3 (δ=7.26 ppm), 
C6H6 (δ=7.16 ppm), (CH3)2SO (δ=2.50 ppm), 1,4-dioxane (3.71 ppm in H2O) or 
(CH3)2CO (δ=2.05 ppm). Data were processed using TOPSPIN 3.2 (Bruker UK). 
Experiments in aqueous solution (90% H2O / 10% D2O) were carried out using  
WATERGATE (water suppression by gradient-tailored excitation) pulse sequences 
for solvent suppression (zggpw5) with five pairs of symmetric pulses (W5),3 128 scans 
into 32k data points over a spectral width of 10 ppm. 
 
2.2.2 Electronic absorption spectroscopy (UV-Vis) 
Electronic absorption spectra were recorded using a Varian Cary 300 Bio scan 
spectrophotometer fitted with a PTP1 Peltier temperature controller. Data were 
recorded using quartz cuvettes (600 μL) at 298 K unless specified otherwise. Path-
length of cell 1 cm, range 800-200 nm, average time 0.1 s, data interval 1 nm; scan 
rate 600 nm min-1. Data were processed using Winlab UV software for Windows.  
 
2.2.3 Elemental analysis 
Elemental analysis (C, H, N) was carried out by Warwick Analytical Services UK on 
an Exeter elemental analyser CE440. 
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2.2.4 Mass spectrometry 
Low resolution ESI-MS spectra were obtained using an Agilent 6130B ESI mass 
spectrometer. Samples were prepared in acetonitrile. Fragments were detected using a 
positive ion scan range of either m/z 400-1000 or m/z 50-500. High resolution mass 
spectra were obtained by Dr. Lijiang Song and Mr. Phil Aston using a Bruker UHR-
Q-TOF MaXis, with a positive ion scan range of m/z 50-3000 (spectra rate of 1 Hz). 
Analysis was carried out through direct infusion (2 µL/min) with a syringe pump, with 
sodium formate (10 mM) calibration. Source conditions: ESI (+); end plate offset: -
500 V; capillary: -3000 V; nebulizer gas (N2): 0.4 bar; dry gas (N2): 4 L/min; dry 
temperature: 453 K; funnel RF: 200 Vpp; multiple RF: 200Vpp; quadruple low mass: 
55 m/z; collision energy: 5.0 eV; collision RF: 600 Vpp; ion cooler RF: 50-250 Vpp 
ramping; transfer time: 121 µs; pre-pulse storage time: 1 µs. 
 
2.2.5 ATR Fourier-transform infrared (FTIR) spectroscopy 
Attenuated total reflection ATR-FTIR spectra were acquired on a Bruker Alpha 
Platinum ATR. Range: 4000-400 cm-1; Spectral resolution: 4 cm-1 using 16 
interferograms. Data were acquired using OPUS software 7.0. 
 
2.2.6 Gas chromatography (GC) 
Gas chromatography was carried out with kind assistance from Dr Roy Hodgkinson 
(University of Warwick, UK) using either a Chrompac cyclodextrin--236M-19, 50 
m x 0.25 mm x 0.25 µm, or a Chrompac-chirasil-DEX CB, 25 m x 0.25 mm x 0.25 
µm, T = 383 K. The carrier gas was H2 or He, P = 18 psi. Data were processed using 
Clarity Chromatography Suite for Windows. 
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2.2.7 X-ray crystallography 
X-ray crystallographic data were acquired by Dr. Guy Clarkson (University of 
Warwick). A suitable crystal was selected and mounted on a glass fibre with Fromblin 
oil and placed on an Oxford Diffraction Gemini diffractometer with a Ruby CCD area 
detector at 150(2) K during data collection. Using Olex2,4 the structure was solved 
with the ShelXS5 structure solution program using Direct Methods and refined with 
the ShelXL5 refinement package using Least Squares minimisation. The enantiopure 
complexes were synthesised from starting materials of known chirality and also gave 
low Flack parameter values for the structural determinations refined using 
BASF/TWIN in Shelx2014. Data were analysed and visualised using Mercury 3.3. 
 
2.2.8 Inductively coupled plasma spectroscopy (ICP) 
ICP techniques were used to determine trace metal concentration(s) in aqueous 
solutions. For osmium analysis, solutions were supplemented with thiourea (10 mM) 
and ascorbic acid (100 mg/L) to stabilise osmium in nitric acid solution and prevent 
formation of osmium tetroxide, known to have a higher nebulizing efficiency.6 The 
standard addition of thiourea and ascorbic acid was not found to affect calibrations of 
iridium, platinum or ruthenium. 
 
Inductively-coupled plasma optical emission spectroscopy. ICP-OES data for Os 
(λ = 225.585, 228.226), Ir (λ = 208.882, 237.277), Ru (λ = 240.272, 349.894) and Pt 
(λ = 265.945, 204.937) were obtained using a Perkin Elmer Optima 5300 DV Optical 
Emission Spectrophotometer. Total dissolved solids did not exceed 0.2 % w/v. 
Calibration standards were freshly prepared (50-700 ppb) in 3.6% v/v nitric acid and 
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samples diluted to within this range. The salinity of the calibration standards and 
calibration blanks was adjusted to match the matrix of the samples by standard 
addition of sodium chloride solution. Data were acquired and processed using 
WinLab32 V3.4.1 for Windows. 
 
Inductively-coupled plasma mass spectrometry. ICP-MS data for 189Os, 193Ir, 101Ru 
and 195Pt were obtained using an ICP-MS Agilent Technologies 7500 series in no-gas 
mode. Data acquisition was carried out using ICP-MS TOP with an internal standard 
of 166Er (50 ppb), and processing was carried out using Offline Data Analysis 
(ChemStation version B.03.05, Agilent Technologies, Inc.). Total dissolved solids did 
not exceed 0.1 % w/v. Calibration standards were freshly prepared (0.1-1000 ppb) in 
3.6% v/v nitric acid and samples diluted to within this range.  
 
2.2.9 Flow Cytometry 
Flow cytometry data were acquired using a Becton Dickinson FACScan Flow 
Cytometer (School of Life Sciences, University of Warwick, UK). Voltages, 
amplitude gains, and compensation were set using negative and positive control 
experiments. Sample preparation is described for individual experiments. Data were 
processed using FlowJo V10 for Windows. 
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2.3 Methods 
 
2.3.1 Transfer hydrogenation kinetics 
Transfer hydrogenation kinetics were calculated based on previously reported 
methods.7 Samples of compounds were prepared in formic acid : triethylamine 
azeotrope (5:2 v/v) with standard addition of 100 µL C6D6. Samples were placed under 
an inert nitrogen atmosphere at 310 K. A substrate molecule of choice was added with 
stirring and the mixture transferred to a 5 mm NMR tube. Proton NMR spectra were 
recorded every 73 s at 310 ± 0.5 K (for 1 h) using a Bruker AV-400 spectrometer.  
Data processing was carried out using TOPSPIN version 3.2 (Bruker UK). 
Experiments were performed in triplicate. Conversion was monitored by two 
integration regions: (the methyl protons (3H) in the reagent (δ = 2.25-2.65 ppm) and 
the quartet of the newly formed CH in the product (δ = 4.55-5.00 ppm). Triethylamine 
(2.9 ppm, quartet) did not overlap either of the integration regions.  
The turnover number at any time-point (TONt; moles of substrate turned over per mole 
of catalyst at time, t) , was calculated for each spectrum and percentage conversion 
was calculated using the formulae: 
 
conversion = 100 − (
𝐼2.25−2.65
3
𝐼4.55−5.00 +
𝐼2.25−2.65
3
×100%) 
 
TON𝑡 =
[conversion]t
100
∙
[substrate]0
[catalyst]
=
δ[TON]t
δt
 
 
The maximum turnover frequency (TOFmax) was calculated using the initial rate of 
reaction (t = 0 h) at which the gradient of a TON vs. time plot was at a maximum. 
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2.3.2 Biological studies (in vitro cell culture) 
Human cell culture experiments were carried out under the guidance of Dr. Isolda 
Romero-Canelón with assistance from Dr. Anthony Knight, Mrs. Ji-Inn Song, Mrs. 
Sukhbinder Heer and Mrs. Hannah E. Bridgewater at the School of Life Sciences and 
Department of Engineering, University of Warwick.8  
A2780, SK-OV-3 and SW-626 human ovarian carcinomas, A2780cis cisplatin-
resistant human ovarian carcinoma, A549 human lung carcinoma, HCT116 human 
colorectal carcinoma, HCT116-p21-/- P21-knockout colorectal carcinoma, HCT116-
p53-/- P53-knockout colorectal carcinoma, HEPG2 human hepatocellular carcinoma, 
OE19 human esophageal carcinoma, MCF7 human breast adenocarcinoma, MRC5 
human fetal fibroblasts, and PC3 human prostate carcinoma cells were purchased from 
the European Collection of Cell Cultures (ECACC). HOF human ovarian fibroblasts 
were purchased from ScienCell. Mycoplasma-free status was confirmed every 6 
months by Public Health England. Cell culture media (RPMI-1640, DMEM, McCoy 
5A), phosphate buffered saline, L-glutamine, penicillin / streptomycin, fetal bovine 
serum and trypsin / EDTA were purchased from PAA Laboratories and kindly 
prepared by technicians at the School of Life Sciences (University of Warwick, UK). 
RPMI-1640 media (without phenol red) and phosphate buffered saline were purchased 
from Lonza. Fibroblast medium was purchased from ScienCell Research Laboratories.  
 
Cell maintenance: Defrosting 
Ampoule(s) were rapidly defrosted in a water bath (310 K). Cells were transferred to 
falcon tubes and centrifuged (5 min, 1000 rpm, 295 K) to remove supernatant freezing 
medium. Pellets were re-suspended in media (5 mL) and transferred to a T25 flask.  
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Cell maintenance: Passaging 
A2780, MRC5 and PC3 cells were grown in Roswell Park Memorial Institute medium 
(RPMI-1640) supplemented with 10% fetal bovine serum, 1% glutamine (2 mM) and 
1% penicillin / streptomycin. A549, HEPG2 and MCF7 cells were grown in 
Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum, 1% glutamine (2 mM) and 1% penicillin / streptomycin. HCT116 cells were 
grown in McCoy’s Modified 5A medium supplemented with 10% fetal bovine serum, 
1% glutamine (2 mM) and 1% penicillin / streptomycin. HOF cells were grown in 
fibroblast growth medium supplemented with 5% fetal bovine serum, 1% penicillin / 
streptomycin and 1% fibroblast growth factor serum.  
Cells were grown as adherent monolayers in 75 cm2 culture flasks (surface-treated, 
fitted with filters) at 310 K in a 5% CO2 humidified atmosphere until 80-90% 
confluence was achieved. 
Upon reaching 80-90% confluence, cells were washed with PBS (5 mL). 0.25% 
trypsin / EDTA (2 mL) was added, and the flask was placed in an incubator (310 K) 
for 3-5 min. Once cells were observed to be detaching from the bottom of the flask, 
the solution was diluted with the corresponding medium to obtain a single cell 
suspension. A suitable volume (typically 1:4) was transferred into a T75 (75 cm2) cell 
culture flask containing fresh media and placed in an incubator (310 K).  
When passaging HOF fibroblasts, trypsin / EDTA activity was quenched with foetal 
bovine serum (FBS: 5 ml, 5 min). The supernatant containing trypsin was removed 
after centrifugation (5 min, 1000 rpm, 295 K) and the pellet re-suspended in 
(supplemented) fibroblast growth medium. Primary cell lines (MRC5 and HOF) were 
not used after passage 5 due to cells entering senescence. 
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Sulforhodamine B (SRB) colorimetric assay 
The sulforhodamine B (SRB) assay can be used to determine cell density based on the 
protein concentration per sample.9 Sulforhodamine B (Figure 2.2) electrostatically 
binds basic amino acid residues present in viable cells under mild acidic conditions. 
Release under mild basic conditions is quantitative, and dye absorbance is linear with 
protein concentration.9  
An alternative assay, the MTT assay (MTT = 3-(4,5)-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), quantifies the number of viable cells by reducing 
colourless MTT into a dark blue (formazan) species, requiring metabolic processes in  
live cells.9, 10 Similarly to the SRB assay, the production of formazan is linear with the 
number of cells.10 Because of the metabolic dependence, the MTT assay can 
distinguish between live and dead cells,10 unlike the SRB assay.9 Reduction of MTT 
may however be influenced by certain reagents, and requires optimisation for some 
cell lines due to the metabolic dependence.9 Conversely, the SRB assay has been found 
to provide better linearity and sensitivity, and is compatible with a range of cell lines, 
including those investigated in this thesis.11 
 
                      
 
Figure 2.2. Colorimetric cell assay dyes: sulforhodamine B (left) and MTT (right). 
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In vitro growth inhibition assay 
Cells were washed with PBS and detached using 2 mM trypsin / EDTA (2 mL) with 
incubation for 5 min (310 K). A single cell suspension was obtained, and counted 
using a haemocytometer.  The suspension was diluted to seed a 96-well plate with 
5000 cells per well using 150 µL (with the exception of SK-OV3 which were seeded 
at a density of 10’000 cells per well using 150 µL) which were left to incubate in drug-
free media for 48 h (310 K). 100 µM drug stock solutions were prepared (0.5% DMSO, 
95% culture medium). Serial dilutions were performed to prepare 6 drug 
concentrations (typically 0.01-100 µM). Solutions (200 µL) were added to the wells 
in triplicate, alongside positive (CDDP) and negative control samples. A drug 
exposure period of 24 h was allowed (310 K). Supernatants were removed, and the 
wells washed with PBS (100 µL). A recovery period of 72h was allowed in drug-free 
medium (200 µL, 310 K). Aliquots of stock solutions (ca. 100 µM) were analysed by 
ICP-OES to determine the exact metal concentration. 
The SRB assay was used to determine cell viability. Cold 50% trifluoroacetic acid 
(TCA, 50 µL) was added to each well for 1 h (277 K). The plate was washed with 
slow running water and dried. 0.4% SRB dye (50 µL, prepared in 1% acetic acid) was 
added for 30 mins (298 K). Excess dye was removed with 1% acetic acid, and the plate 
was dried. 10 mM Tris base solution (200 µL) was added to each well for 1 h (298 K). 
Absorbance was read with a BioRad iMark microplate reader. Survival percentages 
were obtained relative to negative control wells. Data was plotted as survival 
percentage versus the logarithm of drug concentration using OriginPro 2016. IC50 
(half-maximal inhibitory) concentrations were determined as the inflection point of 
the fitted sigmoidal curve. Experiments were performed as duplicates of triplicates 
and standard deviations were calculated.  
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Metal accumulation in cancer cells 
Cells were grown as described previously.8 The medium was removed, cells were 
washed with phosphate-buffered saline (PBS) and detached using 2 mL of trypsin / 
EDTA (2 mM, 310 K, 5 min). The solution was diluted using the corresponding 
medium and mixed to achieve a single cell suspension, and cell density determined 
using a plastic disposable haemocytometer. The suspension was diluted to seed 4 × 
106 cells per well in a P100 petri dish (10 mL).  
After 24 h of pre-incubation, solutions of the complexes (DMSO not exceeding 0.5%) 
and negative controls were added in triplicate to give final (equipotent) concentrations 
equal to the IC50 determined in A2780 (unless stated otherwise). 24 h drug exposure 
was allowed. The experiments did not include any recovery time in drug-free media 
stated otherwise. Cells were incubated at 310 K unless stated otherwise. 
The supernatant was removed. Cells were washed with PBS and detached with trypsin-
EDTA. The number of cells in each sample was determined using a haemocytometer. 
Cells were collected by centrifugation (5 min, 1000 rpm), re-suspended in PBS (1 mL) 
and transferred to glass microwave vials. After further centrifugation (5 min, 1000 
rpm), the supernatant was removed by suction to obtain whole cell pellets. Freshly 
distilled 72% v/v nitric acid (500 µL) was added to the pellets which were digested 
using a CEM Discovery microwave (453 K, 3 min, 300W, 450 psi). Solutions were 
diluted using doubly-distilled milliQ water containing thiourea (10 mM) and ascorbic 
acid (100 mg/L) to achieve a final acid concentration of 3.6% v/v HNO3 (final working 
volume = 10 mL). The amount of metal taken up by the cells was determined by ICP-
MS. The experiments were all carried out in triplicate and the s.d. were calculated. 
Final results were reported as ng Os / Ir / Pt × 106 cells.  
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3. Asymmetric catalytic osmium sulfonamide complexes 
 
3.1 Introduction 
Selective hydrogenation of functional groups with control of enantioselectivity allows 
chemists to synthesise complex products from simple and readily available prochiral 
reagents; an example of which is transfer hydrogenation, which describes the catalysis 
of hydrogen transferral from a donor molecule to a substrate.1-3 The importance of this 
chemistry was highlighted by the award of the 2001 Nobel Prize in Chemistry to 
Professor R. Noyori for his contributions to asymmetric reduction catalysis.2 The first-
generation Noyori catalysts were based on ruthenium coordinated to a diamine and 
BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) chelating ligands, achieving 
high conversion and enantioselectivity for the reduction of ketones.4, 5 Analogous 
osmium complexes, both chiral and non-chiral variants, have since been reported for 
the rapid hydrogenation of carbonyls.6  
Second generation Noyori-type ruthenium transfer hydrogenation catalysts replaced 
the diphosphine ligand with an η6-coordinated arene and a chloride as the leaving 
ligand. The compounds are prepared by the complexation of a sulfonamide with a 
ruthenium-arene chlorido dimer, in the presence of a base (Figure 3.1).1 The resulting 
chlorido pre-catalyst is highly stable and easy to handle, and eliminates HCl to become 
the active catalytic species.7 Isoelectronic Rh(III) and Ir(III) Cp* complexes (Cp* = 
1,2,3,4,5-cyclopentadienyl) have been reported and retain the high conversion and 
enantioselectivity of the ruthenium complex,8, 9 however no examples of osmium 
analogues of the second-generation Noyori catalyst were identified in the literature 
prior to the investigations in this project.  
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Figure 3.1. Synthesis of Noyori-type synthesis of a Ru pre-catalyst in 2-propanol (Ts = tosyl).1 
 
The role of the metal in transfer hydrogenation catalysts is not purely structural. The 
Rh(III) TsDPEN catalyst was found to be more efficient than Ir(III) and Ru(II) 
analogues for the reduction of various ketones in water, achieving 99% ee even at low 
catalyst loading.10  
This Chapter explores the synthesis, chemistry and catalytic properties of osmium 
analogues of the Noyori second-generation ruthenium bifunctional catalyst, 
complexes 1-10 (Table 3.1). Osmium-based catalysts may have previously attracted 
little attention due to the apparent inertness of osmium(II), as commonly observed for 
the ca. 100× slower hydrolysis of Os-Cl, compared to that of Ru-Cl.11 However, recent 
examples demonstrate promise for osmium hydrogenation catalysts bearing various 
bidentate ligands.12-17 As discussed in Chapter 1 (section 1.1.2), many Os catalysts 
achieve high turnover frequencies (TOF = 106 h-1) for the transfer hydrogenation of 
carbonyls, in some cases, at greater rates than the ruthenium isoelectronic analogues.17  
Electrostatic interactions between the arene of the catalyst and the substrate are critical 
in the enantioselectivity of the catalyst,18, 19 but the effect of p-cymene substitution has 
not been widely explored for sulfonamide catalysts. The sulfonamide group is known 
to be important, particularly for interactions with protonated imines and amines.20, 21 
However, few examples of other sulfonamides exist beyond tosyl-diamine complexes. 
In addition, phenyl groups of the diamine were modified by addition of methoxy-
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substituents in an effort to increase water solubility. Such modifications are evaluated 
for their impact on both the chemistry of the complexes, and their catalytic 
performance for the reduction of prochiral ketones, using chemical and computational 
techniques. Osmium analogues 1-10 are compared to Noyori-type ruthenium complex 
11, from which they are derived, to examine the effect changing the metal centre (Ru 
for Os) has on kinetics, stability and reactivity. 
 
   
   
 
p-cymene (p-cym) 
 
biphenyl (bip) 
 
m-terphenyl (m-terp) 
 
Complex Metal ƞ6-arene (R1) R2 R3 
1 Os p-cymene 4-tolyl ((H)TsDPEN) phenyl 
2 Os p-cymene 4-tolyl (TsDPEN) phenyl 
3 Os p-cymene methyl (MsDPEN) phenyl 
4 Os p-cymene 4-nitrophenyl (NsDPEN) phenyl 
5 Os p-cymene 4-fluorophenyl (FbDPEN) phenyl 
6 Os p-cymene phenyl (BsDPEN) phenyl 
7 Os biphenyl 4-tolyl (TsDPEN) phenyl 
8 Os m-terphenyl 4-tolyl (TsDPEN) phenyl 
9 Os p-cymene 4-tolyl (TsBMEN) 4-methoxyphenyl 
10 Os biphenyl 4-tolyl (TsBMEN) 4-methoxyphenyl 
11 Ru p-cymene 4-tolyl ((H)TsDPEN) phenyl 
 
Table 3.1. Structures of complexes 1-11 studied in this chapter. * denotes a chiral centre.  
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3.2 Experimental  
 
3.2.1 Materials 
Osmium trichloride hydrate was purchased from Heraeus. Osmium(II) arene dimers 
[OsCl2(p-cymene)]2, [OsCl2(biphenyl)]2 and [OsCl2(m-terphenyl)]2 were prepared 
following an adapted literature procedure for synthesis using a microwave reactor 
(Chapter 2, section 2.1.2).22 Enantiomerically-pure enantiomers of 1,2-di(4-
methoxyphenyl)ethylenediamine were purchased from Sigma Aldrich. 
Enantiomerically-pure enantiomers of 1,2-diphenylethylenediamine were purchased 
from Arran Chemical Company Ltd (Ireland). Sulfonyl chlorides were purchased from 
Sigma Aldrich. Potassium hydroxide, magnesium sulphate, sodium chloride and all 
non-dried solvents were purchased from Fischer Scientific. Deuterated solvents were 
purchased from Goss Scientific. Water used for biphasic reactions was purified by 
reverse osmosis (RO) unless specified. All other reagents and solvents were purchased 
from Sigma Aldrich and used as received, unless stated otherwise.  
 
Acknowledgements 
Reduced precursors (1,4-dihydro-biphenyl and 1,4-dihydro-m-terphenyl) were kindly 
provided by Miss. Khatija Bhayat, Dr. Russell Needham and Dr. Abraha Habtemariam 
(University of Warwick, UK). Complexes 9 and 10 (and the corresponding 
bis(methoxyphenyl)sulfonamide ligand) were synthesised by Miss. Yasmin Khanom 
(University of Warwick, UK). Both enantiomers of complex 11 were purchased from 
Sigma Aldrich. Methods for NMR, mass spectrometry, UV-visible spectroscopy and 
FT-IR spectroscopy are described in Chapter 2 (section 2.2). 
Chapter 3. Asymmetric catalytic osmium sulfonamide complexes 
62 
3.2.2 Synthesis of diamine sulfonamide ligands  
Both enantiomers of diamine ligands were individually synthesised from 
enantiomerically-pure starting materials, either (1R,2R)-diphenylethylenediamine / 
(1S,2S)-diphenylethylenediamine, or (1R,2R)-bis(4-methoxyphenyl)ethylenediamine 
/ (1S,2S)-bis(4-methoxyphenyl)ethylenediamine (Figure 3.2).  
 
  
TsDPEN MsDPEN 
  
  
NsDPEN FbDPEN 
  
  
BsDPEN TsBMEN 
 
Figure 3.2. Six sulfonamide ligands synthesised from enantiomerically-pure starting materials. Only 
(1R,2R)-ligands shown. 
 
N-(toluenesulfonyl)-1,2-diphenylethylenediamine (TsDPEN). These ligands were 
purchased as enantiomerically-pure compounds, (1R,2R)-TsDPEN and (1S,2S)-
TsDPEN, from Arran Chemical Company Ltd. 
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N-(Methanesulfonyl)-1,2-diphenylethylenediamine (MsDPEN). To either (1R,2R)-
diphenylethylenediamine or (1S,2S)-diphenylethylenediamine (212 mg, 1.0 mmol) 
and triethylamine (202 mg, 2 mmol) in ice-cold dichloromethane (3.2 mL) was added 
methanesulfonyl chloride (138 mg, 1.2 mmol) in dichloromethane (2.1 mL) dropwise 
over 6 h. The product was washed with water, dried over magnesium sulphate and 
concentrated in vacuo to afford an oil which was dissolved in toluene, obtaining a 
white crystalline solid. (113 mg, 0.39 mmol, 39%). 1H NMR (500 MHz, CDCl3, 25°C, 
TMS): δ=7.10-7.40 (m, 10H; ArH), 4.56 (d, 3J(H,H)=5.2 Hz, 1H; CHNHTs), 4.30 (d, 
3J(H,H)=5.2 Hz, 1H; CHNH2), 2.27 (s, 3H; CH3); 
13C NMR (125 MHz, CDCl3, 25°C, 
TMS) δ 128.9, 128.7, 128.6, 128.5, 127.9, 127.8, 127.6, 126.9, 126.7, 63.4, 62.6, 60.2, 
41.9, 40.7; UV/Vis: λmax 227 and 259 nm; HRMS (m/z): [M+H]+ calcd. for 
C15H19N2O2S, 291.1162; found, 291.1164. 
 
N-(4-Nitrobenzenesulfonyl)-1,2-diphenylethylenediamine (NsDPEN). The 
compounds were obtained following the method described for the synthesis of 
MsDPEN, using 4-nitrobenzenesulfonyl chloride (266 mg, 1.2 mmol) in place of 4-
toluenesulfonyl chloride. The product was recrystallized from toluene as a white 
crystalline solid. (230 mg, 0.58 mmol, 58%). 1H NMR (500 MHz, CDCl3, 25°C, 
TMS): δ=7.96 (d, 3J(H,H)=8.7 Hz, 2H; ArH), 7.53 (d, 3J(H,H)=8.7 Hz, 2H; ArH), 
7.18-7.25 (m, 5H; ArH), 7.12-7.18 (m, 5H; ArH), 4.49 (d, 3J(H,H)=4.3 Hz, 1H; 
CHNHSO2R), 4.21 (d, 
3J(H,H)=4.3 Hz, 1H; CHNH2); 
13C NMR (125 MHz, CDCl3, 
25°C, TMS) δ 128.7, 128.6, 128.3, 128.1, 127.9, 127.7, 127.4, 126.8, 126.3, 123.7, 
63.2, 60.1; UV/Vis: λmax 264 nm; HRMS (m/z): [M+H]+ calcd. for C20H20N3O4S, 
398.1169; found, 398.1169. Elemental analysis found (calcd. for (1R,2R)-
C20H19N3O4S): C 60.40 (60.44), H 4.90 (4.82), N 10.41 (10.57); Elemental analysis 
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found (calcd. for (1S,2S)-C20H19N3O4S): C 60.42 (60.44), H 4.87 (4.82), N 10.45 
(10.57). 
 
N-(4-Fluorobenzenesulfonyl)-1,2-diphenylethylenediamine (FbDPEN). The 
compounds were obtained following the method described for the synthesis of 
MsDPEN, using 4-fluorobenzenesulfonyl chloride (934 mg, 4.8 mmol) in place of 4-
toluenesulfonyl chloride. The product was recrystallized from toluene as a white 
crystalline solid. (1076 mg, 2.90 mmol, 73%). 1H NMR (400 MHz, CDCl3, 25°C, 
TMS): δ=7.41 (ddd, 3J(H,H)=5.1 Hz, 3J(H,F)=8.7 Hz, 4J(H,H)=5.0 Hz, 2H; ArH) 
7.06-7.22 (m, 10H; ArH), 6.81 (ddd, 3J(H,H)=9.1, 3J(H,H)=8.6 Hz, 4J(H,F)=5.0 Hz, 
2H; ArH), 4.43 (d, 3J(H,H)=5.1 Hz, 1H; CH), 4.18 (d, 3J(H,H)=5.1 Hz, 1H; CH); 13C 
NMR (125 MHz, CDCl3, 25°C, TMS) δ 129.5, 129.4, 128.4, 127.7, 127.6, 127.5, 
127.0, 126.5, 115.7, 115.5, 63.2, 60.4; UV/Vis: λmax 235 and 260 nm; HRMS (m/z): 
[M+H]+ calcd. for C20H20FN2O2S, 371.1224; found, 371.1230. Elemental analysis 
found (calcd. for (1R,2R)-C20H19FN2O2S): C 64.46 (64.85), H 5.02 (5.17), N 7.48 
(7.56); Elemental analysis found (calcd. for (1S,2S)-C20H19FN2O2S): C 64.51 (64.85), 
H 5.24 (5.17), N 7.51 (7.56). 
 
N-(Benzenesulfonyl)-1,2-diphenylethylenediamine (BsDPEN). The compounds 
were obtained following the method described for the synthesis of MsDPEN, using 
benzenesulfonyl chloride (848 mg, 4.8 mmol) in place of 4-toluenesulfonyl chloride. 
The product was recrystallized from toluene as a white crystalline solid. (569 mg, 1.61 
mmol, 40%). 1H NMR (500 MHz, CDCl3, 25°C, TMS): δ=7.43 (d, 3J(H,H)=7.6 Hz, 
2H; ArH), 7.34 (t, 3J(H,H)=7.4 Hz, 1H; ArH), 7.05-7.22 (m, 12H; ArH), 4.44 (br. d, 
3J(H,H)=5.2 Hz, 1H; CHNHSO2R), 4.18 (br. s, 1H; CHNH2); 
13C NMR (125 MHz, 
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CDCl3, 25°C, TMS) δ 131.9, 128.5, 128.5, 128.3, 127.7, 127.4, 127.0, 126.8, 63.2, 
60.4; UV/Vis: λmax 231, 233 and 260 nm; HRMS (m/z): [M+H]+ calcd. for 
C20H21N2O2S, 353.1318; found, 353.1319. Elemental analysis found (calcd. for 
(1R,2R)-C20H20N2O2S): C 67.87 (68.16), H 5.74 (5.72), N 7.94 (7.95); Elemental 
analysis found (calcd. for (1S,2S)-C20H20N2O2S): C 67.85 (68.16), H 5.73 (5.72), N 
7.93 (7.95). 
 
N-(Toluenesulfonyl)-1,2-bis(4-methoxyphenyl)ethylenediamine (TsBMEN). To a 
either enantiomerically-pure (1S,2S)-di(4-methoxyphenyl)-ethylenediamine or 
(1R,2R)-di(4-methoxyphenyl)-ethylenediamine (300 mg, 1.1 mmol) and triethylamine 
(230 μL, 1.7 mmol) in dichloromethane (50 mL) was added a solution of 4-
toluenesulfonyl chloride (210 mg, 1.1 mmol) in dichloromethane (80 mL) dropwise 
over a period of 30 min. The resulting reaction mixture was washed with water (3 × 
15 mL), followed by saturated brine solution, dried over magnesium sulphate, filtered 
and concentrated in vacuo to yield a transparent oil, which was titurated in diethyl 
ether to afford a white amorphous solid. (363 mg, 0.85 mmol, 74%). 1H NMR (500 
MHz, CDCl3, 25°C, TMS): δ=7.32 (d, 3J(H,H)=8.1 Hz, 2H; ArH), 7.04 (m, 2H; ArH), 
6.98 (d, 3J(H,H)=7.7 Hz, 4H; ArH), 6.67 (d, 3J(H,H)=8.1 Hz, 4H; ArH), 4.34 (br. s, 
1H; TsNHCH), 4.10 (br. s 1H CHNH2), 3.73 (br. s, 3H; OCH3), 3.70 (br. s, 3H; 
OCH3), 2.32 (s, 3H; CH3); 
13C NMR (125 MHz, CDCl3, 25°C, TMS) δ 158.8, 142.4, 
137.3, 129.0, 128.6, 127.0, 113.7, 113.6, 55.2, 55.1, 45.8, 21.4; UV/Vis: λmax 275, 283 
nm; HRMS (m/z): [M+Na]+ calcd. for C23H26N2NaO4S, 449.1505; found, 449.1503. 
Elemental analysis found (calcd. for C23H26N2O4S): C 64.46 (64.77), H 6.10 (6.14), N 
6.60 (6.57).  
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3.2.3 Synthesis of osmium sulfonamide complexes 1-10 
  
(R,R)-1 (S,S)-1 
[OsCl2(η6-p-cymene)(TsDPEN)] (1).23 Either (1R,2R)-(H)TsDPEN or (1S,2S)-
(H)TsDPEN (50 mg, 0.14 mmol) and [Os(η6-p-cymene)Cl2]2 (50 mg, 0.06 mmol) in 
dichloromethane (5 mL) were placed in a CEM Discovery-SP microwave reactor (393 
K, 10 min, 150 W, 250 psi). The product was precipitated with hexane yielding a 
yellow solid (88 mg, 0.12 mmol, 89%). 1H NMR (400 MHz, CDCl3, 25°C, TMS) 
δ=7.41 (d, 3J(H,H)=7.9 Hz, 2H, ArH), 7.17-7.22 (m, 2H, ArH), 7.04-7.08 (m, 2H, 
ArH), 6.89-6.96 (m, 3H, ArH), 6.81-6.86 (m, 3H, ArH), 6.64 (d, 3J(H,H)=7.6, 2H, 
ArH), 6.38 (d, 3J(H,H)=8.3 Hz, H, TsNH), 5.60 (d, 3J(H,H)=5.3 Hz, 1H, ArH), 5.32-
5.37 (m, 2H, ArH), 5.23 (d, 3J(H,H)=5.3 Hz, 1H, ArH), 5.20 (d, 3J(H,H)=11.6 Hz, 1H, 
NH2), 4.50-4.58 (m, 1H, CHNH2), 4.43-4.50 (m, 1H, CHNHTs), 4.20 (t, 
3J(H,H)=10.7 
Hz, 2H, NH2), 2.59 (sept., 
3J(H,H)=6.9 Hz, 1H, CH(CH3)2), 2.20 (s, 3H, CH3), 2.02 
(s, 3H, CH3), 1.13 (d, 
3J(H,H)=6.9 Hz, 3H, CH(CH3)2), 1.08 (d, 
3J(H,H)=6.9 Hz, 3H, 
CH(CH3)2); 
13C NMR (100 MHz, CDCl3, 25°C, TMS) δ 129.3, 128.9, 128.2, 127.7, 
127.4, 127.2, 72.6, 71.5, 70.9, 70.8, 65.1, 63.8, 31.0, 22.6, 22.4, 21.4, 18.7; UV/Vis: 
λmax 264 and 337 nm; νmax 2593 and 3078 cm-1; HRMS (m/z): [M-H]- calcd. for 
C31H35Cl2N2O2OsS, 761.1406; found, 761.1347. Elemental analysis for (R,R)-1: 
found (calcd. C31H36Cl2N2O2OsS): C 48.72 (48.87), H 4.73 (4.76), N 3.76 (3.68); 
Elemental analysis for (S,S)-1: found (calcd. C31H36Cl2N2O2OsS): C 48.78 (48.87), H 
4.75 (4.76), N 3.74 (3.68).  
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(R,R)-2 (S,S)-2 
 
[Os(η6-p-cymene)(TsDPEN)] (2).23 Osmium p-cymene-chlorido dimer (51.4 mg, 
0.065 mmol) and either (1R,2R)- or (1S,2S)-(H)TsDPEN (51.3 mg, 0.14 mmol) were 
stirred in chloroform (5 ml) in the presence of  potassium hydroxide (56.1 mg, 1 
mmol). A colour change from yellow to red was observed in < 1 min. After 5 min, 
deionized water (5 ml) was added with stirring for a further 10 min. The organic layer 
was concentrated in vacuo to yield a red solid, which was recrystallized from 
dichloromethane / hexane (68 mg, 0.10 mmol, 75%). 1H NMR (400 MHz, CDCl3, 
25°C, TMS): δ = 7.41 (d, 3J(H,H)=7.6 Hz, 2H, ArH), 7.05-7.20 (m, 10H, ArH), 6.82 
(d, 3J(H,H)=8.0 Hz, 2H, ArH), 6.80 (br s, 1H, NH), 5.79 (d, 3J(H,H)=5.6 Hz, 1H, Os-
ArH), 5.62 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 5.52 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 
5.42 (d, 3J(H,H)=5.6 Hz, 1H, Os-ArH), 4.42 (s, 1H, CHNH2), 3.94 (d, 
3J(H,H)=4.3 
Hz, 1H, TsNCH), 2.45 (sept, 3J(H,H)=6.9 Hz, 1H, CH(CH3)2), 2.23 (s, 3H, CH3), 2.22 
(s, 3H, CH3), 1.23 (d, 
3J(H,H)=6.9 Hz, 3H, CH(CH3)2), 1.17 (d, 
3J(H,H)=6.9 Hz, 3H, 
CH(CH3)2); 
13C NMR (100 MHz, CDCl3, 25°C, TMS) δ = 127.4, 127.0, 126.8, 126.0, 
125.9, 125.9, 125.4, 81.7, 76.2, 72.4, 70.7, 70.0, 66.2, 22.5, 22.4, 20.2; UV/Vis: λmax 
260, 410 and 478 nm; HRMS (ESI): m/z calculated for C31H35N2O2OsS [M+H
+]: 
691.2028. Found: 691.2031. Elemental analysis for (R,R)-2: found (calcd. 
C31H34N2O2OsS): C 53.66 (54.05), H 4.88 (4.97), 3.95 (4.07); Elemental analysis for 
(S,S)-2: found (calcd. for C31H34N2O2OsS): C 53.71 (54.05), H 4.84 (4.97), N 4.00 
(4.07). 
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(R,R)-3 (S,S)-3 
 
[Os(η6-p-cymene)(MsDPEN)] (3). The complex was synthesised following the 
method described for complex 2. Either (1R,2R)- or (1S,2S)-(H)MsDPEN (41 mg, 0.14 
mmol) was reacted with osmium p-cymene-chlorido dimer (51.4 mg, 0.065 mmol) in 
the presence of potassium hydroxide (56.1 mg, 1 mmol) in chloroform and water. The 
product was isolated as an orange amorphous solid which was recrystallized from 
dichloromethane / hexane. (54 mg, 0.087 mmol, 67%). 1H NMR (500 MHz, CDCl3, 
25°C, TMS): δ = 7.45 (d, 3J(H,H) = 7.3 Hz, 2H, ArH), 7.00-7.40 (m, 9H, ArH), 5.87 
(d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.79 (d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.75 (d, 
3J(H,H) = 5.7 Hz, 1H, Os-ArH), 5.72 (d, 3J(H,H) = 5.7 Hz, 1H, Os-ArH), 4.34 (s, 1H, 
TsNCH), 3.99 (d, 3J(H,H) = 2.8 Hz, 1H, CH), 2.68 (sept, 3J(H,H) = 6.9 Hz, 1H, 
CH(CH3)2), 2.49 (s, 3H, CH3), 2.37 (s, 3H, CH3), 1.36 (d, 
3J(H,H) = 6.9 Hz, 6H, 
CH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ = 128.3, 128.0, 127.4, 127.1, 126.9, 126.4, 
83.0, 75.9, 72.6, 72.5, 70.3, 68.5, 40.3, 32.9, 23.7, 23.5, 21.0. UV/Vis: λmax 409 and 
475 nm; HRMS (ESI): m/z calculated for C25H31N2O2OsS [M+H
+]: 615.1714. Found: 
615.1710. Elemental analysis for (R,R)-3: found (calcd. for C25H30N2O2OsS): C 49.06 
(49.00), H 4.92 (4.93), N 4.66 (4.57); Elemental analysis for (S,S)-3: found (calcd. for 
C25H30N2O2OsS): C 48.72 (49.00), H 4.80 (4.93), N 4.62 (4.57). 
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(R,R)-4 (S,S)-4 
 
[Os(η6-p-cymene)(NsDPEN)] (4). The complex was synthesised following the 
method described for complex 2. Either (1R,2R)- or (1S,2S)-(H)NsDPEN (56 mg, 0.14 
mmol) was reacted with osmium p-cymene-chlorido dimer (51.4 mg, 0.065 mmol) in 
the presence of potassium hydroxide (56.1 mg, 1 mmol) in chloroform and water. The 
product was isolated as an dark red amorphous solid which was recrystallized from 
dichloromethane / hexane. (57 mg, 0.079 mmol, 70%). 1H NMR (500 MHz, CDCl3, 
25°C, TMS): δ = 7.86 (d, 3J(H,H) = 8.9 Hz, 2H, ArH), 7.45 (d, 3J(H,H) = 8.9 Hz, 2H, 
ArH), 7.00-7.25 (m, 11H, ArH), 5.95 (d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.80 (d, 
3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.74 (d, 3J(H,H) = 5.5 Hz, 1H, Os-ArH), 5.68 (d, 
3J(H,H) = 5.5 Hz, 1H, Os-ArH), 4.37 (s, 1H, TsNCH), 4.02 (d, 3J(H,H) = 4.2 Hz, 1H, 
CH), 2.61 (sept, 3J(H,H) = 6.9 Hz, 1H, CH(CH3)2), 2.39 (s, 3H, CH3), 1.35 (d, 
3J(H,H) 
= 6.9 Hz, 3H, CH(CH3)2), 1.28 (d, 
3J(H,H) = 6.9 Hz, 3H, CH(CH3)2). 
13C NMR (125 
MHz, CDCl3): δ = 128.1, 127.9, 127.4, 127.3, 126.9, 126.8, 126.3, 126.2, 123.1, 82.5, 
73.3, 72.0, 71.1, 67.4, 32.9, 24.1, 23.5, 21.0; UV/Vis: λmax 263 and 409 nm; HRMS 
(ESI): m/z calculated for C30H32N3O4OsS [M+H
+]: 722.1722. Found: 722.1716. 
Elemental analysis for (R,R)-4: found (calcd. for C30H31N3O4OsS): C 49.69 (50.05), 
H 4.47 (4.34), N 5.58 (5.84); Elemental analysis for (S,S)-4: found (calcd. for 
C30H31N3O4OsS): C 50.02 (50.05), H 4.22 (4.37), N 5.79 (5.84). 
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(R,R)-5 (S,S)-5 
 
[Os(η6-p-cymene)(FbDPEN)] (5). This complex was synthesised as reported 
previously. Following the method described for complex 2, (1R,2R)- or (1S,2S)-
(H)FbDPEN (52 mg, 0.14 mmol) was reacted with osmium p-cymene-chlorido dimer 
(51.4 mg, 0.065 mmol) in the presence of potassium hydroxide (56.1 mg, 1 mmol) in 
chloroform and water. The product was isolated as an orange amorphous solid which 
was recrystallized from dichloromethane / hexane. (50 mg, 0.072 mmol, 52%). 1H 
NMR (500 MHz, CDCl3, 25°C, TMS): δ = 7.46 (d, 3J(H,H) = 7.5Hz, 2H, ArH), 7.29-
7.34 (m, 2H, ArH), 6.90-7.26 (m, 9H, ArH), 6.75 (m, 2H, ArH), 5.90 (d, 3J(H,H) = 
5.6 Hz, 1H, Os-ArH), 5.73 (d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.64 (d, 3J(H,H) = 5.6 
Hz, 1H, Os-ArH), 5.55 (d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 4.47 (s, 1H, TsNCH), 4.03 
(d, 3J(H,H) = 3.6 Hz, 1H, CH), 2.55 (sept, 3J(H,H) = 6.9 Hz, 1H, CH(CH3)2), 2.32 (s, 
3H, CH3), 1.32 (d, 
3J(H,H) = 6.9 Hz, 3H, CH(CH3)2), 1.25 (d, 
3J(H,H) = 6.9 Hz, 3H, 
CH(CH3)2). 
13C NMR (125 MHz, CDCl3): δ = 129.2, 129.1, 128.1, 127.9, 127.2, 
126.9, 126.6, 126.4, 114.8, 114.6, 82.6, 76.6, 73.5, 72.0, 71.0, 67.3, 32.8, 23.6, 23.4, 
21.0. UV/Vis: λmax 408 and 474 nm; HRMS (ESI): m/z calculated for 
C30H32FN2O2OsS [M+H
+]: 695.1777. Found: 695.1780. Elemental analysis for (R,R)-
5: found (calcd. for C30H31FN2O2OsS): C 51.85 (52.00), H 4.46 (4.51), N 4.09 (4.04); 
Elemental analysis for (S,S)-5: found (calcd. for C30H31FN2O2OsS): C 51.70 (52.00), 
H 4.43 (4.51), N 4.04 (4.04). 
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(R,R)-6 (S,S)-6 
 
[Os(η6-p-cymene)(BsDPEN)] (6). This complex was synthesised as reported 
previously. Following the method described for complex 2, (1R,2R)- or (1S,2S)-
(H)BsDPEN (49 mg, 0.14 mmol) was reacted with osmium p-cymene-chlorido dimer 
(51.4 mg, 0.065 mmol) in the presence of potassium hydroxide (56.1 mg, 1 mmol) in 
chloroform and water. The product was isolated as an orange amorphous solid which 
was recrystallized from dichloromethane / hexane. (44 mg, 0.065 mmol, 46%). 1H 
NMR (500 MHz, CDCl3, 25°C, TMS): δ = 7.48 (d, 3J(H,H) = 7.5 Hz, 2H, ArH), 7.36 
(m, 2H, ArH), 6.90-7.30 (m, 12H, ArH), 5.87 (d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.70 
(d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.60 (d, 3J(H,H) = 5.6 Hz, 1H, Os-ArH), 5.48 (d, 
3J(H,H) = 5.6 Hz, 1H, Os-ArH), 4.55 (s, 1H, TsNCH), 4.05 (d, 3J(H,H) = 4.0 Hz, 1H, 
CH) 2.50 (sept, 3J(H,H) = 6.9 Hz, 1H, CH(CH3)2), 2.27 (s, 3H, CH3), 1.30 (d, 
3J(H,H) 
= 6.9 Hz, 3H, CH(CH3)2), 1.22 (d, 
3J(H,H) = 6.9 Hz, 3H, CH(CH3)2). 
13C NMR (125 
MHz, CDCl3): δ = 130.4, 128.1, 127.8, 127.2, 126.9, 126.5, 82.8, 73.6, 71.9, 70.9, 
67.3, 32.7, 23.6, 23.4, 20.6. UV/Vis: λmax 259, 409 and 475 nm; HRMS (ESI): m/z 
calculated for C30H33N2O2OsS [M+H
+]: 677.1871. Found: 677.1876. Elemental 
analysis for (R,R)-6: found (calcd. for C30H32N2O2OsS): C 53.63 (53.39), H 4.72 
(4.78), N 4.14 (4.15); Elemental analysis for (S,S)-6: found (calcd. for 
C30H32N2O2OsS): C 53.46 (53.39), H 4.75 (4.78), N 4.16 (4.15). 
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(R,R)-7 (S,S)-7 
[Os(η6-biphenyl)(TsDPEN)] (7). Osmium biphenyl dimer [Os(η6-biphenyl)Cl2]2 (67 
mg, 0.081 mmol) and (1R,2R)- or (1S,2S)-TsDPEN (55 mg, 0.15 mmol) were stirred 
in dichloromethane (2.5 mL) in a microwave vial, then placed in a CEM Discovery-
SP microwave reactor for 10 min (393K, 150 W, 250 psi). The yellow-orange solution 
was filtered to remove any remaining osmium dimer, and the resulting solution was 
combined with freshly ground potassium hydroxide (56.1 mg, 1 mmol). Vigorous 
stirring was continued for 30 min until a color change from yellow to red was 
observed. Water (5 mL) was then added with stirring for a further 15 min. The aqueous 
layer was extracted with dichloromethane (3 x 5 mL) and concentrated in vacuo to 
yield a red amorphous solid which was recrystallized from dichloromethane / hexane 
(62 mg, 0.09 mmol, 59%). 1H NMR (500 MHz, CDCl3, 25°C, TMS): δ = 7.50-6.85 
(m, 19H, ArH), 6.25-5.95 (m, 4H, Os-ArH), 4.45 (s, 1H, CH), 3.95 (d, 3J(H,H) = 3.8 
Hz, 1H, CHNH), 2.30 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3): δ = 146.3, 144.1, 
141.2, 140.8, 137.7, 129.2, 128.9, 128.6, 128.2, 128.0, 127.2, 127.0, 126.9, 126.6, 
126.5, 83.3, 73.7, 73.3, 73.1, 70.9, 70.5, 68.3, 21.4. UV/Vis: λmax 358, 416 and 486 
nm; HRMS (ESI): m/z calculated for C33H31N2O2OsS [M+H
+]: 711.1715. Found: 
711.1712. Elemental analysis for (R,R)-7: found (calcd. for C33H30N2O2OsS): C 55.62 
(55.91), H 4.11 (4.27), N 3.88 (3.95); Elemental analysis for (S,S)-7: found (calcd. for 
C33H30N2O2OsS): C 55.60 (55.91), H 4.08 (4.27), N 4.00 (3.95). 
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(R,R)-8 (S,S)-8 
 
[Os(η6-m-terp)(TsDPEN)] (8). Osmium m-terphenyl dimer [Os(η6-m-terphenyl)Cl2]2 
(40 mg, 0.04 mmol) and (1R,2R)- or (1S,2S)-TsDPEN (55 mg, 0.15 mmol) were stirred 
in dichloromethane (2.5 mL) in a microwave vial, then placed in a CEM Discovery-
SP microwave reactor for 10 min (393K, 150 W, 250 psi). The resulting solution was 
combined with freshly ground potassium hydroxide (56.1 mg, 1 mmol). Vigorous 
stirring was continued for 30 min until a color change from yellow to red was 
observed. Water was added with stirring for a further 15 min. The aqueous layer was 
extracted with dichloromethane (3 x 5 mL) and concentrated in vacuo to yield an 
orange amorphous solid which was recrystallized from dichloromethane / hexane (28 
mg, 0.036 mmol, 43%). 1H NMR (400 MHz, CDCl3, 25°C, TMS): δ = 7.80-7.74 (m, 
2H, ArH), 7.57-7.51 (m, 2H, ArH), 7.45-7.36 (m, 6H, ArH), 7.33-7.28 (m, 2H, ArH), 
7.19-7.03 (m, 8H, ArH), 7.00-6.94 (m, 2H, ArH), 6.89 (br. d, 1H, NH), 6.80-6.75 (m, 
2H, ArH), 6.70 (d, 3J(H,H) = 5.7 Hz, 1H, ArH), 6.60 (s, 1H, ArH), 6.46 (d, 3J(H,H) = 
5.5 Hz, 1H, ArH), 6.30 (t, 3J(H,H) = 5.7 Hz, 1H, ArH), 4.41 (s, 1H, CHNTs), 3.84 (d, 
3J(H,H) = 4.3 Hz, 1H, CHNH), 2.28 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3): δ = 
129.2, 129.0, 128.8, 128.7, 128.6, 128.4, 128.3, 128.0, 127.8, 127.3, 126.9, 126.7, 
126.3, 83.2, 74.6, 73.9, 68.9, 66.7. UV/Vis: λmax 419 and 490 nm; HRMS (ESI): m/z 
calculated for C39H35N2O2OsS [M+H
+]:  787.2029. Found: 787.2033. 
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(R,R)-9 (S,S)-9 
 
[Os(η6-p-cymene)(TsBMEN)] (9). Complex 9 was synthesised by Miss. Yasmin 
Khanom. Following the method described for 2, osmium p-cymene-chlorido dimer 
(44.1 mg, 0.056 mmol) was reacted with (1R,2R)- or (1S,2S)-(H)TsBMEN (50.0 mg, 
0.17 mmol). After concentration in vacuo, the red oil was precipitated with hexane 
yielding an orange solid, then recrystallized from dichloromethane / hexane (9.0 mg, 
0.01 mmol, 21%). 1H NMR (500 MHz, CDCl3, 25°C, TMS): δ=7.37 (d, 3J(H,H) = 8.4 
Hz, 2H, ArH), 7.26 (d, 3J(H,H) = 7.7 Hz, 2H, ArH), 7.03 (d, 3J(H,H) = 8.4 Hz, 2H, 
ArH), 6.93 (d, 3J(H,H) = 7.7 Hz, 2H, ArH), 6.77 (d, 3J(H,H) = 8.4 Hz, 2H, ArH), 6.70 
(d, 3J(H,H) = 8.4 Hz, 2H, ArH), 6.61-6.42 (m, 1H, NH), 5.83 (d, 3J(H,H) = 5.4 Hz, 
1H, ArH), 5.65 (d, 3J(H,H) = 5.4 Hz, 1H, ArH), 5.60 (d, 3J(H,H) = 5.4 Hz, 1H, ArH), 
5.49 (d, 3J(H,H) = 5.4 Hz, 1H, ArH), 4.37 (s, 1H; NHCH), 3.91 (d, 3J(H,H) = 3.6 Hz, 
1H, TsNCH), 3.80 (s, 3H; OCH3), 3.78 (s, 3H; OCH3), 2.51(sept, 1H; CH), 2.32 (br. 
s, 3H; CH3), 2.30 (br. s, 3H; CH3), 1.29 (d, 
3J(H,H) = 6.8 Hz, 3H, CH3), 1.24 (d, 
3J(H,H) = 6.8 Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3, 25°C, TMS) δ 141.5, 140.6, 
138.7, 136.7, 128.4, 128.0, 127.4, 126.9, 113.2, 91.0, 82.0, 82.4, 80.2, 72.7, 71.6, 70.8, 
67.2, 55.3, 32.7, 23.5, 21.3, 20.7; UV/Vis: λmax 275, 410, 477 nm; HRMS (m/z): 
[M+H]+ calcd. for C33H39N2O4OsS, 751.2240; found, 751.2243. Elemental analysis 
for (R,R)-9: found (calcd. for C33H38N2O4OsS): C 53.39 (52.92), H 5.12 (5.11), N 3.89 
(3.74).  
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(R,R)-10 (S,S)-10 
 
[Os(η6-biphenyl)(TsBMEN)] (10). Complex 10 was synthesised and characterised 
by Miss. Yasmin Khanom. Following the method described for 2, osmium p-cymene-
chlorido dimer (48.1 mg, 0.058 mmol) was reacted with either (1R,2R)- or (1S,2S)-
(H)TsBMEN (50 mg, 0.17 mmol). The purple oil was precipitated with hexane 
yielding an amorphous purple solid, which was recrystallized from dichloromethane / 
hexane (22 mg, 0.03 mmol, 50%). 1H NMR (500 MHz, CDCl3, 25°C, TMS): δ=7.40-
7.49 (m, 2H, ArH), 7.28-7.35 (m, 3H, ArH), 7.24 (m, 1H, ArH), 7.19 (m, 1H, ArH), 
7.17 (d, 3J(H,H) = 8.1 Hz, 2H, ArH), 7.05 (br. s, 1H, NH), 6.86 (d, 3J(H,H) = 8.3 Hz, 
2H, ArH), 6.81 (d, 3J(H,H) = 7.8 Hz, 2H, ArH), 6.63 (d, 3J(H,H) = 8.3 Hz, 2H, ArH), 
6.60 (d, 3J(H,H) = 8.3 Hz, 2H, ArH), 6.18 (d, 3J(H,H) = 5.3 Hz, 1H, ArH), 6.12 (d, 
3J(H,H) = 5.3 Hz, 1H, ArH), 6.08 (d, 3J(H,H) = 5.3 Hz, 1H, ArH), 5.97 (d, 3J(H,H) = 
5.3 Hz, 1H, ArH), 5.91 (d, 3J(H,H) = 5.3 Hz, 1H, ArH), 4.25 (s, 1H, CH), 3.75 (d, 
3J(H,H) = 3.8 Hz, 1H, CH), 3.71 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 2.24 (s, 3H, CH3); 
13C NMR (125 MHz, CDCl3, 25°C, TMS) δ 157.8, 157.2, 140.1, 139.6, 137.4, 136.6, 
135.0, 128.0, 127.7, 127.4, 126.9, 126.4, 112.3, 81.8, 71.9, 69.7, 69.5, 67.2, 54.3, 20.3; 
UV/Vis: λmax 275, 415, 486 nm; HRMS (m/z): [M+Na]+ calcd. for C35H34NaN2O4OsS, 
771.1929; found, 771.1920. Elemental analysis for (R,R)-10: found (calcd. for 
C35H34N2O4OsS): C 54.67 (54.67), H 4.74 (4.46), N 3.89 (3.64). 
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Os-H hydride formation.23 (R,R)-1 was titrated with triethylamine (4.0 mol equiv.) 
and formic acid (2 µL), allowing the observation of osmium hydride resonances. 1H-
NMR (600 MHz, C6D6, 298 K) δ = -5.89 (s, 1H; Os-H), -6.04 (s, 1H; Os-H). 
 
3.2.4 X-ray crystallography 
Single crystals of (R,R)-2, and (R,R)-7·2CHCl3 were grown from CHCl3 / hexane. 
Crystallographic data were acquired and processed by Dr. Guy Clarkson (University 
of Warwick) as described in Chapter 2 (section 2.2.7).24, 25 
 
3.2.5 Catalytic reactions 
Studies were carried out with kind assistance from Dr. Roy Hodgkinson and Dr. Ivan 
Prokes (University of Warwick, UK). Transfer hydrogenation reactions using 
complexes 9 and 10 were carried out by Miss. Yasmin Khanom (University of 
Warwick, UK).  
 
Racemic reduction of ketones with NaBH4.23 To an ice-cold solution of sodium 
borohydride (100 mg, 2.53 mmol, 2 mol equiv of H-) in ethanol (1.5 mL) was added a 
prochiral ketone (5.14 mmol) dropwise under an atmosphere of nitrogen over 1 h, then 
allowed to warm to ambient temperature overnight. A white solid was precipitated by 
addition of HCl (3 M, 0.5 mL) which was extracted with diethyl ether (5 mL) and 
washed with water (5 mL). The organic layer was separated, dried over magnesium 
sulphate, and concentrated in vacuo yielding a colourless liquid. The product was 
characterised by ESI-MS and 1H-NMR, and data obtained matched those previously 
reported. 
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Asymmetric reduction of ketones (S/C = 200).23 5:2 v/v formic acid / triethylamine 
azeotrope (500 µL) was added to a nitrogen-purged flask containing the catalyst (5 
µmol, 1 mol equiv). A prochiral ketone was injected (1 mmol, 200 mol equiv) and 
stirred for 24 h. Aliquots of reaction solution were placed into 1 mL EtOAc and 1 mL 
NaHCO3 and filtered through a plug of silica. Conversion and ee were analysed by 
GC-FID (Chrompac cyclodextrin-β-236M-19, 50 m x 0.25 mm x 0.25 μm, P = 15 psi, 
gas H2; temperature varied for substrates) using Clarity Chromatography Suite.  
 
Transfer hydrogenation kinetics. Catalyst 2-11 (5 µmol, 1 mol equiv) was dissolved 
in d6-benzene (100 µL) and formic acid / triethylamine azeotrope (5:2, 500 µL) under 
a nitrogen atmosphere for 30 min (310 K). Acetophenone (1 mmol, 200 mol equiv) 
was injected and the mixture transferred to an NMR tube. Final solution 
concentrations: substrate 1.67 M; Os catalyst 8.33 mmol. Spectra were recorded in 
triplicate every 73 s at 310.0 ± 0.5 K for 1 h using a Bruker AV-400 spectrometer 
(Figure 3.3). Data processing is described in Chapter 2 (section 2.3.1). 
 
 
 
t = 90 min 
 
 
 
t = 60 min 
 
 
 
t = 30 min 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Reduction of acetophenone using (R,R)-2 in formic acid / triethylamine, forming 1-
phenylethanol (1H, quartet, 4.77 ppm) observed by time-dependent 1H-NMR (400 MHz, 310 K, C6D6). 
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3.2.6 Density Functional Theory (DFT) calculations 
Density functional theory (DFT) calculations were carried out using Gaussian 03W26 
with assistance from Dr. Adam Millett and Robbin Vernooij (University of 
Warwick).27 
Gas phase geometry optimization was carried out using the hybrid Perdew-Burke-
Ernzerhof functional (PBE0)28 which is a combination of DFT (75%) and Hartree-
Fock (25%) methods. The Lanl2DZ basis set including effective core potential was 
used for Os and 6-31+G** basis set for all other atoms.29, 30 The calculations 
converged to optimized geometries by allowing all parameters to relax and they 
correspond to true energy minima, as revealed by the lack of imaginary values in the 
vibrational mode calculations. Structures were optimized using the x–ray 
crystallographic data as a starting guess and modifications made accordingly using 
GaussView 3.0.31 Electrostatic potential surfaces (EPS) were mapped onto total 
electron density (isovalue = 0.04), represented with a colour scale from red (-0.025 
au) to blue (0.250 au).  
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3.3 Results 
 
3.3.1 Synthesis and characterisation of novel osmium(II) catalysts 
The low-temperature reaction of a sulfonyl chloride with a chiral diamine, either (R,R) 
or (S,S)-configured, successfully yielded the mono-substituted sulfonamides (Figure 
3.4a), which were readily recrystallized from toluene. Noyori-type ruthenium chlorido 
complexes are readily prepared by combining a metal-arene dimer [RuCl2(ƞ6-arene)]2 
and chiral sulfonamide in 2-propanol with triethylamine,1 however the poor solubility 
of osmium-arene dimers in isopropanol meant that an alternative strategy was 
required.23 We looked to previous methods used to isolate the active Ru catalyst, using 
a biphasic reaction with dichloromethane and water.7  
    
 
 
 
Figure 3.4. (a) General synthesis of sulfonamide ligands from the corresponding sulfonyl chloride, 
shown for (R,R)-diamine; (b) Synthesis of osmium 16-electron catalyst 2 via complex 1, which was 
isolated and fully characterised. Scheme (b) applies for the synthesis of complexes 7-8, and 10;23 (c) 
One-step synthesis of Os complex 2. Scheme (c) applies for the synthesis of complexes 2-6, and 9. 
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Without addition of base, pale yellow 18-electron di-chlorido complexes were 
obtained (e.g. complex 1, Figure 3.4b) which were readily synthesised using a 
microwave reactor. Upon treatment of 1 with a base, a red 16-electon amido complex 
2 was obtained. analogous to the active ruthenium catalyst.7, 23  Alternatively, direct 
reaction of the osmium p-cymene dimer with either enantiomer of the sulfonamide 
and a base at room temperature provided a one-step alternative synthetic strategy to 
obtain catalysts 2-6 and 9 (Figure 3.4c).23 The poor solubility of the osmium biphenyl 
and terphenyl dimers in dichloromethane at room temperature meant that direct 
isolation of 7, 8 or 10 at room temperature was not possible, so these complexes were 
synthesised by method (b). In each case, both enantiomers of the 16-electron osmium 
complexes (2-10) were individually synthesised by reacting the osmium dimer with 
either an (R,R) or (S,S)-ligand to obtain enantiomerically-pure complexes. 
Treatment of (R,R)-1 with triethylamine and formic acid allowed for observation of 
osmium hydride complex [OsH(p-cymene)(TsDPEN)] by 1H-NMR. The hydride was 
detected as two singlets, δ = -5.89 ppm and -6.04 ppm, suggesting formation of two 
diastereomers, with 187Os satellites (1J(187Os,1H) = 44 Hz). The ratio between the 
singlets changed over 30 min, from 3:1 (left), to 1.2:1 (right) shown in Figure 3.5.23 
 
0 min 
 
30 min 
 
Figure 3.5. 1H-NMR spectrum (600 MHz, C6D6, 298 K) of (R,R)-1 treated with formic acid / 
triethylamine showing the peaks for Os-H species with 187Os satellites (1.96% abundance).23 
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3.3.2 X-ray crystallography 
 
 
 
 
Figure 3.6. ORTEP diagrams of p-cymene complex (R,R)-2 (above) and biphenyl complex (R,R)-7 
(below). Thermal ellipsoids shown at 50% probability level, coloured and labelled by element. See 
appendix Tables A1-A2 for Cartesian atom coordinates.23  
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Table 3.2. X-ray crystallographic data for p-cymene (R,R)-2 and biphenyl (R,R)-7 complexes.23 
 (R,R)-2 (R,R)-7 • 2CHCl3 
Crystal character red block red rod 
Empirical formula C31H34N2O2OsS C33H30N2O2OsS • 2CHCl3 
MW / gmol-1 688.86 947.59 
Temperature / K 150(2) 150(2) 
Crystal system orthorhombic orthorhombic 
Space group P212121 P212121 
a (Å) 10.6100(3) 7.95564(14) 
b (Å) 13.8464(3) 16.3879(3) 
c (Å) 18.9830(5) 26.8668(5) 
α / ° 90 90 
β / ° 90 90 
γ / ° 90 90 
Volume / Å3 2788.79(11) 3502.80(11) 
Z 4 4 
µ / mm-1 4.678 mm-1 4.194 
F (000) 1368.0 1864.0 
Crystal size / mm3 0.16 × 0.10 × 0.10 0.35 × 0.01 × 0.01 
Reflections measured 33345 49980 
Independent reflections 8053 10869 
R1 [I>2σ(I)] 0.0333 0.0333 
wR2 0.0927 0.0574 
ρcalc / gcm-3 1.641 1.797 
Radiation Mo Kα (λ = 0.71073) Mo Kα (λ = 0.71073) 
Flack parameter -0.023(5) -0.012(4) 
2Θ range for collection / ° 4.836 to 61.698 5.2 to 63.1 
Goodness-of-fit on F2 1.162 1.020 
CCDC number 1035611 1507733 
 
Single crystals of both enantiomers of 2 and 7 suitable for x-ray diffraction were 
obtained from a saturated solution of the complex in dichloromethane with addition 
of n-hexane at 253 K (see appendix Tables A1-A2 for Cartesian atom coordinates). 
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3.3.3 Storage stability of osmium sulfonamide complexes 
Storage of the solid catalyst in atmospheric air at 298 K was studied by 1H-NMR (400 
MHz, CDCl3). No evidence of ligand release was identified after three months.
23 After 
twelve months, the formation of a new septet (2.87 ppm) was apparent, corresponding 
to release of p-cymene (Figure 3.7). 
0 months 
 
3 months 
 
12 months 
 
Figure 3.7. 1H-NMR (400 MHz, CDCl3, TMS, 298 K) of complex (S,S)-2 stored under ambient 
conditions (298 K, atmospheric air): (a) day of synthesis; (b) three months; (c) twelve months. ● p-
cymene ArCH(CH3)2 (coordinated ligand); ▲ p-cymene ArCH(CH3)2 (uncoordinated ligand). 
● ▲ 
● 
● 
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3.3.4 Solution stability of osmium sulfonamide complexes 
Aqueous stabilities were investigated in phosphate-buffered saline by UV-visible 
spectroscopy over a 24 h period at 310 K. Though previous studies use water/methanol 
solutions to probe the aqueous chemistry of half-sandwich piano stool compounds,32 
the possibility of methanol acting as a hydride donor (becoming itself reduced to 
formaldehyde) means that an alternative solubilising agent was required. In 
accordance with biological experiments carried out later in this thesis, 
dimethylsulfoxide (DMSO, 5 % v/v) was used. All osmium complexes displayed 
surprisingly high stability in phosphate buffered saline (137 mM NaCl, 5 % DMSO, 
310 K) with no change observed in the absorbance profile (Figure 3.8 – representative 
example for parent osmium tosyl complex 2). Though solubility in PBS was poor, 
arene extension in complexes 7-8 did not affect the aqueous stability. Similarly, 
neither sulfonamide variation in complexes 3-6, nor methoxy substitution to the 
phenyl groups at the chiral centres in complexes 9-10, affected stability in phosphate-
buffered saline (137 mM NaCl, 5 % DMSO, 310 K) 
 
Figure 3.8. Representative example (complex (S,S)-2) of UV-visible spectroscopy stability study in 
phosphate-buffered saline containing 5% v/v DMSO (24 h, 310 K) recorded every 1 h. 
0.00
0.02
0.04
0.06
250 350 450
A
b
s
o
rb
a
n
c
e
wavelength / nm
Chapter 3. Asymmetric catalytic osmium sulfonamide complexes 
85 
Though dimethylsulfoxide (DMSO) is commonly used to aid dissolution of 
hydrophobic complexes in aqueous solution, DMSO can act as a ligand, either through 
sulphur or oxygen coordination, and so it is important to investigate whether any 
interaction between the complex and solvent occurs. This was examined using 1H-
NMR spectroscopy over a 24 h period (Figure 3.9), after incubation at 310 K. The 
spectra were unchanged for all complexes after 24 h, suggesting that the osmium 
complexes are either highly stable in DMSO and do not form solvent adducts, or 
adducts form very fast quickly. 
t = 0 h 
 
t = 24 h 
 
 
Figure 3.9. 1H-NMR spectroscopy stability study in d6-DMSO (24 h, 310 K). Representative example 
shown for complex (S,S)-2. 
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The active catalysts are rapidly synthesised using a biphasic solvent system of 
dichloromethane (containing the metal arene dimer and ligand) and water (containing 
a base, typically potassium hydroxide), Figure 3.4. An inert atmosphere was not 
necessary during synthesis. Controlled deprotonation of intermediate 1 can occur, the 
organic layer isolated (base removed with aqueous extractions), and the compound 
slowly precipitated from dichloromethane on addition of a suitable hydrocarbon 
solvent (n-hexane) to yield 2 as a red solid.23 Substitution of the sulfonamide, arene 
and phenyl groups at the chiral centres was not found to affect the stability of the active 
16-electron catalyst, and so an analogous method may be utilised to obtain complexes 
3-10, using the corresponding diamine ligand and osmium arene chlorido dimer. 
The active 16-electron osmium complexes proved highly stable under storage in both 
atmospheric air and aqueous solution. The aqueous reactivity of Os(II) complexes has 
previously been shown to be highly dependent on the chelating ligand(s), as while the 
rate of hydrolysis of [Os(arene)(acac)Cl] was too fast to observe by NMR (298 K), the 
hydrolysis of [Os(arene)Cl(ethylenediamine)]+ is ca. 40× slower than the isoelectronic 
ruthenium analogue.33 Third-row transition metal ions are typically more kinetically 
inert than second-row ions, which likely discouraged investigation of the osmium 
TsDPEN analogues. This work demonstrates that the osmium 16-electron catalysts are 
kinetically inert, and stable upon storage and in solution. 
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3.3.5 Asymmetric transfer hydrogenation 
Reduction of acetophenone, a widely used prochiral ATH substrate, was studied using 
formic acid as a hydride donor in the presence of a base (triethylamine), catalysed by 
complexes 1-11. Conversion and enantioselectivity were determined using chiral gas 
chromatography,23 and maximum turnover frequencies (TOFmax) were determined by 
1H-NMR (Table 3.4). All complexes achieved >92% conversion and higher TOFmax 
than Ru catalyst 11 under identical conditions.  
  
Table 3.4. Reduction of acetophenone using formic acid catalysed by 2-10 or Ru analogue 11.23  
 
  
Catalyst S/C [a] Temp. / K conv. [b] ee (%) [b] config. [b] TOF / h-1 [c] 
(R,R)-2 200 310 99 99 (R) 63.6 ± 0.6 
(S,S)-2 200 310 99 99 (S) 63.9 ± 0.3 
(S,S)-3 200 310 99 96 (S) 58 ± 2 
(S,S)-4 200 310 99 95 (S) 61 ± 2 
(S,S)-5 200 310 99 96 (S) 40 ± 2 
(S,S)-6 200 310 92 97 (S) 58 ± 1 
(R,R)-7 200 310 98 92 (R) 78.2 ± 0.4 
(S,S)-7 200 310 99 95 (S) 78 ± 1 
(S,S)-8 200 310 99 99 (S) 43 ± 2 
(R,R)-9 200 310 98 99 (R) 35 ± 1 
(R,R)-10 200 310 99 99 (R) 61.4 ± 0.6 
(S,S)-11 200 310 99 99 (S) 23 ± 1 
[a] Substrate / catalyst ratio. [b] Determined by chiral GC. [c] Maximum turnover frequency (initial linear reaction 
rate) determined by 1H-NMR. 
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Catalyst 1 was screened for the reduction of alpha- and para-substituted acetophenone 
derivatives (Table 3.5), for comparison with ruthenium complex 11. The osmium 
complexes maintained high enantioselectivity but conversion was decreased for 
reduction of propiophenone (Y = Et) and 4’-methoxyacetophenone (X = OMe).23 1 
and 2 were also investigated after 2 months storage in atmospheric conditions and 
retained high conversion and enantioselectivity (Table 3.6).23 
 
Table 3.5. Reduction of acetophenone-derived ketones by pre-catalyst 1, compared to the Noyori 
second-generation ruthenium(II) analogue, 11.23  
 
 
Ketone Catalyst S/C conv.[a] ee (%)[a] config.[a] 
 
(R,R)-1 100 99 98 (R) 
(S,S)-1 100 99 98 (S) 
(S,S)-11 200 99 99 (S) 
 
(R,R)-1 100 98 96 (R) 
(S,S)-1 100 97 94 (S) 
(S,S)-11 200 99 95 (S) 
 
(R,R)-1 100 67 N.D.[b] (R) 
(S,S)-1 100 70 99 (S) 
(S,S)-11 200 99 97 (S) 
 
(R,R)-1 100 97 94 (S) 
(S,S)-1 100 92 84 (R) 
(S,S)-11 1000 36[c] 91[c] (R) 
 
(R,R)-1 100 56 96 (R) 
(S,S)-1 100 54 95 (S) 
(S,S)-11 200 96 97 (S) 
[a] Determined by chiral GC. [b] e.e. undetermined for the reduction of α-chloroacetophenone (R2 = CH2Cl) due to 
poor separation of enantiomers. [c] Reduction of propiophenone (Y = Et) with RuII catalyst was conducted in 1.0 
M EtOAc with S/C = 1000  
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Table 3.6. Reduction of acetophenone by formic acid catalysed by Os (pre)catalysts 1 and 2. 
Conversion and enantiomeric excess remain high after several months of storage under ambient 
conditions.23 
 
 
Catalyst Storage S/C Temp. / K conv.[a] ee (%)[a] 
(R,R)-1 2 months 200 310 99 98 
(R,R)-2 2 months 200 310 95 98 
[a] Determined by chiral GC.  
 
 
3.3.6 Density Functional Theory (DFT)  
Density functional theory was used to examine the effect of sulfonamide substitution 
on key bonds involved in the Noyori-type catalytic mechanism, and visualisation of 
the distribution of charge density across the molecule. Calculations were carried out 
at the PBE0/Lanl2DZ/6-31+G** level.29 Only (R,R)-complexes were assessed by 
DFT. The input guesses for the geometry optimisations were based on the crystal 
structures of (R,R)-2 and (R,R)-7 and modified accordingly. The obtained ground state 
geometries of the complexes 2-10 were compared to the crystal structures. Calculated 
Cartesian coordinates are listed in Appendix Tables A3-A11. 
Calculated bond lengths were found to correlate well with crystallographic data, and 
selected bond lengths are shown in Table 3.7. No significant trends were observed 
between the compounds with regards to the selected bond lengths. 
Electrostatic potential surfaces were obtained by mapping electrostatic potential onto 
the total electron density surface for Os(II) sulfonamide complexes 2-10. The 
calculated surfaces provide an indication of charge distribution on the overall 
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complex, and were used to identify sites at which electrostatic interactions with a 
substrate molecule may occur (such as the highly polarised sulfonamide). 
Furthermore, the EPS surfaces could be used to assess the effect of different 
substitutions on the electrostatics within the series of complexes (Figure 3.10). 
Substitution at the sulfonamide group results in localised charge effects only, clearly 
identifiable for 4 (R = nitrophenyl) and 5 (R = fluorophenyl). No significant charge 
effect is observed at the metal centre, p-cymene ring (in the case of 2-6) nor at the 
nitrogen atoms of the diamine, which are considered essential for transfer 
hydrogenation by M-TsDPEN complexes.34 Methoxy-substituents in 9 and 10 cause 
the chiral aromatic groups to become slightly more negatively charged due to electron-
donation from OMe into the π system from the oxygen lone pair. This donation 
strengthens the C-O bond, observed by the shorter bond length (1.36 Å), compared to 
a typical C-O (1.43 Å).  
 
Table 3.7. Calculated (DFT) bond lengths of 2-10 compare well to x-ray crystallographic data. Data 
were calculated at the PBE0/Lanl2DZ/6-31+G** level.29      
 Os-N(H) Os-N(S) C-N(S) C-N(H) C-C S-N(S) 
2 (XRD) [a] 1.916 2.046 1.447 1.469 1.557 1.611 
2 1.917 2.017 1.465 1.450 1.541 1.646 
3 1.914 2.021 1.464 1.451 1.542 1.646 
4 1.916 2.024 1.468 1.451 1.540 1.636 
5 1.916 2.021 1.466 1.450 1.540 1.644 
6 1.917 2.020 1.456 1.450 1.541 1.644 
7 (XRD) [a] 1.902 2.066 1.477 1.465 1.546 1.59] 
7 1.908 2.024 1.467 1.454 1.546 1.649 
8 1.903 2.023 1.472 1.454 1.542 1.655 
9 1.915 2.018 1.466 1.451 1.541 1.644 
10 1.905 2.025 1.467 1.455 1.547 1.647 
11 (XRD) [a] 1.897 2.065 1.472 1.454 1.551 1.592 
[a] From published crystallographic data.7, 23 
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(R,R)-2 
 
(R,R)-3 
 
(R,R)-4 
   
   
 
(R,R)-5 
 
(R,R)-6 
 
(R,R)-7 
   
   
 
(R,R)-8 
 
(R,R)-9 
 
(R,R)-10 
 
Figure 3.10. Electrostatic potential surfaces for osmium sulfonamide complexes 2-10 (calculated at the 
PBE0/Lanl2DZ/6-31+G** level) mapped onto total electron density. Isovalue = 0.04. (R,R)-configured 
catalysts only. Surface mapping colours range from red (-0.025 au) to blue (+0.250 au). Calculated 
Cartesian atom coordinates are fully listed in appendix Tables A3-A11.  
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3.4 Discussion 
 
3.4.1 Structure elucidation of a novel osmium(II) pre-catalyst 
It was anticipated that Os complexes synthesised in the absence of base would differ 
structurally from the analogous Ru species containing a bidentate diamine.7 Elemental 
analysis suggested that complex 1 contained the diamine coordinated only by the 
terminal amine, while two chlorido ligands remained complexed to the metal centre. 
By infrared (FT-IR) spectroscopy, the TsN-H bond stretch (2859 cm-1) remains 
unchanged between 1 and the free ligand, whilst terminal amine N-H stretches were 
shifted from 3344 and 3281 cm-1 to 3078 and 2953 cm-1 upon coordination. Dichlorido 
1 was also identified by high resolution mass spectrometry ([M-H]- calculated for 
C31H35Cl2N2O2OsS, 761.1406; found, 761.1347).
23  
 
3.4.2 X-ray crystallography 
The crystal structures of 2 and 7 were determined to have a Flack parameter greater 
than 2σ from zero however this is within an acceptable range for complexes 
synthesised from compounds of known chirality.23, 35 The osmium(II) structures are 
remarkably similar to the known 16-electron Ru(II) analogue (CCDC 686925).7 
Catalyst 7 was isolated as a single crystal co-crystallised with two molecules of 
dichloromethane (Figure 3.6). The N-H bond in the osmium biphenyl compound is 
found to resemble closely that of the Noyori complex N-H (0.88 Å). In the case of 
both enantiomers of p-cymene complexes 2, a single hydrogen bond is observed in the 
solid state between the NH proton and sulfonamide oxygen (2.11 Å), however 
complexes 7 (biphenyl complexes) do not display such hydrogen bonding. In addition, 
no π-π stacking < 4 Å was observed in any of the structures.  
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3.4.3 Transfer hydrogenation catalysis 
Formic acid was utilised as a sacrificial source of hydride. Unlike reversible hydride 
donation by alcohols such as isopropanol,1, 36 formic acid provides an effectively 
irreversible solution due to the evolution of carbon dioxide.37 Treatment of 1 with 
formic acid allowed for the observation of an osmium hydride intermediate by 1H-
NMR, observed as two singlets (-5.89 and -6.04 ppm) corresponding to the two 
hydride complex diastereomers (Figure 3.11). 187Os (I = ½, 1.6% natural abundance) 
satellites were also observed, with a coupling constant (1J(187Os,1H) = 44 Hz) similar 
to other reported osmium hydrides (14.4-38.1 Hz).38 Over 30 min, the ratio between 
the hydride resonances decreased, from 3:1 to 1.2:1. Though both hydrides form, 
enantioselectivity of ketone reduction likely results from either (a) greater rate of 
reactivity of one hydride isomer, as suggested for the analogous ruthenium hydride;39, 
40 or (b) thermodynamically favourable interaction between a specific hydride 
enantiomer and the ketone.23 
The traditionally-accepted mechanism of enantioselectivity by Noyori-type catalysts 
involves a combination of steric effects (involving the phenyl groups at the chiral 
centres of the diamine, Figure 3.11) and electrostatic interaction between the catalyst 
arene and the aromatic group of the substrate, occurring via a concerted outer-sphere 
transition state.2, 41 However, recent studies suggest that a step-wise mechanism 
involving the solvent may more accurately describe face-specific hydrogen transfer.  
                          
Figure 3.11. The osmium hydride [OsH(arene)(diamine)].forms as a mixture of diastereomers.  
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Catalytic activity of osmium sulfonamide complexes 
Tosyl-DPEN complexes (2, 7, 8-10) achieved remarkably high enantioselectivity and 
conversions (> 99% ee).23 Similarly to the parent ruthenium analogue 11, (R,R)-
configured catalysts afforded the corresponding (R)-alcohol, and (S) catalysts afforded 
the (S)-alcohol, respectively.19, 37 No statistically-significant difference in activity was 
observed between enantiomers of 2 or 7. Sulfonamide substitution (3-6) led to a 
reduction in enantioselectivity, however the complexes still achieved high conversion 
in 24 h. Reported studies have suggested that the disfavoured transition state may be 
destabilised by an unfavourable interaction with the sulfonyl of the ligand.19, 42, 43 The 
addition of methoxy-substituents on complexes 9-10 did not have an effect on the 
enantioselectivity of the catalyst. 
All osmium catalysts investigated displayed hydrogenation rates (TOF) greater than 
that of parent Ru catalyst 9 under identical conditions (23 ± 1 h-1), even after allowing 
the ruthenium active catalyst to form in situ. The highest turnover frequency was 
achieved by the biphenyl catalyst 7 (78.2 ± 0.4 h-1). Both sulfonamide substitution and 
methoxy substitution were found to reduce significantly the TOF relative to the tosyl 
compound 2 (63.9 ± 0.3). The fluorine atom of complex 5 may have led to a hindrance 
of reaction rate by forming a hydrogen bond with another catalyst molecule (Figure 
3.12) however this is difficult to prove experimentally. 
 
 
Figure 3.12. Suggested intermolecular hydrogen bonding between molecules of 5.  
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Dichlorido osmium complex 1 is also able to act as a catalyst for ATH reactions (Table 
3.4). Upon treatment with a base, osmium complex 2 forms in situ.23 The high stability 
of osmium catalyst 2 allows for it to be prepared and used directly, and hence the 
catalysed reaction occurs immediately without a lag phase. This is unlike the reaction 
profile of Ru complex 11, which requires chloride dissociation before catalysis is 
initiated (Figure 3.13). Whilst the ruthenium 16-electron active catalyst has been 
isolated and fully characterised, it is not sufficiently stable to warrant use over the 
Ru(II) chlorido pre-catalyst.  
Reduction of acetophenone-derived ketones using complex 1 exhibited similar 
behaviour for Ru and Os catalysts. In both cases, conversion is decreased for ketones 
bearing electron-donating substituents (e.g. MeO) while ketones containing electron 
withdrawing groups maintain high conversion but exhibit decreased enantiomeric 
excess. The resulting enantioselectivity therefore results from a combination of both 
steric and electronic effects in the substrate. 
 
 
Figure 3.13. Ru catalyst 11 (●) must first dissociate chloride, observed as a lag-phase in the first hour 
of reduction. Os catalyst 2 (▲) exhibits instantaneous rate linearity. 
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Based on experimental data, the postulated mechanism of transfer hydrogenation is 
summarised in Figure 3.14. Pre-catalyst 1 eliminates chloride ligands to form active 
catalyst 2. Hydride is then transferred to 2 from formic acid, yielding an intermediate 
hydride complex as a mixture of diastereomers. Favourable CH-π interactions between 
a prochiral ketone substrate and the catalyst orientate the transition state to favour 
reduction of the carbonyl on a specific face, controlled by steric interactions with the 
chiral diamine of the catalyst. After transfer, the 16-electron catalyst is regenerated. 
 
 
Figure 3.14. Proposed mechanism of transfer hydrogenation by Os sulfonamide complexes 1 and 2.  
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3.4.4 Density Functional Theory (DFT) 
To better understand and compare the catalytic performance of the osmium 
complexes, we looked to theoretical methods. In particular, Density Functional Theory 
(DFT) is a valuable tool for an N-body system, where solving the Schrödinger 
equation would be computationally impossible. Instead, DFT provides an 
approximation of the solution, using the electron density. Mixed basis sets 
(Lanl2DZ/6-31+G**) are frequently used to simulate organometallic complexes.44 
The metal centre was approximated by using Los Alamos National Laboratory basis 
set with an effective core potential (ECP; Lanl2DZ)29 and all other atoms by the Pople 
basis set, (6-31+G**).  
DFT calculations for complexes 2-10 show high similarity between all systems, in 
agreement with high conversions and enantioselectivities observed in catalytic studies. 
The more positive electrostatic potentials of p-cymene and biphenyl (compared to the 
phenyl groups) are due to the donation of electrons from aromatic π orbitals to form σ 
and π-bonds with metal-based orbitals. The metal is also capable of δ-backbonding 
interactions with aromatic molecular orbitals. Activating groups such as OMe in 
complexes 9 and 10 give rise to localised charge effects, with some donation of 
electron density into the corresponding aromatic rings. Little effect, however, is 
observed at the metal centre. This is mostly likely due to the distance of the 
substitution site from the inner coordination sphere. This could explain why 9-10 
retain the high activity and enantioselectivity of parent compounds 2 and 7, 
respectively. The low TOF for acetophenone reduction using catalyst 5 may be due to 
the presence of intermolecular hydrogen bonding via fluorine, observed as a charge 
localisation at the point of substitution. However, this is difficult to prove 
experimentally as well as computationally and goes beyond the scope of this thesis.  
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3.5 Conclusions 
Coordinatively-unsaturated 16-electron osmium sulfonamide complexes can be 
prepared from their corresponding metal-arene dimer and diamine ligand in the 
presence of a base, in under an hour. Structural modifications are readily introduced, 
by substitution of various groups at the sulfonamide or chiral phenyl groups, or by 
arene chain extension. Though coordinatively-unsaturated, complexes 2-10 were 
found to be highly stable in both air and in both PBS and DMSO solutions. 
Crystallographic data were obtained for p-cymene (2) and biphenyl (7) complexes, 
and were found to be similar to the Ru catalyst to which they are related (Table 3.7). 
Upon treatment of complex 1 with formic acid as a hydride source, an osmium-hydride 
intermediate was observed by 1H-NMR, evidence for the postulated transfer 
hydrogenation mechanism. All osmium catalysts exhibited higher turnover 
frequencies for the reduction of acetophenone than the ruthenium sulphonamide 11, 
under identical conditions. The osmium catalysts demonstrated good tolerance of 
electron donating and withdrawing substituents on acetophenone-derived ketone 
substrates, maintaining high conversion and enantioselectivity. The structure of a 
novel dichlorido osmium complex (1) was elucidated, which was shown to be equally 
as useful as a catalyst as the 16-electron active catalyst. DFT calculations highlight the 
similarity between the Os series, and that substitution on complexes 3-6 and 9-10 
appears to only cause localised effects. 
The complexes would benefit from future investigation into scope of the catalytic 
reactions; including more challenging substrates (such as imines and aliphatic ketones) 
or exploration of tolerance towards forcing reaction conditions (i.e. increased 
temperature, lower catalyst loading). Overall, Os sulfonamide complexes offer a 
viable and useful alternative to existing Ru catalysts in ATH reactions.  
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4. Contrasting biological activities of Os(II) / Ir(III) 
sulfonamide complexes 
  
4.1 Introduction 
Research into metal-based anticancer agents was stimulated by the discovery of the 
platinum complex cis-[PtCl2(NH3)2] in the 1960s. While the commonly accepted 
mechanism of action of platinum complexes is DNA binding leading to apoptotic cell 
death,1 this approach does not allow discrimination between cancer cells and healthy 
proliferating tissues. In addition to increasing tumour selectivity, novel organometallic 
compounds that exhibit a unique, or multiple mechanism(s) of action may circumvent 
inherent or acquired drug resistance. This is of great importance when considering the 
high incidence of cisplatin-resistant tumours, because platinum-based drugs are 
currently used in over half of all chemotherapy regimens.2 
Organometallic compounds of ruthenium have been explored and reviewed 
extensively,3-6 and a ruthenium indazole complex (NKP-1339: sodium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)]) has entered a phase II clinical trial for 
the treatment of solid cancers.7 While complexes of Os(II), Ir(III) and Rh(III) have 
shown promise as alternatives to platinum-based therapies, achieving high potency 
against cancer cells while circumventing cross-resistance, none have yet reached 
clinical application.8-13 These organometallic complexes are commonly multi-
targeted, and one mechanism of action involved is the induction of reactive oxygen 
species (ROS) in cells.14-17 For example, the highly potent Os(II) complex [Os(p-
cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]PF6 was shown to disrupt cellular 
metabolism by generation of ROS while also inducing apoptotic cell death.18 
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This chapter compares the novel Os(II) sulfonamide complexes explored in Chapter 3 
(section 3.3.1, page 78) to structurally-similar Ir(III) compounds to evaluate the role 
of the catalytic metal centre on the biological properties (Figure 4.1). Since the 
compounds are able to catalyse transfer hydrogenation reactions, the catalytic 
oxidation of NADH (an important cellular hydride source) to NAD+ is investigated. 
The consequences of altering the NADH/NAD+ ratio are explored by detecting 
oxidative stress in cells. This chapter also evaluates the efficacy of sulfonamide 
complexes as anti-cancer agents, describes the time, temperature and concentration 
dependence of drug accumulation by A2780 cells, and explores metal 
compartmentalisation. Metallodrugs prove advantageous for such studies, since trace 
levels of the xenobiotic metal may be detected using various techniques, including 
ICP-MS (atomic mass), ICP-OES (atomic emission spectra) and x-ray fluorescence.19  
 
 
   
Cp*         . CpxPh         CpxBip 
Complex Metal ƞ5-arene (R1) R2 R3 
12 Ir Cp* 4-tolyl (TsDPEN) phenyl 
13 Ir CpxPh 4-tolyl (TsDPEN) phenyl 
14 Ir CpxBip 4-tolyl (TsDPEN) phenyl 
15 Ir Cp* 4-tolyl (TsBMEN) 4-methoxyphenyl 
16 Ir CpxPh 4-tolyl (TsBMEN) 4-methoxyphenyl 
17 Ir CpxBip 4-tolyl (TsBMEN) 4-methoxyphenyl 
 
Figure 4.1. Iridium complexes 12-17 introduced in this chapter.   
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4.2 Experimental 
  
4.2.1 Materials 
Precursor iridium dimer [IrCl2(Cp*)]2 was synthesised as described in Chapter 2 
(Section 2.1.2). TsDPEN was purchased as an optically pure compound from Arran 
Chemical Company (Ireland). DPEN and BMEN were purchased as optically pure 
compounds from Sigma Aldrich (UK). Potassium hydroxide, magnesium sulphate, 
sodium chloride (TraceSELECT, ≥99%) and all non-dried solvents were purchased 
from Fischer Scientific. L-ascorbic acid (≥99%), cis-diaminedichloroplatinum(II) 
(CDDP, cisplatin, ≥99%), DMSO (> 99%, molecular biology grade), 1-octanol 
(anhydrous, ≥99%), thiourea (≥99%) and (±)-verapamil hydrochloride (≥99%) were 
purchased from Sigma Aldrich and used as received. Deuterated solvents were 
purchased from Goss Scientific. Water used for biphasic reactions was purified by 
reverse osmosis (RO) unless specified. Ultrapure grade nitric acid (72% v/v) was 
freshly distilled before use. All other reagents and solvents were purchased from 
Sigma Aldrich and used as received, unless stated otherwise.  
The FractionPREP kit for cellular fractionation was purchased from BioVision, and 
stored at 253 K before use. The ROS / Superoxide detection kit was purchased from 
Sigma Aldrich and stored at 253 K before use. 
Iridium arene chlorido dimer complexes [IrCl2(Cp
xPh)]2 and [IrCl2(Cp
xBip)]2 were 
kindly provided by Dr. Abraha Habtemariam (University of Warwick, UK). 4-
Methoxyphenyl-substituted complexes 15-17 were synthesised and fully characterised 
by Miss Yasmin Khanom (University of Warwick, UK). 
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4.2.2 Synthesis of iridium sulfonamide complexes 12-17 
  
 
 
 
(R,R)-12 
 
[Ir(Cp*)((1R,2R)-TsDPEN)] (12). The synthesis of 12 has been previously 
reported.20 [Ir(Cp*)Cl2]2 (120 mg, 0.15 mmol) and (1R,2R)-(H)TsDPEN (110.6 mg, 
0.30 mmol) were stirred in chloroform (10 mL) with freshly ground KOH (168 mg, 3 
mmol). A colour change from orange to purple was observed < 1 min. After 5 min, 
water (10 mL) was added with stirring for a further 10 min. The organic layer was 
removed and concentrated in vacuo to yield a purple oil, which was dissolved in the 
minimum amount of DCM, followed by precipitation with n-pentane. The product was 
collected as a purple crystalline solid. (144 mg, 0.21 mmol, 69%). 1H NMR (400 MHz, 
CDCl3, 25°C, TMS): δ=7.55 (d, 3J(H,H)=7.4 Hz, 2H), 7.06-7.36 (m, 10H), 6.79 (d, 
3J(H,H)=8.0 Hz, 2H), 5.34 (s, 1H; CHNTs), 4.15 (br. d, 1H; CHNH), 2.24 (s, 3H; 
CH3), 1.92 (s, 15H; Cp*); 
13C NMR (100 MHz, CDCl3, 25°C, TMS) δ 128.2, 127.8, 
127.6, 126.9, 126.6, 126.5, 126.2, 85.2, 80.3, 74.1, 10.2; UV/Vis: λmax 429 and 536 
nm; HRMS (m/z): [M+H]+ calcd. for C31H36IrN2O2S, 693.2121; found, 693.2118; 
analysis (calcd. for C31H35IrN2O2S, found): C (53.81, 53.80), H (5.10, 5.09), N (4.05, 
4.02). 
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(R,R)-13 
 
[Ir(CpxPh)((1R,2R)-TsDPEN)] (13). This complex was obtained following the 
method described for complex 12 using dimer [Ir(CpxPh)Cl2]2 (50.3 mg, 0.055 mmol) 
and (1R,2R)-(H)TsDPEN (40 mg, 0.11 mmol). The product was isolated as a dark 
purple amorphous solid. (50 mg, 0.066 mmol, 61%).1H NMR (500 MHz, CDCl3, 
25°C, TMS): δ=7.58 (d, 3J(H,H)=7.5 Hz, 2H), 7.08-7.53 (m, 15H), 6.79 (d, 
3J(H,H)=8.0 Hz, 2H), 5.67 (br. d, 3J(H,H)=4.0 Hz, 1H; NH), 4.42 (s, 1H; CHNTs), 
4.20 (d, 3J(H,H)=4.0 Hz, 1H; CHNH), 2.25 (s, 3H; CH3), 2.07 (s, 3H; Cp*), 2.02 (s, 
3H; Cp*), 1.89 (s, 3H; Cp*), 1.88 (s, 3H; Cp*); 13C NMR (125 MHz, CDCl3, 25°C, 
TMS) δ 146.7, 146.5, 141.1, 140.1, 131.5, 130.9, 128.6, 128.2, 127.9, 127.7, 126.9, 
126.7, 126.6, 126.3, 89.8, 88.0, 87.5, 84.8, 83.8, 80.5, 74.2, 21.2, 10.7, 10.6, 10.5, 
10.3; UV/Vis: λmax 432 and 547 nm; HRMS (m/z): [M+H]+ calcd. for C36H38IrN2O2S, 
755.2278; found, 755.2268; analysis (calcd. for C36H37IrN2O2S, found): C (57.35, 
56.94), H (4.95, 4.96), N (3.72, 3.70). 
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(R,R)-14 
 
[Ir(CpxBip)((1R,2R)-(TsDPEN)] (14). This complex was obtained following the 
method described for complex 12 using dimer [Ir(CpxBip)Cl2]2 (58.6 mg, 0.055 mmol) 
and (1R,2R)-(H)TsDPEN (40 mg, 0.11 mmol). The product was isolated as a dark 
purple crystalline solid. (33 mg, 0.040 mmol, 37%). 1H NMR (500 MHz, CDCl3, 
25°C, TMS): δ= 7.52-7.64 (m, 8H), 7.44-7.50 (m, 2H), 7.35-7.42 (m, 1H), 7.07-7.30 
(m, 10H), 6.80 (d, 3J(H,H)=8.0 Hz, 2H; ArH), 5.67 (d, 3J(H,H)=4.0 Hz, 1H; NH), 4.43 
(s, 1H; CHTs), 4.22 (d, 3J(H,H)=4.0 Hz, 1H; CHNH), 2.25 (s, 3H; CH3), 2.09 (s, 3H; 
Cp*), 2.03 (s, 3H; Cp*), 1.94 (s, 3H; Cp*), 1.93 (s, 3H; Cp*); 13C NMR (125 MHz, 
CDCl3, 25°C, TMS) δ 146.7, 146.5, 141.1, 141.0, 140.4, 140.1, 131.3, 128.9, 128.6, 
127.9, 127.7, 127.6, 127.3, 127.1, 127.1, 127.0, 126.7, 126.6, 126.3, 89.4, 88.1, 87.6, 
84.8, 83.9, 80.6, 74.2, 21.25, 10.8, 10.6, 10.5, 10.3; UV/Vis: λmax 430 and 547 nm; 
HRMS (m/z): [M+H]+ calcd. for C42H42IrN2O2S, 831.2592; found, 831.2599; analysis 
(calcd. for C42H41IrN2O2S, found): C (60.77, 61.21), H (4.98, 5.07), N (3.37, 3.34). 
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(R,R)-15 
 
[Ir(Cp*)((1R,2R)-TsBMEN)] (15). Complex (R,R)-15 was synthesised by Miss 
Yasmin Khanom. This complex was obtained following the method described for 
complex 12 using dimer [Ir(Cp*)Cl2]2 (46.7 mg, 0.058 mmol) and (1R,2R)-
(H)TsBMEN (50 mg, 0.17 mmol). The product was isolated as a dark purple 
amorphous solid. (37.5 mg, 0.049 mmol, 86%).1H NMR (500 MHz, CDCl3, 25°C, 
TMS): δ=7.44 (d, 3J(H,H)=8.4 Hz, 2H; ArH), 7.25 (d, 3J(H,H)=8.2 Hz, 2H; ArH), 7.04 
(d, 3J(H,H)=8.5 Hz, 2H; ArH), 6.82 (d, 3J(H,H)=8.0 Hz, 2H; ArH), 6.79 (d, 
3J(H,H)=8.5 Hz, 2H; ArH), 6.65 (d, 3J(H,H)=8.6 Hz, 2H; ArH), 5.36 (br. s, 1H; NH), 
4.18 (s, 1H; TsNCH), 4.05 (s, 1H; CHNH), 3.78 (s, 3H; OCH3), 3.78 (s, 3H; OCH3), 
2.26 (s, 3H; CH3), 1.91 (s, 15H; CH3); 
13C NMR (125 MHz, CDCl3, 25°C, TMS) δ 
158.5, 158.1, 140.9, 138.9, 138.7, 128.2, 127.1, 126.7, 113.1, 85.1, 79.8, 73.4, 55.3, 
21.2, 10.2; UV/Vis: λmax 285, 430, 538 nm; HRMS (m/z): [M+H]+ calcd. for 
C33H40IrN2O4S, 753.2333; found, 753.2336; analysis (calcd. for C33H39IrN2O4S, 
found): C (52.71, 53.03), H (5.23, 5.43), N (3.73, 3.65). 
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(R,R)-16 
 
[Ir(CpxPh)((1R,2R)-TsBMEN)] (16). Complex (R,R)-16 was synthesised by Miss 
Yasmin Khanom. This complex was obtained following the method described for 
complex 12 using dimer [Ir(CpxPh)Cl2]2 (53.9 mg, 0.058 mmol) and (1R,2R)-
(H)TsBMEN (50 mg, 0.17 mmol). The product was isolated as a dark purple 
amorphous solid. (35.5 mg, 0.044 mmol, 75%).1H NMR (500 MHz, CDCl3, 25°C, 
TMS): δ=7.51 (d, 3J(H,H)=6.9 Hz, 2H; ArH), 7.47 (d, 3J(H,H)=8.5 Hz, 2H; ArH), 7.39 
(br. s, 1H; NH), 7.32-7.38 (m, 3H; ArH), 7.28 (d, 3J(H,H)=8.2 Hz, 2H; ArH), 7.05 (d, 
3J(H,H)=8.5 Hz, 2H; ArH), 6.82 (d, 3J(H,H)=7.9 Hz, 2H; ArH), 6.77 (d, 3J(H,H)=8.5 
Hz, 2H; ArH), 6.65 (d, 3J(H,H)=8.5 Hz, 2H; ArH), 4.30 (s, 1H; CHNTs), 4.10 (s, 1H; 
CHNH), 3.79 (s, 3H; OCH3), 3.78 (s, 3H; OCH3), 2.26 (s, 3H; CH3), 2.07 (s, 3H; CH3), 
2.02 (s, 3H; CH3), 1.89 (s, 3H; CH3), 1.88 (s, 3H; CH3); 
13C NMR (125 MHz, CDCl3, 
25°C, TMS) δ 158.6, 158.2, 141.2, 140.0, 138.8, 131.5, 130.9, 128.6, 128.2, 127.9, 
127.2, 126.7, 113.1, 89.8, 87.9, 87.5, 84.6, 84.0, 80.0, 73.5, 55.3, 21.2, 10.7, 10.6, 
10.5, 10.4; UV/Vis: λmax 278, 433, 549 nm; HRMS (m/z): [M+H]+ calcd. for 
C38H42IrN2O4S, 815.2490; found, 815.2485; analysis (calcd. for C38H41IrN2O4S, 
found): C (56.07, 55.98), H (5.08, 5.31), N (3.44, 3.31). 
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(R,R)-17 
 
[Ir(CpxBip)((1R,2R)-TsBMEN)] (17). Complex (R,R)-17 was synthesised by Miss 
Yasmin Khanom. This complex was obtained following the method described for 
complex 12 using dimer [Ir(CpxPh)Cl2]2 (62.2 mg, 0.058 mmol) and (1R,2R)-
(H)TsBMEN (50 mg, 0.17 mmol). The product was isolated as a dark purple 
amorphous solid. (30.7 mg, 0.034 mmol, 60%).1H NMR (500 MHz, CDCl3, 25°C, 
TMS): δ=7.61 (d, 3J(H,H)=7.5 Hz, 2H; ArH), 7.57 (d, 3J(H,H)=5.1 Hz, 2H; ArH), 
7.44-7.51 (m, 4H; ArH), 7.39 (m, 2H; ArH), 7.30 (d, 3J(H,H)=8.0 Hz, 2H; ArH), 7.16 
(d, 3J(H,H)=8.5 Hz, 1H; ArH), 7.07 (d, 3J(H,H)=8.4 Hz, 2H; ArH), 6.96-7.04 (br. s, 
1H; NH), 6.84 (d, 3J(H,H)=8.0 Hz, 2H; ArH), 6.79 (d, 3J(H,H)=8.5 Hz, 2H; ArH), 
6.66 (d, 3J(H,H)=8.5 Hz, 2H; ArH), 4.31 (s, 1H; CHNTs), 4.11 (s, 1H; CHNH), 3.79 
(s, 3H; OCH3), 3.78 (s, 3H; OCH3), 2.27 (s, 3H; CH3), 2.09 (s, 3H; CH3), 2.04 (s, 3H; 
CH3), 1.94 (s, 3H; CH3), 1.93 (s, 3H; CH3); 
13C NMR (125 MHz, CDCl3, 25°C, TMS) 
δ 158.6, 158.2, 141.2, 141.0 140.4, 140.1, 138.8, 131.3, 128.9, 128.2, 127.9, 127.7, 
127.3, 1271, 126.7, 113.6, 113.2, 113.1, 89.2, 88.0, 87.6, 84.7, 84.0, 80.0, 73.5, 61.2, 
55.3, 21.2, 10.9, 10.7, 10.5, 10.4; UV/Vis: λmax 263, 431, 548 nm; HRMS (m/z): 
[M+H]+ calcd. for C44H46IrN2O4S, 891.2803; found, 891.2800. 
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4.2.3 Conversion  of NADH to NAD+ 
The conversion of nicotinamide adenine dinucleotide (1,4-NADH) to its oxidised form 
(NAD+) under biologically-relevant conditions (phosphate buffered saline, DMSO < 
1.0% v/v, pH = 7.4) was determined using either catalyst 2 [Os(p-cymene)(TsDPEN)] 
or 12 [Ir(Cp*)(TsDPEN)], monitored using UV-visible spectroscopy. Stock solutions 
of 2 or 12 (ca. 100 μM) were prepared in 5% v/v DMSO / 95% v/v phosphate-buffered 
saline (PBS, pH 7.4). A separate stock solution of 1,4-NADH was prepared in PBS 
(ca. 5 mM). Solutions were diluted to achieve final working concentrations: metal 
complex, 10 μM; NADH, 124 μM (A340 nm = 0.77). Spectra (800-200 nm, scan rate: 
600 nm min-1) were acquired every 1 h over a 24 h period (298 K). The final DMSO 
concentration in the working solution did not exceed 1.0 % v/v.  
The oxidation of 1,4-NADH to NAD+ was determined by recording the absorbance at 
340 nm (ε(NADH) = 6.22 cm-1 mM-1). Absorbance data were plotted as a function of 
time. Additionally, a plot of ln(absorbance) as a function of time was constructed to 
demonstrate that the reaction rate was first order with respect to NADH. The turnover 
number after 24 h incubation (TON, 24 h) and maximum observed turnover frequency 
(TOFmax / h
-1) were determined after quantification of the metal stock solution 
concentration using ICP-OES.  
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4.2.4 Octanol-water partition coefficients (Log P) 
Octanol / water partition coefficients for complexes 2-17 were determined using the 
shake-flask method.21 1-Octanol saturated water (OSW) and water saturated 1-octanol 
(WSO) were prepared by stirring equal quantities of each solvent overnight (ca. 200 
mL), and allowing 24 h before separation of the two phases. Saturated aqueous 
solutions of each complex were prepared using octanol-saturated water. The saturated 
solutions were filtered, then shaken with equal volumes of water saturated octanol (2 
mL + 2 mL) for 24 h using an IKA Vibrax VXC basic shaker (1000 g/min). The 
experiment was conducted at ambient temperature (~293 K).  
The osmium / iridium concentration of the aqueous layer was determined by ICP-MS 
before and after shaking. Analysis was conducted immediately after solution 
preparation or equilibration time in all cases. Serial dilutions were performed using 
dilute nitric acid (3.6% v/v) containing thiourea (10 mM) and ascorbic acid (100 mg/L) 
to stabilise osmium in nitric acid solution, using dilution factors i and j, for t = 0 h and 
t = 24 h samples, resepectively.22 ICP-MS analysis for 189Os and 193Ir was performed 
as described in Chapter 2 (section 2.2.8, page 47, calibration range: 0.1-1000 ppb) 
using an internal standard (50 ppb 166Er). Log P values and calculated standard 
deviations were determined as duplicates of triplicates as part of two independent 
experiments using separately-prepared sample batches (Formula 4.1).  
 
Log P = (
[M]octanol
[M]aqueous 
)  
Log P = (
𝑖[M]aqueous (t = 0 h)−𝑗[M]aqueous (t = 24 h)
𝑗[M]aqueous (t = 24 h)
)  
 
Formula 4.1. Determination of partition coefficient (Log P) using metal concentrations in the aqueous 
layer determined by ICP-MS, where i and j are the corresponding ICP dilution factors.  
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4.2.5 Biological studies 
Cell maintenance, in vitro growth inhibition assays and cellular metal accumulation 
experiments undertaken at the University of Warwick were carried out with assistance 
from Dr Isolda Romero-Canelón, Mrs Hannah E Bridgewater, Mrs Ji Inn Song and 
Mrs Sukhbinder Heer (University of Warwick, UK). The relevant methods are 
described in Chapter 2 (section 2.3.2, page 57).  
 
Maintenance of A2780cis (cisplatin-resistant ovarian cancer cells). Approximately 
every 10 passages, cells were exposed to cisplatin (10 μM; ca. 10× IC50 of CDDP in 
A2780 cancer cells) for 24 h, washed with PBS and supplied with drug-free media. 
 
Cellular accumulation studies. Cell accumulation experiments were carried out as 
described in Chapter 2 (section 2.3,2, page 54). Variations on the cellular 
accumulation protocol are described:  
 
(1) Concentration dependence. Experiments were carried out using 4 metal 
concentrations (0.25, 0.50, 1.00, 1.50 × IC50 concentration) and 24 h drug 
exposure. No recovery time. Incubation at 310 K;  
 
(2) Time dependence. Experiments were carried out with 3 h, 6 h, and 24 h 
drug exposure. No recovery time. Cells were incubated at 310 K;  
 
(3) Temperature dependence. Experiments were carried out at 277 K and 310 
K using IC50 concentrations of the complexes with 24 h drug exposure. No 
recovery time;  
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(4) P-gp involvement in metal efflux. Experiments were carried out using IC50 
concentrations. The drug was removed after 24 h, cells were washed with PBS, 
and either fresh media, or media containing a known P-gp inhibitor (verapamil: 
20 μM), was added. Cells were incubated at 310 K and collected after 24 h, 48 
or 72 h recovery.  
 
Metal distribution in cancer cells. Cell pellets were obtained in triplicate as 
described for cellular metal accumulation using 1× IC50 equipotent concentrations 
(section 2.3.2, page 54), and fractioned using the Fraction PREP kit (BioVision). The 
fractions (cytosolic, membrane, nucleic, cytoskeletal) were digested in concentrated 
72% v/v nitric acid (200 µL, 343 K, 24 h) then diluted with milliQ water containing 
thiourea and ascorbic acid to stabilise Os in nitric acid, achieving 3.6% v/v final 
working acid concentration. Metal concentrations (Os / Ir) were determined by ICP-
MS in triplicate (section 2.2.8, page 48), and normalised to cell count in order to report 
% distributions and standard deviations.  
 
Reactive oxygen species (ROS) determination. ROS and superoxide were detected 
in A2780 cancer cells using the ROS / Superoxide detection kit (Enzo Life Sciences). 
A 6-well plate was seeded with 1.5 × 106 A2780 cells per well, and incubated for 24 
h (310 K). Cells were exposed to complex 2 or 12 (1.0 × IC50) for 24 h. Cells were 
washed, pellets collected by centrifugation (1000 rpm, 5 min, 277 K), then re-
suspended in PBS (500 μL) and stained with green and orange fluorescent reagents (2 
μL). Positive control samples were treated with pyocyanin (5 μL, 30 min) and stained 
either green, orange, or were dual-stained (for compensation purposes). Data were 
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collected using a Becton Dickson FACScan Flow Cytometer (FL1 for total ROS, 
Ex/Em: 490/525 nm; FL2 for superoxide, Ex/Em: 550/620 nm) and were processed 
using FlowJo V10 for Windows. 
 
Redox modulation by co-administration of L-BSO. Antiproliferative activities were 
determined as described in Chapter 2 (section 2.3.2, page 60) with the following 
modification: Complex 2 or 12 was co-administered to A2780 cells with a non-toxic 
concentration of L-BSO (5 μM), added independently, but within 5 min of each other. 
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4.3 Results 
 
4.3.1 Synthesis of Ir(III) sulfonamide complexes 
For comparison to Os transfer hydrogenation catalysts 2-10, introduced in Chapter 3 
(section 3.3.1, page 78), a series of structurally similar Ir(III) complexes was 
synthesised. Complex 12 [Ir(Cp*)(TsDPEN)] has previously been reported as a 
catalytic intermediate,20 however its biological activity, at the time of writing, had not 
been explored. The 16-electron extended arene (13-14) and methoxy-substituted (15-
17) series were synthesised by the same method described for Os complexes, rapidly 
forming a purple solution upon addition of base to a solution of the chiral diamine 
ligand and metal dimer [Ir(Cpx)Cl2]2 in dichloromethane (Figure 4.2). The products 
were recrystallised from dichloromethane / hexane, yielding stable purple solids.  
 
 
   
12 13 14 
   
15 16 17 
 
Figure 4.2. Synthesis of iridium(III) complexes 12-17 using the method described in Chapter 3.  
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Solution stability of Ir(III) sulfonamide complexes in PBS and DMSO 
Complexes 12-17 were investigated for their stability in phosphate-buffered saline 
(containing < 5% v/v DMSO to solubilise the complexes) by UV-visible spectroscopy, 
and stability in d6-DMSO by 1H-NMR, as first described in Chapter 3 (section 3.3.4, 
page 85). After incubation at 310 K for 24 h, no changes were observed in UV-visible 
spectra, and no new peaks (or shifted peaks) were observed by 1H-NMR (Figure 4.3), 
suggesting that the Ir(III) complexes are highly stable and comparable to their Os(II) 
counterparts. Though it is possible that chemical modification in solution may occur 
on a timescale that is more rapid than the time taken to acquire the first spectrum, the 
chemical species identified in the first spectrum acquired (after ca. 10 min for UV-
visible, or 20 min for 1H-NMR) remained unchanged for the 24 h period investigated 
and does not undergo (further) structural modification in either solvent.  
 0 h 21 min [a] 
 
24 h 21 min 
 
 
Figure 4.3. Representative 1H-NMR (d6-DMSO, 24 h, 310 K) shown for complex 12. Complexes 13-
17 are also highly stable in DMSO. [a] Time delay: lock, shim, temperature, average point of acquisition. 
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4.3.2 Conversion of NADH to NAD+ 
The co-factor 1,4-NADH is an important hydride source in cells. The conversion 
(oxidation) of 1,4-NADH to NAD+ by 2 (Os) or 12 (Ir) was monitored using UV-
visible spectroscopy for 24 h at 298 K (124 μM NADH, ~10 μM complex). Conversion 
was determined from the absorbance at 340 nm, corresponding to 1,4-NADH. 
Turnover number (per mol of catalyst in 24 h) and maximum turnover frequency (TOF 
/ h-1) were calculated. Both Os and Ir complexes show activity for the oxidation of 1,4-
NADH to NAD+ (Figure 4.4). The initial rate was greater for Ir catalyst 12 (TOF = 0.3 
h-1) compared to Os catalyst 2 (TOF = 0.12 h-1). However, the rate of oxidation of 1,4-
NADH catalysed by Ir complex 12 decreased after ca. 6 h, resulting in an equal 
turnover number of ca. 3 equivalents of 1,4-NADH per mole of substrate in 24 h. 
 
 
 Complex TON (24 h) TOFmax / h-1 
2 [Os(p-cymene)(TsDPEN)] 2.99 0.12 
12 [Ir(Cp*)(TsDPEN)] 2.92 0.30 
 
Figure 4.4. Conversion of 1,4-NADH to NAD+ in PBS (pH 7.4) using either complex 2 or 12 (~10 μM) 
over 24 h at 298 K (<1% v/v DMSO). (a) Representative UV-visible spectrum for oxidation of 1,4-
NADH (124 μM) by 12, showing decrease in absorption at 340 nm; (b) Representative plot of 
conversion as a function of time for oxidation by 12.  
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Figure 4.5. First-order kinetics plot of ln(absorance) at 340 nm as a function of time for the oxidation 
of 1,4-NADH to NAD+ by complex 2 (Os) or 12 (Ir). Oxidation by Os(II) catalyst 2 shows typical first-
order kinetics, however oxidation by catalyst 12 shows non-first order kinetics for the first 6 h of the 
reaction, after which time first-order kinetics are observed.  
 
First order kinetic plots (ln abs plotted as a function of time) yielded a linear plot for 
Os complex 2, confirming the first-order kinetics with respect to 1,4-NADH (Figure 
4.5). The rate constant, k, for oxidation by Os complex 2 was 7.8 × 10-5 min-1, an order 
of magnitude less than the rate constant determined for NADH oxidation by other 
organometallic complexes (4.03 × 10-4 min-1 for oxidation by Ir(III) 2-phenylpyridine 
complexes). The same first order kinetic plot for the reaction catalyst by Ir complex 
12 was not linear until after ca. 6 h, and non-first order kinetics were observed in the 
first hours of oxidation. In this case, a second-order kinetic plot (abs-1 as a function of 
time) also did not produce a linear relationship, however the same unusual kinetic 
profile seen here with complex 12 (which reverts to first-order kinetics after 6 h) has 
also been observed with other Ir(III) complexes.8 To investigate the hypothesised 
transfer hydrogenation mechanism, the detection of metal hydride resonances were 
attempted using 1H-NMR however solution concentrations were not sufficient to 
facilitate observation. 
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4.3.3 Partition coefficient determination (Log P)  
A detailed understanding of the cellular internalisation of candidate drug molecules is 
necessary to help explain biological interactions. A crucial step in this process is 
passage across the cell membrane. While large macromolecules are accumulated via 
endocytosis, smaller molecules may cross the membrane by either passive diffusion, 
or energy-dependent pathways, depending on their molecular weight, hydrophobicity 
and charge.23 The octanol / water partition coefficient (Log P) describes the 
comparative hydrophobicity between compounds, whereby more polar (and 
commonly, charged) substances exhibit a more negative Log P, and more hydrophobic 
complexes have a more positive Log P. A partition coefficient of 0.0 indicates no 
preference for either the aqueous or organic phases.  
Partition coefficients were determined for complexes 2-17 using the shake-flask 
method (Table 4.1).24 All Log P values determined for both osmium and iridium 
complexes were positive, consistent with the low water solubility of the compounds, 
and ranged from Log P = 0.03-2.3 (Table 1). As anticipated, the more hydrophobic 
complexes with extended arene rings exhibited higher partition coefficients. All 
complexes investigated were assumed to be highly stable in water based on evidence 
from 1H-NMR and UV-visible spectroscopic studies (see 4.3.1 for Ir complexes, 
Chapter 3 section 3.3.1, page 78 for Os complexes) in which no changes in spectra 
were observed over 24 h. The partition co-efficient for both enantiomers of osmium 
complexes 2, 7 and 8 were studied independently, and found to not be statistically 
different. The most hydrophilic complex was [Ir(Cp*)(TsBMEN)] complex 15 (0.03 
± 0.04) demonstrating that methoxy-substitution increased water solubility, and the 
most hydrophobic complex was [Os(m-terphenyl)(TsDPEN)] complex 8 (2.3 ± 0.2). 
All partition coefficients were positive, indicative of preference for the octanol phase.  
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4.3.4 Antiproliferative activity and total cellular metal accumulation 
The antiproliferative activities (half-maximal growth inhibitory concentrations, IC50) 
of sulfonamide complexes 2-17 were determined in A2780 human ovarian cancer 
cells, using 24 h drug exposure and 72 h recovery time in drug-free medium. Final 
concentrations used in dose-response sigmoidal curves were corrected by ICP-OES 
analysis of stock solutions for Ru, Os, Pt and Ir concentrations. Both Ru(II) complex 
11 and Ir complex 12 have been studied for the transfer hydrogenation of ketones and 
imines by Noyori and co-workers,25-28 but their biological activities, to the best of my 
knowledge, have not been investigated.  
 
Antiproliferative activities towards A2780 ovarian cancer cells 
Across the series of complexes studied, antiproliferative activities towards A2780 
cancer cells span over an order of magnitude, ranging from highly potent in the case 
of [Ir(CpxBip)(TsDPEN)] 17 (0.7 ± 0.1 μM, comparable in activity to cisplatin) to only 
moderately active for [Os(p-cymene)(MsDPEN)] 3 (30 ± 2 μM). For both osmium and 
iridium complexes, lower IC50 values were determined for complexes with extended 
arenes: Os: 8 (m-terphenyl) > 7 (biphenyl) > 2 (p-cymene); Ir: 14 (CpxBip) > 13 (CpxPh) 
> 12 (Cp*). While Os complexes were typically more active than their Ir counterparts 
(2>12, 7>13, 8>14), methoxy-substitution in iridium complexes 15-17 greatly 
enhanced antiproliferative activities by up to 24× for [Ir(CpxBip)(TsBMEN)] 17 
compared to [Ir(CpxBip)(TsDPEN)] 14, achieving IC50 = 0.7 μM (17) compared to IC50 
= 17 μM (14). In contrast, the antiproliferative activities of methoxy-substituted 
osmium complexes differed little from the respective un-substituted compounds, 
achieving only 1.5× potency increase (10 μM and 15.5 μM) in the case of Os complex 
9 (methoxyphenyl) compared to 2 (phenyl), respectively.  
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Metal accumulation in A2780 ovarian cancer cells 
Metal accumulation was compared at equipotent doses (1 × IC50) after 24 h drug 
exposure with no recovery period (Table 4.1). Intracellular metal concentrations were 
determined by ICP-MS in no-gas mode, after digestion in nitric acid (72% v/v) 
followed by subsequent dilution to working acid concentration (3.6% v/v).  
Cellular metal accumulations in A2780 cancer cells spanned almost an order of 
magnitude between the various sulfonamide complexes (8 to 89 ng Ir × 106 cells, and 
4.8 to 32 ng Os × 106 cells). Metal accumulations were typically higher for iridium 
complexes, with the highest metal accumulation observed for iridium Cp* TsDPEN 
complex 14  (89 ± 4 ng Ir × 106 cells). In contrast, the lowest accumulation was for 
osmium p-cymene MsDPEN complex 3 (4.8 ± 0.8 ng Os × 106 cells), and the highest 
Os accumulation for complex 2 (32 ± 3 ng Os × 106 cells). The internalisation of the 
anticancer complex cisplatin was particularly low in comparison to the sulfonamide 
series (0.51 ± 0.07 ng Pt × 106 cells), likely due to the negative partition coefficient 
(corresponding to a lower lipophilicity). No correlation was observed between total 
metal accumulation and antiproliferative activity in A2780 cancer cells. For example, 
while the antiproliferative activities (IC50) of 2 and 6 are similar (15.5 and 13.5 μM, 
respectively), Os accumulation in cells treated with 6 was ~5× lower than those treated 
with 2 (5.8 and 30 ng Os × 106 cells, respectively). While antiproliferative activities 
were found to increase with arene chain extension for Os (2 < 7 < 8) and Ir (12 < 13 < 
14) complexes, neither the accumulation of Os (7 < 2 = 8) or Ir (13 < 12 < 14) followed 
the same trend. The absence of correlation between accumulation and IC50 has been 
observed previously for Pt complexes,29 however the correlation was identified for 
similar Ir complexes.30 It is therefore apparent that the in vitro biological activities or 
extent of metal accumulation cannot be readily predicted.  
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Table 4.1. Octanol / water partition coefficients (Log P), antiproliferative activities (IC50 / μM) and 
cellular metal accumulations (ng Os / Ir / Pt × 106 cells) determined for complexes 2-17 in A2780 
human ovarian cancer cells, compared to the anticancer drug, cisplatin cis-[PtCl2(NH3)2]. 
 
 Complex Log P (oct / water) IC50 / μM [a] 
ng Os / Ir / Pt 
× 106 cells [b] 
(R,R)-2 [Os(p-cymene)(TsDPEN)] 1.45 ± 0.02 15.5 ± 0.5 30 ± 2 
(S,S)-2 [Os(p-cymene)(TsDPEN)] 1.45 ± 0.07 15.2 ± 0.5 32 ± 3 
(R,R)-3 [Os(p-cymene)(MsDPEN)] 0.18 ± 0.04 30 ± 2 4.8 ± 0.8 
(S,S)-3 [Os(p-cymene)(MsDPEN)] - 29.9 ± 0.5 - 
(R,R)-4 [Os(p-cymene)(NsDPEN)] 0.709 ± 0.008 19.9 ± 0.5 8.1 ± 0.3 
(S,S)-4 [Os(p-cymene)(NsDPEN)] - 19.4 ± 0.9 - 
(R,R)-5 [Os(p-cymene)(FbDPEN)] 0.28 ± 0.03 17 ± 1 10 ± 2 
(S,S)-5 [Os(p-cymene)(FbDPEN)] - 17 ± 1 - 
(R,R)-6 [Os(p-cymene)(BsDPEN)] 0.85 ± 0.02 13.5 ± 0.9 5.8 ± 0.7 
(S,S)-6 [Os(p-cymene)(BsDPEN)] - 14 ± 2 - 
(R,R)-7 [Os(biphenyl)(TsDPEN)] 1.91 ± 0.04 6.5 ± 0.3 13 ± 1 
(S,S)-7 [Os(biphenyl)(TsDPEN)] 1.85 ± 0.01 6.3 ± 0.1 13.3 ± 0.4 
(R,R)-8 [Os(m-terphenyl)(TsDPEN)] 2.28 ± 0.10 4.4 ± 0.3 31.9 ± 0.4 
(S,S)-8 [Os(m-terphenyl)(TsDPEN)] 2.3 ± 0.2 4.50 ± 0.07 - 
(R,R)-9 [Os(p-cymene)(TsBMEN)] 0.24 ± 0.08 10 ± 1 6.6 ± 0.2 
(R,R)-10 [Os(p-cymene)(TsBMEN)] 0.59 ± 0.05 9 ± 1 11.8 ± 0.1 
(R,R)-11 [RuCl(p-cymene)(TsDPEN)] - 8.2 ± 0.7 - 
(S,S)-11 [RuCl(p-cymene)(TsDPEN)] - 9 ± 1 - 
(R,R)-12 [Ir(Cp*)(TsDPEN)] 0.86 ± 0.02 20.9 ± 0.7 52 ± 1 
(R,R)-13 [Ir(CpxPh)(TsDPEN)] 1.41 ± 0.02 14 ± 2 41.7 ± 0.7 
(R,R)-14 [Ir(CpxBip)(TsDPEN)] 2.24 ± 0.02 10.2 ± 0.6 89 ± 4 
(R,R)-15 [Ir(Cp*)(TsBMEN)] 0.03 ± 0.04 17 ± 1 8 ± 1 
(R,R)-16 [Ir(CpxPh)(TsBMEN)] 0.32 ± 0.02 8.0 ± 0.8 13 ± 1 
(R,R)-17 [Ir(CpxBip)(TsBMEN)] 0.62 ± 0.03 0.7 ± 0.1 5.3 ± 0.2 
Cisplatin [PtCl2(NH3)2] -2.21 ± 0.06 [c] 1.20 ± 0.03 0.51 ± 0.07 
[a]Antiproliferative activities determined using 24 h drug exposure + 72 h recovery time in drug-free medium. [b] 
Metal accumulation (investigated for (R,R)-configured complexes only) using equipotent concentrations (1.0 × 
IC50) for 24 h with no recovery time. [c] Literature value for the partition coefficient (octanol/water) of cisplatin.31  
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Multi-cell line antiproliferative activity screening 
Tosyl-DPEN complexes of Os 2, 7, 8 and Ir complexes 12-14 were further assessed 
for antiproliferative activity in other human cancer cell lines from different tissue 
origins: A2780cis (cisplatin-resistant A2780), A549 (lung), HCT116 (colon), OE19 
(oesophageal), MCF7 (breast), PC3 (prostate), SK-OV-3 (ovarian) and SW626 
(ovarian) cancer cells; as well as two non-cancerous primary cell lines: MRC5 (non-
cancerous lung fibroblasts) and HOF (non-cancerous ovarian fibroblasts). The 
complexes achieved high potency against A2780, PC3 and MCF7 cancer cells; 
particularly complex 14 (3.7 ± 0.7 μM against MCF7 cells).  
Antiproliferative activities typically increased with arene chain extension (p-cymene 
< biphenyl < terphenyl for Os; Cp* < CpxPh < CpxBip for Ir) in A2780, HEPG2, HOF, 
MCF7, MRC5 and OE19, however this trend was not observed for A549 or HCT116 
cells. Interestingly, arene extension did not significantly affect the activities of 
osmium complexes 2, 7 and 8 in PC3, however the trend was still apparent for iridium 
complexes 12-14. Overall, complexes of iridium were typically less active than their 
osmium counterparts. Both osmium and iridium complexes were only moderately 
active (or inactive in the concentration range investigated) in HCT116 colon and OE19 
oesophageal cells (Table 4.2). Compared to the parental cell line (HCT116), all 
sulfonamide complexes exhibited significantly decreased activities in p21- and p53- 
knockout cells (HCT116-p21-/- and HCT116-p53-/- respectively), suggesting that the 
mechanism of action is likely to be dependent on p21 and/or p53.  
The ratio between IC50 concentrations in non-cancerous fibroblasts (HOF and MRC5) 
compared to cancer cells (A2780 and A549, respectively) provides an indication of 
drug selectivity. Here, a distinct difference was observed depending on the nature of 
the metal. Os complexes 7-8 exhibited the greatest selectivity for ovarian cancer cells 
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compared to normal ovarian fibroblasts (6.7× and 5.5× respectively), with greater 
selectivity achieved with arene extension (2 < 7 ~ 8). In contrast, Ir complexes 12-14 
showed significantly less selectivity (0.9-1.5×) which differed little upon arene 
extension. Upon comparison of cancerous lung cells (A549) with non-cancerous lung 
fibroblasts (MRC5), selectivity ratios were lower than those determined using ovarian 
cells (up to 3× for complex 8), suggesting that the complexes may offer selective 
targeting and could be useful for the treatment of cancers of specific tissues. 
Activities of the sulfonamide complexes in a laboratory-induced cisplatin-resistant 
cell line (A2780cis) appeared to be highly dependent on the nature of the metal centre. 
Activities of the osmium complexes, in particular osmium biphenyl complex 7 (IC50 
= 25.9 μM in A2780cis compared to 6.5 μM in cisplatin-sensitive A2780), were 
particularly decreased in cisplatin-resistant cells. However, unlike the Os sulfonamide 
series, the decrease in potency was less pronounced for iridium complexes 12-14 
(arene = Cp*, CpxPh, CpxBip) against cisplatin-resistant cells (17, 18 and 6.3 μM) 
compared to cisplatin-sensitive cells (20.9, 14 and 10.2 μM). Antiproliferative 
activities were also determined in SK-OV-3 and SW626 ovarian cancer cells which 
are both also insensitive to cisplatin, but were directly derived from a patient, and not 
laboratory-induced. Compared to platinum-sensitive A2780 ovarian cancer cells, SK-
OV-3 cells were found to be particularly insensitive to cisplatin (IC50 16.8 ± 0.8 μM 
compared to 1.2 ± 0.3 μM in A2780 cells). Similarly, both osmium and iridium 
sulfonamide complexes exhibited lower antiproliferative activities against both SK-
OV-3 (IC50 range: 32-64 μM) and SW626 (IC50 range: 26.0-48.8 μM) cell lines, 
consistent with observations of cross-resistance determined in A2780cis. These data 
suggest that mechanisms of resistance (increased efflux, reduced metal accumulation, 
in-cell deactivation by GSH) may be maintained in the sulfonamide series.32  
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Table 4.2. Antiproliferative activities determined for Os complexes 2, 7, 8 and Ir complexes 12-14 
against fourteen human cell lines, compared to Pt complex cisplatin (CDDP). 
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24 h drug exposure + 72 h recovery in drug-free medium. N.D. = not determined. 
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4.3.5 Metallodrug accumulation in cancer cells 
Further cellular metal accumulations were determined in seven cancer cell lines using 
parental osmium(II) and iridium(III) tosyl complexes 2 [Os(p-cymene)(TsDPEN] and 
12 [Ir(Cp*)(TsDPEN], in order to determine whether the apparent selectivity (higher 
antiproliferative activity) for particular tumour types arises from a greater influx of 
metal into the cell (Figure 4.6).  
Greater antiproliferative activity was clearly observed in cell lines that exhibited 
increased cellular metal accumulation. The correlation was observed for both osmium 
complex 2 and iridium complex 12 (Figure 4.6). For both complexes, accumulation 
was greatest in MCF7 breast cancer cells (33 ng Os × 106 cells and 74 ng Ir × 106 cells, 
respectively) and lowest in OE19 oesophageal cancer cells (2.23 ng Os × 106 cells and 
6.2 ng Ir × 106 cells, respectively). Accumulation of iridium complex 12 was typically 
2-3-fold greater than the accumulation of osmium complex 2, except for metal 
accumulation in PC3 cancer cells, where accumulation of both complexes was 
statistically equal (32 ± 2 and 31 ± 1 ng metal × 106 cells for complexes 2 and 12, 
respectively). Metal accumulations could not be determined in primary cell lines 
(MRC5 and HOF) due to the large number of cells required (4 × 106 cells seeded on 
day 1). The passage number required to grow this quantity of cells would result in the 
cells entering replicative senescence or differentiation. 
Metal accumulations were also determined in cisplatin-resistant A2780 cancer cells 
(A2780cis), and were significantly decreased by approximately one third of the metal 
accumulation, relative to the cisplatin-sensitive cell line (A2780) for both osmium 
complex 2 and iridium complex 12. Osmium complex 2: 9.5 ng Os × 106 cells 
compared to 30 ng Os × 106 cells. Iridium complex 12: 16.5 ng Ir × 106 cells compared 
to 52 ng Ir × 106 cells (Figure 4.6). 
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  ng Os / Ir × 106 cells 
  [Os(p-cymene)(TsDPEN)] 2 [Ir(Cp*)(TsDPEN)] 12 
A2780 Ovarian 30 ± 2 52 ± 1 
A2780cis Ovarian [a] 9.5 ± 0.7 16.5 ± 0.5 
A549 Lung 18 ± 2 27 ± 3 
HCT116 Colon 9.1 ± 0.6 13 ± 2 
HEPG2 Liver 17 ± 3 53.8 ± 0.9 
MCF7 Breast 33 ± 2 74 ± 5 
OE19 Oesophageal 2.23 ± 0.05 6.2 ± 0.3 
PC3 Prostate 32 ± 2 31 ± 2 
[a] Cisplatin-resistant ovarian cancer cells derived from parental cell line, A2780. 
Figure 4.6. Total metal accumulation (ng Os / Ir per million cells) in eight cancer cell lines, exposed to 
equipotent concentrations of complexes 2 (●) or 12 (●) for 24 h with no recovery time.  
 
Further detailed cellular accumulation studies were carried out in A2780 ovarian 
cancer cells using complexes 2 [Os(p-cymene)(TsDPEN)] and 12 
[Ir(Cp*)(TsDPEN)].  The concentration, time and temperature-dependence of drug 
accumulation were explored, as well as the role of metal efflux in the total 
accumulation of the compounds over 24 h drug exposure (and with up to 72 h recovery 
time, in the same way antiproliferative activities were determined) to better understand 
how the accumulation profiles differ between Os and Ir complexes.  
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Concentration-dependent metal accumulation 
The concentration-dependence of metal accumulation was investigated in A2780 
ovarian cancer cells treated using four different concentrations of either osmium 
complex 2 or iridium complex 12 (0.25, 0.5, 1.0, 1.5 × IC50), administered for 24 h at 
310 K with no recovery time (Figure 4.7).  
As observed in equipotent-concentration (1× IC50) experiments, the accumulation of 
iridium complex 12 was found to be significantly greater (ca. 1.6×) than the 
accumulation of osmium complex 2. Nonetheless, the extent of cellular metal 
accumulation in cells treated with either complex 2 or 12 was linearly dependent with 
respect to the concentration of the drug in solution.  
 
 
  Cellular accumulation (ng Os / Ir × 106 cells) 
 Complex 0.25 × IC50 0.5 × IC50 1.0 × IC50 1.5 × IC50 
2 [Os(p-cymene)(TsDPEN)] 7 ± 1 16 ± 1 30 ± 2 53 ± 7 
12 [Ir(Cp*)(TsDPEN)] 9 ± 1 20 ± 2 52 ± 1 84 ± 1 
 
Figure 4.7. Concentration-dependent accumulation of complexes 2 (●) and 12 (●) in A2780 cells: 0.25, 
0.5, 1, 1.5 × IC50. (310 K, 24 drug exposure, no recovery period).  
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Time-dependent metal accumulation 
Metal accumulation in A2780 cancer cells treated with either complex 2 or 12 was 
investigated in after 3, 6, 18 and 24 h drug exposure in an equipotent manner (fixed 
concentration equal to IC50 in A2780) at 310 K. After 24 h, the drug solution was 
removed. Cells were washed with PBS and allowed to recover in drug-free culture 
medium for 24 h (indicated by black line in Figure 4.8). Internalisation of iridium 
complex 12 was both greater and more rapid (maximum accumulation at 3 h, 53 ng Ir 
× 106 cells) than for osmium complex 2 (maximum accumulation of 42 ng Os × 106 
cells after 6 h exposure, compared with accumulation at 3 h, p=0.03), suggesting that 
accumulation of Os / Ir may be associated with different transport mechanisms. 
 
 
  Cellular accumulation (ng Os / Ir × 106 cells) 
 Complex 3 h 6 h 18 h 24 h 48 h 
2 [Os(p-cymene)(TsDPEN)] 32 ± 4 42 ± 1 33 ± 1 30 ± 2 19 ± 2 
12 [Ir(Cp*)(TsDPEN)] 53 ± 2 53 ± 3 51 ± 1 52 ± 1 17 ± 2 
 
Figure 4.8. Time-dependent accumulation (24 h drug exposure and 24 h recovery in drug-free cell 
culture medium) of complexes 2 (●) and 12 (●) in A2780 cells: 3, 6, 18, 24 h drug exposure (310 K, no 
recovery period, 1 × IC50) and with 24 h recovery time in drug-free medium. Drug removal time shown 
in black (24 h).  
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Interestingly, the greater internalisation of 12 goes against the frequently identified 
link between the higher internalisation of more hydrophobic complexes,8, 29 since 
experimentally-determined hydrophobicities (Log P) (Os-2 = 1.45 ± 0.02, Ir-12 = 0.86 
± 0.02) show 2 to be more hydrophobic than 12. These data suggest that the metal 
centre, rather than discrepancy between p-cymene and Cp* (reflected in the 
hydrophobicities of the complexes) appears to influence the accumulation of metal. 
Rapid accumulation of iridium complexes has been previously reported in many cases, 
achieving up to 80% of total iridium accumulation in the first hour of exposure.33 
Os(II) and Ir(III) efflux profiles were significantly different. The amount of Os in cells 
treated with complex 2 accumulated decreased linearly after reaching a maximum at 
6 h. No significant change in Ir accumulation in cells treated with complex 12 was 
observed between 3 h until drug removal after 24 h (Figure 4.8). After removal of the 
drug supernatant media at 24 h, cells were washed with PBS and allowed to recover 
in drug-free culture medium. Upon comparison of the amount of Os / Ir (ng metal × 
106 cells) in cells after 24 h recovery with the levels of accumulation after 24 h drug 
exposure, a rapid efflux of iridium was identified, with only ca. 32% of the Ir 
accumulation remaining after 24 h recovery. In contrast, ca. 63% of the internalised 
Os remained inside cells after 24 h recovery in drug-free culture medium. This 
variance in the accumulation of osmium / iridium provides useful information in the 
design of structurally-similar metallodrugs. The rapid accumulation and efflux profile 
of iridium complex 12 may facilitate a highly-controlled exposure time in cells, 
minimising drug clearance times (pharmacological half-life), whereas the gradual 
slow detoxification of Os complex 2 may be better suited for a catalytic metallodrug, 
that itself possesses only moderate activity, but could be activated in vitro in order to 
target cancer cells.   
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Temperature-dependent metal accumulation 
A2780 cancer cells were treated with equipotent concentrations (1× IC50) of either Os 
complex 2 or Ir complex 12 over a period of six hours under two different incubation 
temperatures (277 K and 310 K) as part of two independent experiments (each carried 
out in triplicate), to explore the contribution of passive / active mechanisms in the 
accumulation of metal into the cell. The Os accumulation at 277 K in cells treated with 
complex 2 was found to be significantly decreased (p = 0.0013) at both 3 h (ca. 10% 
of the Os accumulation at 310K) and 6 h (ca. 25% of the Os accumulation at 310 K).  
 
     
  Metal accumulation (ng Os / Ir × 106 cells) 
 Complex Temp. / K 3 h 6 h 
2 [Os(p-cymene)(TsDPEN)] 277 3 ± 2 10.2 ± 0.1 
2 [Os(p-cymene)(TsDPEN)] 310 32 ± 4 42 ± 1 
12 [Ir(Cp*)(TsDPEN)] 277 26 ± 3 36 ± 9 
12 [Ir(Cp*)(TsDPEN)] 310 53 ± 2 53 ± 3 
 
Figure 4.9. Cellular accumulation of complexes 2 (● 277 K, ● 310 K) and 12 (● 277 K, ● 310 K) in 
A2780 cancer cells at two incubation temperatures for 0, 3, 6 h drug exposure (1.0 × IC50 concentration). 
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The accumulation of iridium in cells treated with complex 12 was also affected by 
temperature (p = 0.0069) with ca. 49% of the Ir accumulation determined at 310K 
after 3 h, and 68% of the accumulation determined at 310K after 6 h. In contrast to the 
accumulation of Os in cells treated with complex 2, the decrease in iridium 
accumulation at lower temperature was markedly less dramatic (Figure 4.9). The low 
accumulation of osmium at 277 K suggests that the accumulation may be largely active 
(energy-dependent) in nature, in contrast to complex 12, whose Ir accumulation may 
be contributed to by both active (energy-dependent) and passive (energy-independent) 
mechanisms.  
 
Metal efflux and evolvement of the P-gp efflux pump in ovarian cancer cells 
A2780 cancer cells treated with complex 2 or 12 were also incubated with a known 
efflux pump (P-glycoprotein) inhibitor, verapamil (20 μM), for 72 h recovery period 
after 24 h drug exposure at 1.0 × IC50 equipotent concentrations, with cells collected 
and analysed after 0, 24, 48 and 72 h recovery time in either the presence and absence 
of verapamil.  
Verapamil was found to significantly affect the efflux of both Os (complex 2) and Ir 
(complex 12)  from treated cells (P < 0.05, Figure 4.10) however the effect was more 
apparent (P < 0.05) at an earlier time for Os complex 2 (24 h) compared to Ir complex 
12 (48 h). The efflux of metal from treated cells was statistically the same after 72 h, 
regardless of verapamil concentration, suggesting that either the efficacy of verapamil 
is short-lived, or that a plateau in drug efflux was reached.  
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   % accumulation (recovery time) 
 Cell line     Verapamil / μM 0 h 24 h 48 h 72 h 
2 A2780 0 100 ± 2 34 ± 4 19 ± 2 15 ± 2 
2 A2780 20 100 ± 2 54 ± 7 30 ± 2 17.8 ± 0.3 
12 A2780 0 100 ± 6 40 ± 5 25 ± 3 24 ± 1 
12 A2780 20 100 ± 6 46 ± 3 40 ± 5 27 ± 5 
 
Figure 4.10. Percentage metal efflux (normalised) of complexes 2 (●) and 12 (●) from Pt-sensitive 
A2780 cancer cells and Pt-resistant A2780cis cancer cells in: (a) drug free medium; (b) the presence of 
verapamil (20 μM) – a known PgP inhibitor. Verapamil significantly inhibits the efflux of Os and Ir 
from A2780 cancer cells (* P<0.05). Statistics calculated using a two-tailed t-test assuming unequal 
variances (Welch’s t-test). 
 
4.3.6 Cellular metal distribution in cancer cells 
The distribution of Os or Ir inside A2780 cancer cells was investigated using the 
BioVision Fraction PREP kit (Figure 4.11). Four fractions were isolated: cytosolic 
(soluble cytoplasmic proteins), membrane (soluble membrane proteins and 
organelles), nucleic (soluble nuclear membranes and proteins) and the cytoskeletal 
(insoluble proteins). Metal distribution was found to differ significantly between Os 
and Ir complexes. Membrane localisation was significantly lower for Ir complex 12 
than Os complex 2 (p < 0.01), while a lower metal percentage distribution was 
determined for the cytoplasmic fraction for Os complex 2 than Ir complex 12 (p < 
0.05). Nuclear and cytoskeletal accumulations were low for both metal complexes.  
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 Normalised population % 
 Cytosol Membrane Nucleus Cytoskeleton 
2 47 ± 2 48 ± 3 1.6 ± 0.5 2.9 ± 0.3 
12 63 ± 7 26 ± 2 2.3 ± 0.3 8.5 ± 0.5 
 
Figure 4.11. Cellular Os / Ir distribution in A2780 cancer cells exposed to complexes 2 and 12 (1.0 × 
IC50) for 24 h without recovery time. * P<0.05, ** P<0.01. Four fractions: cytosolic (soluble 
cytoplasmic proteins; ●), membrane (soluble membrane proteins and organelles; ●), nucleic (soluble 
nuclear membranes and proteins; ●) and the cytoskeletal (insoluble proteins; ●). 
 
4.3.7 Generation of reactive oxygen species (ROS) and superoxide 
The generation of reactive oxygen species (ROS; hydrogen peroxide, hydroxyl-
radicals, singlet oxygen, and superoxide) by complexes 2 and 12 (1 × IC50) was 
investigated in A2780 cancer cells and HOF ovarian fibroblasts by flow cytometry 
using a ROS/superoxide detection kit (Enzo Life Sciences). Levels of ROS were 
determined after 24 h drug exposure without recovery time (since reactive oxygen 
species are short-lived). Both complexes of osmium and iridium produced large bursts 
of ROS and superoxide (Q2) in A2780 cancer cells after 24 h drug exposure (96 ± 1 
% and 96 ± 2 % for 2 and 12, respectively; Figure 4.12), which was statistically similar 
for both 2 (Os p-cymene) and 12 (Ir Cp*). The detection of ROS/superoxide by 
complex 2 was further explored using ovarian fibroblasts (HOF, non-cancerous cells), 
and the generation of superoxide was remarkably reduced in non-cancerous cells. 
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Untreated (-) / Pyocyanin (+)              Complex 2                        Complex 12 
        
 % Population ± SD 
Complex Q1 [a] Q2 [b] Q3 [c] Q4 [d] 
2 1.2 ± 0.2 96 ± 1 0.3 ± 0.1 2.4 ± 0.9 
12 1.4 ± 0.2 96 ± 2 0.22 ± 0.08 2 ± 1 
Untreated 0.05 ± 0.05 0.01 ± 0.02 0.00 ± 0.00 99.93 ± 0.06 
Pyocyanin 1.01 ± 0.08 94.4 ± 0.4 1.23 ± 0.01 3.4 ± 0.2 
 
Figure 4.12. Flow cytometry data for complexes 2 and 12 in A2780 cancer cells. ROS and superoxide 
are generated after 24 h drug exposure with no recovery time. Positive control = pyocyanin. [a] Q1: FL1-
FL2+ (superoxide), [b] Q2: FL1+FL2+ (superoxide and oxidative stress), [c] Q3: FL1+FL2- (oxidative 
stress), [d] Q4: FL1-FL2- (no superoxide or oxidative stress). 
 
The Q2 population (FL1+ / FL2+ for superoxide and total reactive oxygen species) 
decreased from 96% in A2780 cancer cells (Figure 4.12) to 38% in HOF fibroblasts 
(Table 4.3) suggesting a lower amount of total ROS in the non-cancerous cells, 
however the Q3 population (total ROS) was increased from 0.3% in A2780 cancer 
cells to 45.4% in HOF fibroblasts treated with 2. 
 
Table 4.3. Flow cytometry data for complex 2 in HOF ovarian fibroblasts. ROS and superoxide are 
generated after 24 h drug exposure with no recovery time. Positive control = pyocyanin [a] Q1: FL1-
FL2+ (superoxide), [b] Q2: FL1+FL2+ (superoxide and oxidative stress), [c] Q3: FL1+FL2- (oxidative 
stress), [d] Q4: FL1-FL2- (no superoxide or oxidative stress). 
 % Population ± SD 
Complex Q1 [a] Q2 [b] Q3 [c] Q4 [d] 
2 9.1 ± 0.8 38 ± 1 45.4 ± 0.7 7.3 ± 0.5 
Untreated 17 ± 2 0.2 ± 0.2 0.4 ± 0.2 83 ± 2 
Pyocyanin 8 ± 2 90 ± 2 1.2 ± 0.2 1.2 ± 0.5 
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4.3.8 Combination with L-buthionine sulfoximine 
The redox chemistry of osmium complex 2 was further explored by determining the 
IC50 concentration in the presence of a non-toxic concentration (5 μM) of L-buthionine 
sulfoximine (L-BSO), an inhibitor of γ-glutamylcysteine synthetase, an enzyme 
essential to the synthesis of the antioxidant molecule, glutathione (GSH). L-BSO was 
administered to cells independently of the osmium complex, but within 5 minutes of 
exposure to 2 or 12. 
The activity of complex 2 was significantly increased at the 95% confidence level, 
suggesting that GSH depletion and enhanced redox sensitivity increased the potency 
of the Os complex. The IC50 concentration decreased by ca. 36% in the presence of 5 
µM L-BSO, from 15.74 ± 0.07 μM to 10.0 ± 0.7 μM (Table 4.4). Conversely, the 
anticancer activity of complex 12 was unaffected by the presence of 5 µM L-BSO 
(20.9 ± 0.7 μM compared to 21.7 ± 0.9 μM; P = 0.3112). These data suggest that GSH 
may a play a role in the detoxification of osmium complex 2 inside the cell, but is 
unlikely to affect the potency of iridium complex 12. Alternatively, ROS generation 
by iridium complex 12 may be so great that the concentration of intracellular GSH is 
not adequate to sequester the effect. If so, inhibition of GSH synthesis by 
administration of L-BSO would not significantly improve the activity of 12. 
 
Table  4.4. Modulation of the antiproliferative activity of complex 2 or 12 by co-administration of a 
non-toxic concentration of L-BSO (5 μM), in A2780 cancer cells (24 h drug exposure, 72 h recovery 
time in drug-free medium). 
   L-buthionine sulfoximine  
 Complex 0 μM 5 μM t-test [a] 
2 [Os(p-cymene)(TsDPEN)] 15.74 ± 0.07 10.0 ± 0.7 * P = 0.0050 
12 [Ir(Cp*)(TsDPEN)] 20.9 ± 0.7 21.7 ± 0.9 P = 0.3112 
[a] Two-tailed t-test with unequal variances (Welch’s t-test). * P<0.05 
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4.4 Discussion 
 
4.4.1 Synthesis and stability of Ir(III) sulfonamide complexes 
Though the synthesis of [Ir(Cp*)(TsDPEN)] 12 has been previously described,20 the 
biological activities of 12, extended arene complexes 13-14, and methoxy-substituted 
complexes 15-17 have not been explored. The purple 16-electron active complexes 
(Figure 4.2) were all readily isolated by the same method described for Os complexes 
2-10 (Chapter 3, section 3.3.1, page 78), and were readily recrystallised from 
dichloromethane / n-hexane. Examples of stable coordinatively-unsaturated Ir(III) 16-
electron N,O-phosphoramidate and hydride-pincer complexes are known,34, 35 and 
similarly the Ir(III) complexes described here were also stable. 
Ir(III) complexes 12-17 all display high stabilities in phosphate-buffered saline 
solution in the presence of DMSO. Changes in UV-visible or 1H-NMR spectra were 
not observed over a 24 h period (Figure 4.3), suggesting that it is unlikely that aqua, 
DMSO, or chloro- adducts form, unless the formation is immediate, and the formation 
cannot be detected before the acquisition of the first spectra. While iridium 
phenylpyridine complexes are known to form aqua adducts in solution,33 the apparent 
inertness of coordinatively-unsaturated iridium sulfonamide complexes was also 
observed for the osmium series in Chapter 3 (section 3.3.4, page 85). Both extension 
of the aromatic unit, and introduction of methoxy-substituents onto the chiral pendant 
phenyl groups of the diamine, were found not to affect the aqueous stability. Methoxy 
groups have been shown to increase the in vivo half-lives of sulfonamides.36 This 
substitution noticeably improved the aqueous solubility of 15-17, reflected in the 
lower partition coefficients determined by the shake-flask method (12-14: 0.86, 1.41, 
and 2.24; 15-17: 0.03, 0.32, and 0.62 respectively).  
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4.4.2 Hydrophobicity, metal accumulation and anticancer activity 
In the design of novel anticancer metal complexes, a trade-off between hydrophobicity 
(greater cellular accumulation) and hydrophilicity (solubility in blood plasma to reach 
cells) is required. Octanol / water partition coefficients (Log P) are commonly used to 
model the distribution of molecules across lipid membranes, such as those present in 
cells. Compounds with greater partition coefficients (more hydrophobic) are 
anticipated to readily diffuse from the aqueous phase into the organic (octanol phase), 
whereas those with lower (or negative) partition coefficients.  
Both osmium and iridium complexes were found to have high-to-moderate activity in 
A2780 cancer cells (Table 4.1) with IC50 values ranging from 0.7 μM (complex 17) to 
30 μM (complex 3). Osmium complexes typically exhibited higher antiproliferative 
activities (15.5, 6.5, 4.4 μM for Os complexes 2 (p-cymene), 7 (biphenyl), 8 (m-
terphenyl) compared to 20.9, 14, 10.2 μM for Ir complexes 12-14), despite generally 
lower cellular metal accumulation (30, 13, 31.9 ng Os × 106 cells for complexes 2, 7, 
8 compared to 52, 41.7, 89 ng Ir × 106 cells for complexes 12-14). This suggests that 
the efficiency of the osmium(II) complexes inside cells may be higher than analogous 
iridium(III) complexes, which may relate to the lower oxidation state of Os(II), 
rendering the complex less prone to attack by nucleophiles present inside the cell (such 
as glutathione, and negatively charged amino acids such as cysteine and serine). 
Arene ring extension is clearly shown to increase hydrophobicity for both the Os (3 > 
2 > 1) and Ir (6 > 5 > 4) DPEN series as well as the BMEN Os (10 > 9) and Ir (17 > 
16 > 15) series, which in turn correlates with antiproliferative activity against cancer 
cells (Figure 4.13). The low hydrophobicity of methanesulfonyl complex 3 (Log P = 
0.18) may explain its lower antiproliferative activity (30 μM) compared to the rest of 
the Os sulfonamide complexes. The same trend between Log P and IC50 is commonly  
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Figure 4.13. Correlation between antiproliferative activity (IC50 in A2780) and octanol / water partition 
coefficient (Log P) for both diphenylethylenediamine (DPEN) and bis(4-methoxyphenyl)-
ethylenediamine (BMEN) complexes. R2 = 0.74 (DPEN), 0.84 (BMEN). 
 
 
identified for similar late-transition metal compounds,37-39 and we now show that this trend is 
also observed for the sulfonamide complexes. Interestingly, while methoxy-substituted 
compounds 9-10 and 15-17 had lower hydrophobicity than their DPEN counterparts 
(achieving greater water solubility), the BMEN complexes were generally more active 
against A2780 cancer cells (Table 4.1 and Figure 4.13), which was particularly 
prominent for Ir CpxBip complex 17 (IC50 = 0.7 μM; 15× more active than parent 
complex 14, IC50 = 10.2 μM). The introduction of polar substituents, such as methoxy 
groups, may aid interaction with biological moieties inside cells which are often highly 
charged, such as nucleic acids and proteins.  
Only slight correlation was observed between total metal accumulation in A2780 
cancer cells and Log P for osmium DPEN sulfonamide series 2-8 (Figure 4.14, R2 = 
0.35) while no correlation is observed for BMEN complexes (R2 < 1 × 10-5). This does 
not appear to correlate with arene ring extension, since if lipophilicity was the only 
factor determining cellular accumulation, the expected trend would be m-terphenyl (8) 
> biphenyl (7) > p-cymene (2). A similar lack of correlation between accumulation 
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Figure 4.14. Lack of correlation between total drug accumulation (ng metal × 106 cells) in A2780 
cancer cells and Log P for diphenylethylenediamine (DPEN). No correlation is observed for bis(4-
methoxy-phenyl)ethylenediamine (BMEN) complexes. Pearson’s r = 0.35 (DPEN), < 0.01 (BMEN). 
 
and hydrophobicity was previously identified for a series of Pt complexes.29 Complex 
lipophilicity may not be the only factor that governs cellular accumulation. If the 
complexes were only internalised in cells by passive diffusion, the accumulation trend 
should be linear with respect to lipophilicity. However, contribution from energy-
dependent (active) mechanisms (such as ATP-dependent transporter proteins) would 
differ significantly from the hypothesised relationship between hydrophobicity and 
(passive) drug accumulation, as identified in the sulfonamide series. 
 
4.4.3 Multi-cell line antiproliferative activity screening 
Osmium tosyl (TsDPEN) 2 (p-cymene), 7 (biphenyl) and 8 (m-terphenyl), and iridium 
complexes 12-14 (Cp*, CpxPh and CpxBip) showed broad activity across the majority 
of cell lines investigated (Table 4.2), and in particular, the complexes showed promise 
in cancers of the reproductive organs, specifically of the breast, ovary and prostate 
(MCF7, A2780 and PC3, respectively). This trend could be linked to the fact that 
cancers of these tissues are typically hormone-responsive, and the mechanism of 
action may involve interactions with receptor sites or hormone-dependent pathways.  
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Ruthenium conjugates of the peptide hormone somatostatin have been designed to 
increase cancer cell selectivity by generation of 1O2 upon light irradiation, utilising the 
overexpression of somatostatin receptors in various cancer cell types relative to 
healthy cells.40 Ruthenocene complexes derived from the anticancer drug Tamoxifen 
were found to bind to estrogen receptor alpha (up to 85% binding, compared to 39% 
for hydroxytamoxifen) but did not exhibit potency towards ER-α-negative cells.41  
Os and Ir sulfonamide complexes displayed particularly low antiproliferative activities 
(in some cases, >50 μM) in gastrointestinal cell lines (OE19 and HCT116), suggesting 
selectivity for cells of particular tissues – an important property in the design of new 
anti-cancer agents. In addition to specific tumour selectivity, efficacies of the 
complexes were investigated between cancer cells (A2780 and A549) and two non-
cancerous primary cell lines, ovarian (HOF) and lung fibroblasts (MRC5) as a model 
for healthy cells. Ovarian fibroblasts were chosen for comparison to A2780 ovarian 
cancer cells, in which the complexes were highly active. In this case, Os complexes 2 
(p-cymene), 7 (biphenyl), and 8 (m-terphenyl) displayed good selectivity for cancer 
cells over healthy cells. Many other osmium complexes have displayed similar 
positive selectivity towards cancerous cells.18, 42 Iridium compounds 12-14 were not 
as selective, achieving only ca. 2× selectivity. The selectivity of iridium complexes 
for cancer cells over normal cells is highly dependent on the nature of the bidentate 
ligand.33, 43 While cyclometalated iridium bipyridine complexes were found to possess 
ca. 11-fold selectivity for cancer cells over healthy cells, Ir(III)-curcumin complexes 
lack the selectivity found in structurally similar Ru(II)-curcumin derivatives.44 In this 
study, both Ir(III) and Os(II) sulfonamide complexes were poorly selective between 
cancerous (A549) and healthy (MRC5) lung cells, largely due to the low activity in 
the cancerous lung cell line.  
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Table 4.5. Resistance factors (A2780cis/A2780) calculated for complexes of Os (2, 7-8) and Ir (12-14). 
 
Complex 2 7 8 12 13 14 
Metal Os Os Os Ir Ir Ir 
Arene p-cym bip m-terp Cp* CpxPh CpxBip 
A2780 15.5 ± 0.5 6.5 ± 0.3 4.4 ± 0.3 20.9 ± 0.7 14 ± 2 10.2 ± 0.6 
A2780cis 21.6 ± 0.2 25.9 ± 0.7 10.4 ± 0.5 17 ± 2 18 ± 1 6.3 ± 0.8 
R.F. [a] 1.4 4.0 2.4 0.8 1.3 0.6 
[a] Resistance factor (R.F.) defined as the ratio of the IC50 determined in A2780cis / A2780. 
 
Osmium(II) complexes 2 (p-cymene), 7 (biphenyl), and 8 (m-terphenyl) exhibited less 
potency towards cisplatin-resistant cells (A2780cis) compared to cisplatin-sensitive 
cells (resistance factor > 1; Table 4.5). Less cross-resistance was observed with 
iridium complexes 12-14 and in fact Ir complexes 12 and 14 were more potent in the 
resistant cell line (resistance factor = 0.8 and 0.6, respectively). This is in agreement 
with other iridium(III) half-sandwich complexes.10, 30 Importantly, all sulfonamide 
complexes of osmium and iridium investigated exhibited less cross resistance than 
cisplatin (resistance factor = 11.2). This is an important finding, since the treatment of 
drug-resistant tumours is a problem of clinical significance, as cisplatin-resistant cells 
have been shown to decrease drug transport, modify apoptotic pathways and develop 
drug detoxification mechanisms to maintain proliferative growth.45  
In addition to comparing between different cancer cell types, antiproliferative 
activities were determined in 3 ovarian cancer cell lines: A2780, SW626 and SK-OV-
3. A2780 are a platinum-sensitive cell line, while SW626 and SK-OV-3 are 
increasingly platinum-insensitive cell lines (cisplatin: 1.2 µM, 15.7 µM and 16.8 µM, 
respectively). Similarly, the antiproliferative activities of both osmium sulfonamide 
(2, 7, 8) and iridium sulfonamide (12, 13, 14) complexes are in agreement with this 
trend, with complexes exhibiting highest potency in A2780 and lower potency in the 
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platinum-insensitive cell lines. Taken in combination with the reduced cellular metal 
accumulation in A2780cis (platinum-resistant) cells, a resistance mechanism is likely 
common to Pt drug exposure and treatment with Os / Ir complexes.  
Comparing antiproliferative activities between parental HCT116 colorectal cancer 
cells and derived cell lines with genetically-engineered knockouts of key genes (P21 
and the tumour-suppressor gene P53, in HCT116-p21-/- cells and HCT116-p53-/- 
cells, respectively) provides an indication of the gene’s involvement in the mechanism 
of action. If the gene is involved in the mechanism, the determined IC50 concentration 
would be higher (less active) in the knock-out cell line. Conversely, the IC50 
determined in a knock-out cell line would not be affected if the gene is not critical to 
the mechanism of action. For cisplatin, antiproliferative activities are decrease in both 
the p21 (9.2 µM) and p53 (36.7 µM) knock-out cell lines, relative to the parental line 
(5.2 µM). This trend is also conserved in both the osmium and iridium sulfonamide 
series of complexes, which all exhibited the highest relative activity in the parental 
cell line. In each case, these data suggest that it is likely that p21 and/or p53 are 
involved in the mechanism of action, reflected in the decreased antiproliferative 
activities determined in the knock-out cell lines. 
Since complexes 2 and 12 have been shown to carry out the catalytic oxidation of 1,4-
NADH to NAD+ under biologically-relevant conditions, it is likely that the complexes 
may interfere with cellular metabolic pathways, which require NADH as a hydride 
source for the reduction of substrates, for example, the conversion of pyruvate to 
lactate, which cancer cells utilise to respire (described by the Warburg Effect).46-48 
However, perturbation of the NADH/NAD+ ratio is also known to induce the 
production of ROS by complex I of the mitochondrial electron transport chain.49 In 
fact, other metabolic-targeting compounds have previously been associated with p21-
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dependent cell death.  While expression of the cyclin-dependent kinase inhibitor 
(CDK) p21 is known to be up-regulated by p53 in response to anticancer agents, its 
expression can also be regulated without functional p53.50 A structurally-similar 
osmium(II) half-sandwich complex [Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-
dimethylaniline)I]PF6 generates mitochondrial ROS, leading to the up-regulation of 
both p53 and p21, implicating their involvement in the mechanism of action.18 Since 
p53 and p21 appear to also be involved in the mechanism of action of 2 (less activity 
the knock-out cell lines), which also produces ROS and superoxide in A2780 cancer 
cells, Os(II) arene complexes may share a common mechanism of action. 
Overall, osmium(II) complexes typically exhibit higher antiproliferative activities 
than their Ir(III) counterparts, though at the expense of slightly increased cross-
resistance against platinum-resistant cells. However, the accumulation of iridium in 
cells treated with Ir complexes 12-17 surpassed the levels of osmium internalised by 
cells treated with Os complexes 2-10. Since examples of both Os and Ir sulfonamide 
complexes have been shown to convert NADH to NAD+ under biologically relevant 
conditions, it may be possible that the mode of action is catalytic in cells. While both 
osmium and iridium complexes have been shown to be highly stable in biological 
media, the higher charge of Ir(III) compared to Os(II) may more readily promote 
catalyst deactivation by nucleophilic components in the cell, such as nucleophilic 
amino acid side-chains: cysteine (R-SH) serine (R-OH), histidine (R-NHR) and lysine 
(R-NH2).  
While the nature of the metal centre appears to be crucial when comparing biological 
activities of Os and Ir complexes (both the antiproliferative activity of the complex 
and the extent of metal accumulation into the cell), exchange of the arene to afford 
neutral complexes (for example, Os-p-cymene for Ir-Cp*) does mean that specific 
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conclusions about the role of the metal cannot be made. Even if the directly analogous 
complexes, [Os(Cp*)(diamine)]- or [Ir(p-cymene)(diamine)]+ complexes could be 
synthesised, the anionic / cationic nature of the complexes would likely dramatically 
alter their properties; by increasing water solubility (and therefore would have a lower 
octanol / water partition coefficient, Log P) which may influence the antiproliferative 
activity towards cancer cells, cellular accumulation, and ability to carry out the 
catalytic oxidation of NADH.  
 
Cellular accumulation in other cancer cell lines 
The cellular metal accumulation was determined in seven cancer cell lines (Figure 4.6) 
treated with equipotent concentrations of either Os complex 2 or Ir complex 12. ICP-
MS was used to detect xenobiotic elements in cell pellets digested in acidic solution. 
Despite the lower osmium cellular accumulation compared to iridium across the range 
of cell lines investigated (30 ng Os × 106 cells for complex 2 compared to 52 ng Ir × 
106 cells for complex 12 in A2780), osmium complexes were typically more potent 
than their iridium counterparts (15.5 ± 0.5 μM for Os complex 2 compared to 20.9 ± 
0.7 μM for Ir complex 12 in A2780). Structurally similar osmium half-sandwich 
compounds have been determined to accumulate in cancer cells at similar 
concentrations (20-60 ng Os × 106 cells) to complexes 2-10 investigated in this chapter 
(ranging from 5-30 ng Os × 106 cells, depending on the nature of the arene and 
sulfonamide ligand),51 while previous iridium arene complexes have been shown to 
accumulate rapidly in cells,33 similarly to finding using complex 12. 
Across multiple cell lines treated equipotent concentrations of either complex 2 or 12, 
increased metal accumulation in treated cells correlated with increased drug potency 
(ranging from 2.32-32 ng Os × 106 cells for 2, and 6.2-74 ng Ir × 106 cells for complex 
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12, with corresponding IC50 values between 10.9-50 μM, and 14.6-50 μM 
respectively). Particular cell lines may be more specialised for the internalisation of 
hydrophobic molecules, or conversely, efflux xenobiotic species more efficiently than 
other types of cell. Specifically, gastrointestinal (GI) epithelial cells are particularly 
adapted to circumvent toxin bio-accumulation,52 which may explain the low 
antiproliferative activities determined in OE19 (esophageal) and HCT116 (colorectal) 
cell lines. However, the cellular accumulation of anticancer compounds in GI cancers 
may be increased by functionalisation of molecules with substrates for nutrient 
transporters.52 Additionally, vitamin B12 is readily absorbed via receptor-mediated 
endocytosis.53 B12 conjugates of nanoparticles and peptides have been explored to 
increase GI tract drug adsorption.53, 54 A similar strategy could be explored for 
accumulation of future anticancer drugs, increasing oral bio-availability. 
The metal accumulation studies in this thesis were normalised by cell number but did 
not account for cell volume, which varies greatly between cell lines, so an accurate in-
cell concentration cannot be determined. Cell volume may be determined using flow 
cytometry, a Coulter counter,55 or more recently, by use of a confocal laser scanning 
microscope combined with 3D reconstruction software.56 Suspended microchannel 
resonators have been described which measure simultaneously the volume, density 
and mass of single cells,55 however this work goes beyond the scope of this thesis. 
Alternatively, single-cell ICP techniques could allow for the evaluation of metal 
accumulation in cells, providing data concerning the accumulation of metal in a 
population of cells, rather than whole-pellet digest.  
Accumulation of Os and Ir in cisplatin-resistant cells (A2780cis) decreased to 
approximately ⅓ of the metal accumulation in the platinum-sensitive cell line (30 to 
9.5 ng Os × 106 cells). Reduction in total metal accumulation has also been observed 
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with platinum drugs for various ovarian cancer cell lines, in many cases reduced by 
the same amount as observed for the sulfonamide complexes (for cisplatin, this is 
between 36-66% of the accumulation determined in platinum-sensitive cells, 
depending on the study and cell lines investigated).57-59 Platinum resistance has been 
shown to result in approximately one order of magnitude fewer platinum-DNA 
adducts forming.60 As well as decreased drug accumulation, resistance has also been 
associated with increased platinum drug efflux.32 More detailed studies of the 
mechanism(s) of drug uptake and efflux may therefore help to explain the apparent 
absence of a trend between total accumulation and drug hydrophobicity. For example, 
the P-glycoprotein efflux pump (a translocating ATPase) has a broad specificity for 
many hydrophobic drugs, which are known to include many anticancer agents,61 and 
cells from particular tissues may be better adapted for the accumulation of molecules. 
 
4.4.4 Differences in drug accumulation between Os(II) and Ir(III) complexes 
Cellular accumulations were studied in greater detail, using equipotent concentrations 
of either complex 2 or 12 as representative examples from the Os and Ir series, 
respectively, in A2780 cancer cells. Equipotent concentrations of each drug were used 
to directly compare the amount of metal required to achieve the same pharmacological 
effect.  
In concentration-dependent studies, for both metal complexes, the accumulation was 
found to be linear with respect to concentration, with no system (e.g. transporter 
channel) saturation observed up to the highest concentration tested (1.5 × IC50, Figure 
4.7). This is comparable with other metal-based chemotherapeutics, such as cisplatin, 
which is known to accumulate linearly over two orders of magnitude (0.25-100 µM).58 
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It is therefore likely that the accumulation of osmium or iridium is not dependent on a 
single mechanism, and is likely to involve contributions from multiple mechanisms of 
internalisation.  
Incubation of cells at 277 K (Figure 4.9) significantly decreased the accumulation of 
both 2 and 12 after 3 h drug exposure (to ~9% of the accumulation at 310 K for cells 
treated with Os-2, and to 50% of the accumulation at 310 K for cells treated with Ir-
12). It is likely that the accumulation of 12 involves contributions from both energy-
dependent and passive diffusion, which has also been observed for iridium Cp* 
benzoquinoline complexes, where Ir accumulation at 277 K was reduced to 26% of 
the accumulation at 310 K.30 In contrast, the very low Os accumulation (3 ± 2 ng Os 
× 106 cells) at 277 K suggests that the accumulation of 2 is largely active in nature.  
Future experimentation could confirm this hypothesis by depletion of ATP using 2-
deoxyglucose or oligomycin, inhibitors of glycolysis and oxidative phosphorylation, 
respectively,62 or by using copper chloride to examine the role of CTR1/CTR2 copper 
transporter proteins.24 The contribution of passive diffusion is more challenging to 
study, since the accumulation is not affected by molecular inhibitors. However, 
changes to the fluidity of the cell membrane (by cholesterol depletion using methyl-
β-cyclodextrin) can influence passive diffusion,62 but this was not explored here. 
Time-dependent accumulation (Figure 4.8) showed a faster rate of metal accumulation 
in A2780 cancer cells treated with Ir complex 12, reaching equilibrium between drug 
influx and efflux (53 ± 2 ng Ir × 106 cells) after just 3 h drug exposure, which was 
maintained throughout drug exposure (52 ± 1 ng Ir × 106 cells after 24 h). However, 
the level of internalised iridium sharply decreased after removal of the drug-containing 
medium (17 ± 2ng Ir × 106 cells after 24 h recovery time), which would be consistent 
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with an energy-independent (passive diffusion) uptake pathway; whereby the uptake 
of metal is determined by the concentration gradient. In contrast, the accumulation of 
osmium complex 2 reached a maximum after 6 h drug exposure (42 ± 1 ng Os × 106 
cells). After this time, the rate of drug efflux exceeded influx, and even after removal 
of the drug medium, the rate of efflux remained linear. These data reflect the 
contrasting biological interactions experienced by complexes 2 (Os) and 12 (Ir). 
Similar gradual detoxification of osmium from the cell has previously been observed 
with [Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]PF6 in A549 cells,51 
which appears to be a common trait for Os p-cymene complexes. Multi-drug resistant 
(MDR) transporter proteins MRP1-3 are known to transport neutral molecules,63 and 
may more readily efflux Ir compared to Os, reflected in the rapid rate of efflux.  
P-glycoprotein (P-gp) is a drug efflux transporter which is widely selective for many 
hydrophobic compounds.61 Cisplatin exposure is known to increase the expression of 
P-gp, while Pt-sensitivity can be restored by administration of verapamil, a P-gp 
inhibitor. The effect of P-gp inhibition on the efflux of metal from cells treated with 2 
or 12 was examined by allowing cells, treated with complex for 24 h, to recover in 
culture medium containing 20 µM verapamil (Figure 4.10). Verapamil was found to 
significantly reduce the efflux of 2 and 12 (p<0.05).  
While this effect has been previously described for similar Ir(III) and Ru(II) 
complexes,30, 37 this work appears to be the first example of efflux inhibition by 
verapamil in cells treated with an Os(II) complex. The remaining metal in the cell after 
recovery time might not be excreted due to binding with various cellular components 
(e.g. membrane proteins, formation of adducts with GSH). Future work may explore 
the efflux of 2 and 12 from cisplatin-resistant cells to assess the contribution efflux 
has on the observed drug resistance. 
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4.4.5 Contrasting cellular metal distribution 
Cellular distributions of 2 and 12 were investigated in A2780 cancer cells. 
Interestingly, the cellular distributions significantly differed between the Os / Ir 
complexes. Membrane accumulation was decreased in the case of 12 (48%) compared 
to Os complex 2 (26%). Other organo-osmium complexes have been shown to 
accumulate highly in the mitochondria of A549 lung cancer cells (leading to 
mitochondria mediated apoptosis and S-phase cell cycle arrest), suggesting a possible 
sub-cellular target.51 For complexes 2 and 12, the differences between cytoplasmic 
(47% and 63%, respectively) and membrane (48% and 26%, respectively) 
distributions may also be attributed to the hydrophobicity of the complexes, as 12 was 
found to be less lipophilic than complex 2 (log P = 0.86 ± 0.02 compared to 1.45 ± 
0.02) and may not cross the lipid bilayer as readily. Though nucleic fractions did not 
contain large quantities of Os and Ir (2: 1.6 ± 0.5 %, 12: 2.3 ± 0.3 %) and did not 
significantly differ between the complexes (p = 0.1982), the low nucleic accumulation 
should not discount DNA interaction as a possible mechanism of action. The generally 
accepted mechanism of action of cisplatin involves the formation of intra and 
interstrand cross-links with DNA, and despite its low (~1%) nucleic accumulation, 
cisplatin is still a DNA targeting agent.64 Overall, the wide cellular dispersion of 2 and 
12 in the cytoplasm and membrane fractions suggests that the antiproliferative 
properties of the complexes may not rely on a single mechanism of action, and may 
potentially decrease the likelihood of the cancer cell acquiring drug resistance. 
Furthermore, the difference in metal distribution may contribute to the differing 
antiproliferative activities between Os and Ir sulfonamide complexes, since the sub-
cellular metal distribution of similar metal-arene complexes has been previously 
shown to determine the cell’s fate.63 
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4.4.6 Redox-targeting mechanism of sulfonamide complexes 
Complexes 2 [Os(p-cymene)(TsDPEN)] and 12 [Ir(Cp*)(TsDPEN)] are known to be 
efficient catalysts for transfer hydrogenation reactions.28, 65 In cells, The co-factor 1,4-
NADH is important in maintaining redox balance, and acts as a hydride source for 
metabolic reductions, itself becoming oxidised to NAD+. In fact, perturbation of the 
NADH/NAD+ ratio has been implicated in the mechanism of action of other Ir(III) and 
Os(II) metal complexes.33, 66 
Complex 2 and 12 were therefore explored as potential catalysts for the oxidation of 
NADH to NAD+ using UV-visible spectroscopy. NADH exhibits a characteristic 
absorption band at 340 nm (ε = 6220 cm-1M-1), while NAD+ does not absorb at 340 
nm. Both complexes were found to catalyse the oxidation of NADH, though oxidation 
was found to proceed at a significantly faster rate when using Ir catalyst 12 than when 
using Os catalyst 2 (TOF = 0.12 h-1 for Os complex 2; TOF = 0.30 h
-1 for Ir complex 
12).  
While the Os-catalysed oxidation (using complex 2) exhibited first order kinetics with 
respect to 1,4-NADH throughout the reaction, non-first order kinetics were observed 
in the first 6 h of NADH oxidation by Ir complex 12, followed by first order kinetics 
up to 24 h (Figure 4.5). The metal-NADH adduct formation has been implicated as the 
rate-determining step for NADH oxidation by metal complexes,67 and the same non-
first order kinetic profile seen here with complex 12 (later becoming first-order) has 
been observed with other Ir(III) catalysts for the oxidation of NADH.8 The mechanism 
for similar iridium complexes has been shown to proceed via the formation of a metal-
hydride species, which were detected in aqueous solution by 1H-NMR.8, 68 However, 
the hydride species was not readily identifiable for the sulfonamide complexes, owing 
to their low aqueous solubility. 
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Perturbation of the NADH/NAD+ ratio has been linked to the generation of reactive 
oxygen species in living cells.69 Complex I (NADH:ubiquinone oxidoreductase) of the 
mitochondrial electron transport chain is known to produce reactive oxygen species 
(ROS), and the production of which is strongly dependent on the ratio of 
NADH/NAD+.70 Cancer cells, in particular, are under high levels of redox stress to 
maintain uncontrolled proliferation.71 However, high levels of reactive oxygen species 
(ROS) can cause damage to DNA, mitochondrial dysfunction, or oxidation of cysteine 
residues in proteins,72 ultimately leading to cell death. It may be possible that Os 
complex 2 and Ir complex 12 may carry out NADH oxidation inside cells, as a means 
of inducing ROS production by mitochondrial complex I.  
To explore whether the complexes could generate ROS in vitro, cells were treated with 
either complex 2 (Os) or 12 (Ir) at IC50 concentration. A large burst of reactive oxygen 
species was detected after 24 h drug exposure (Q2 population for superoxide and total 
ROS: 96% for cells treated with either complex 2 or 12; Figure 4.12) suggesting that 
ROS are likely to be involved in the mechanism of action in vitro. Many other 
metallodrugs have been shown to alter the redox balance in cells by generation of 
reactive oxygen species.72, 73 A structurally similar iridium transfer hydrogenation 
catalyst [Ir(CpxBip)(2-phenylpyridine)(pyridine)]+ has been shown to catalyse the 
formation of hydrogen peroxide, via hydride transfer from NADH to O2.
33 
Importantly, significantly less ROS/superoxide were detected in non-cancerous HOF 
ovarian fibroblasts, compared to A2780 cancer cells, treated with complex 2 (Table 
4.3). Rapid and unregulated proliferation places cancer cells under heightened redox 
stress, unlike healthy cells.71 The decrease in the levels of reactive oxygen species and 
superoxide in non-cancerous cells suggests that targeting the inherent redox 
vulnerability of cancer cells may present an opportunity for the design of novel 
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chemotherapy drugs with higher selectivity for cancerous tissues over healthy 
proliferating cells. Furthermore, the catalytic nature of the sulfonamide complexes 
(e.g. for oxidation of NADH) facilitate preferential generation of ROS in cancer cells 
whilst administering lower concentrations.  
The activity of osmium complex 2 was found to be enhanced by co-administration 
with L-BSO, a known inhibitor of γ-glutamylcysteine synthetase. This enzyme 
catalyses the rate-limiting step in the synthesis of GSH,73 an important cellular 
antioxidant,74 making cancer cells more vulnerable to redox stress. The IC50 was 
reduced to 64% in the presence of L-BSO (15.07 ± 0.07 μM to 10.0 ± 0.7 μM; Table 
4.4). This is consistent with a mechanism of action that exploits the redox-sensitivity 
of the cancer cell, and has previously been observed for other half-sandwich 
complexes of Os(II) as well as structurally-similar Ir(III) complexes.33, 63, 73 
 
4.5 Conclusions 
A series of highly stable 16-electron Ir(III) sulfonamide complexes were synthesised 
for comparison to structurally-similar Os(II) catalysts reported in Chapter 3 (section 
3.3.1, page 78). This chapter demonstrates that in a biological context, the metal centre 
is not purely structural. Hydrophobicities were found to correlate with antiproliferative 
activities towards cancer cells, determined in fourteen human cell lines, which in turn 
were found to correlate with the amount of metal internalised by the cells. Though 
iridium accumulation was greater than that of osmium, osmium complexes typically 
exhibited greater activities towards cancer cells, albeit at the expense of greater cross-
resistance towards platinum-resistant cells, unlike their iridium counterparts. 
Furthermore, the antiproliferative activity of osmium complex 2 towards A2780 
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cancer cells was enhanced by co-adminstration with the γ-glutamylcysteine synthase 
inhibitor, L-BSO, suggesting that the important cellular antioxidant, GSH, may be 
involved in the detoxification of such metal complexes inside cells. 
Further metal accumulation studies in A2780 cancer cells focused on Os complex 2 
and Ir complex 12 as representative examples from each series. Ir accumulation and 
efflux were found to be particularly rapid. Conversely, the efflux of Os was gradual, 
irrespective of the extracellular drug concentration. Both complexes exhibited 
temperature-dependent accumulation, and efflux was decreased by co-administration 
of a known PgP inhibitor. Os complex 2 showed significantly more membrane (and 
organelle) distribution, compared to Ir complex 12 which was mainly found in the 
cytoplasm, in agreement with its lower partition coefficient (Log P).  
In this chapter, the known Os and Ir transfer hydrogenation catalysts were 
demonstrated to catalytically oxidise the co-factor 1,4-NADH to NAD+ under 
biologically-relevant conditions in a model system at pH 7.4. Though turnover 
frequencies were modest in the model system, it is expected that the same process 
occurs in cells likely contributes to the catalytic generation of reactive oxygen species 
observed in cancer cells.  
Overall, once internalised, the osmium and iridium complexes appear to act 
catalytically inside cells. The transfer hydrogenation of NADH explored in this 
chapter, in combination with data showing that inhibition of GSH synthesis increases 
potency (using L-BSO), strongly implicates a mechanism of action involving catalytic 
redox-modulation to achieve cancer cell death. Crucially, the inherent redox stress 
experienced by cancer cells makes them more vulnerable to such a mechanism, 
thereby generating mechanistic selectivity for cancer cells over non-cancerous cells, 
which are better-equipped to adapt to drug-induced redox stress.  
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5. Osmium(II)-catalysed in cell asymmetric transfer 
hydrogenation 
  
5.1 Introduction 
The catalytic properties of many metal complexes are well understood,1-3 and the role 
of catalysts in medicine is a rapidly-expanding field of research. Catalytic medicines 
would facilitate lower dosages, with a view to circumventing deleterious side effects.4 
This builds on pioneering research surrounding the design of traditional non-catalytic 
metallodrugs, and notably the success story of cisplatin;5 a widely established Pt(II) 
chemotherapy complex,6 used to treat soft tissue, bone, muscle, and blood vessel 
cancers.7 While many platinum drugs are known, the only example of an osmium 
compound in the clinic is osmium tetroxide, which acts to catalyse the conversion of 
the superoxide anion radical to oxygen and hydrogen peroxide, and is used in the 
treatment of arthritis.8 However, Os(II) arene complexes have shown in vivo activity 
against human cancer xenografts in mice, with negligible toxicity, suggesting that 
Os(II) complexes may warrant further exploration as anticancer agents.9  
A catalytic metallodrug is likely to have a unique or even range of mechanisms of 
action, potentially avoiding drug resistance – a problem inherently associated with 
platinum-based treatments.6, 7 Compared to metalloenzymes, which protect the metal 
centre from unfavourable substitution or redox chemistry involving large proteins, the 
catalytic centre of a small-molecule metal complex is easily accessible to cellular 
components, increasing the likelihood of catalyst deactivation (poisoning) in a 
biological system.4 By rational design of kinetically stable complexes, metallodrugs 
can catalyse a range of bio-orthogonal reactions, such as the modification of functional 
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groups and carbon-carbon bond formation.4 Previous research from Sadler et al. has 
shown that transfer hydrogenation reactions may be carried out in cancer cells, using 
sodium formate as a biologically-compatible alternative to the formic acid 
triethylamine hydrogen donor system traditionally used for the reduction of ketone 
substrates.4, 10 Sodium formate was found to increase the potency of ruthenium(II) 
compounds, enabling the complexes to catalyse the formation of the co-enzyme 
NADH and perturb the already sensitised redox balance in the cell.10 
It is well established that the metabolism of cancerous tissue differs from that of 
healthy tissue.11 The ‘Warburg Effect’ summarises the observation that cancer cells 
(and other rapidly proliferating tissues) show a preference for the production of lactate 
from glucose, independent of oxygen availability.12 In the presence of oxygen, non-
proliferating tissues metabolise glucose to pyruvate (via glycolysis) and then oxidise 
pyruvate to carbon dioxide by oxidative phosphorylation. Only in the absence of 
oxygen would such cells utilise lactate production as a means of acquiring energy.13 
A key step in the Warburg Effect is the reduction of pyruvate to lactate (a chiral 
alcohol) – a process that may also be achieved using transfer hydrogenation. 
In Chapter 3, a series of osmium(II) compounds were reported to catalyse asymmetric 
transfer hydrogenation (ATH) reactions of ketones.14 This chapter details in cell 
transfer hydrogenation, including the reduction of pyruvate to lactate, whilst retaining 
enantioselectivity. Using Os(II) complexes in combination with a hydride source, the 
extent of the catalytic effect is compared between cancer cells (A2780 ovarian 
carcinoma) and normal cells (HOF ovarian and MRC5 lung fibroblasts). Additionally, 
enzymes that produce formate are overexpressed in certain cancer cells, and this was 
explored as a potential mechanism of increasing drug selectivity. This, to the best of 
our knowledge, represents the first report of enantioselective in cell ATH catalysis. 
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5.2 Experimental 
  
5.2.1 Materials 
Cisplatin (cis-diaminedichloroplatinum(II)), separate enantiomers of complex 11 
[RuCl(TsDPEN)(p-cymene)], N-acetyl-methionine, N-formyl-methionine, sodium 
acetate, sodium formate, sodium pyruvate, pyruvic acid, propidium iodide, Annexin 
V-FITC conjugate and all other reagents were purchased from Sigma Aldrich and used 
directly without previous purification or modification, unless indicated otherwise. 
Enzymatic assay kits for L-lactate and D-lactate were purchased from Cayman and 
stored at 255 K before use. Phosphate buffered saline (PBS) and cell culture media 
were purchased from Lonza. Cell maintenance, in vitro growth inhibition assays, metal 
accumulation experiments, and methods used for ICP-OES / ICP-MS are described in 
Chapter 2 (section 2.2.8, page 54).  
 
5.2.2 Transfer hydrogenation reduction of pyruvate to lactate 
 
Reduction of pyruvic acid in formic acid / triethylamine azeotrope (5:2). The 
reduction of pyruvic acid was performed as described for acetophenone reductions 
(Chapter 3, section 3.2.5, page 83), using 1H-NMR to monitor % conversion (1 mmol 
substrate, 500 μL formic acid : triethylamine azeotrope, 100 μL C6D6). Data were 
processed using TopSpin 3.2 (Bruker, UK). Final solution concentrations: pyruvate, 
1.4M; catalyst, 6.9 mM. Reactions were monitored for 1 h unless specified otherwise, 
and were carried out in triplicate. Turnover frequencies (TOF / h-1) are reported and 
their standard deviations calculated.  
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Reduction of pyruvate by (R,R)-2 in phosphate buffered saline (PBS). 
Concentrations of D- and L-lactate were determined individually using enantio-
specific detection assay kits (Cayman Chemical) as described in the manufacturer’s 
instructions. Either complex (R,R)-2 or (S,S)-2 (15 µM, IC50 concentration) was 
incubated in PBS solution (supplemented with 5% v/v DMSO to aid solubility of the 
complexes) with sodium pyruvate (1 mM) for 24 h at 310 K. The experiment was 
repeated in the presence of sodium formate (2 mM). Using instrumental duplicates of 
duplicates, fluorescence measurements were acquired using a Promega GloMax 
Multi+ microplate reader (λex: 530-540 nm, λem: 585-595 nm) and averages and 
standard deviations were calculated. 
 
Determination of the enantiomeric excess (ee) for the reduction of pyruvate. In 
phosphate-buffered saline (PBS, containing 5% v/v DMSO) were prepared stock 
solutions of: sodium formate (100 mM), sodium pyruvate (100 mM) and complex 
(R,R)-2 (saturated solution, which was filtered and osmium concentration determined 
using ICP-OES). Solutions were added independently to clean sterile 15 mL Falcon 
tubes with the addition of D2O (10% v/v) to achieve final working concentrations: 
catalyst, 10 μM; pyruvate, 2 mM; formate 4 mM or 30 mM. 1H-NMR data were 
acquired using a Bruker AV 600 spectrometer (600 MHz, 90% H2O / 10% D2O, 310 
K) at 11 min time intervals using water suppression techniques (ZGGPW5)  and data 
were processed using Topspin 3.2 (Bruker UK). Spectra baseline-correction was 
performed using the SPLINE algorithm. Percentage conversion (and turnover 
frequency, TOF / h-1) for the reduction of pyruvate to lactate was determined using 
peak integrals: δ = 2.40 ppm (CH3, pyruvate) and lactate (δ = 1.36 ppm, (CH3, lactate). 
Chapter 5. Osmium(II)-catalysed in cell asymmetric transfer hydrogenation 
169 
5.2.3 Biological studies 
Biological experiments and cell maintenance were carried out at the School of Life 
Sciences and the Department of Engineering (University of Warwick, UK) as 
described in Chapter 2 (section 2.3.2, page 57) under the guidance of Dr. Isolda 
Romero-Canelon (University of Warwick, UK) with kind assistance from Dr. Anthony 
Knight, Mrs Hannah Bridgewater, Mrs Ji-Inn Song and Mrs Sukhbinder Heer 
(University of Warwick, UK).  
 
Cell viability modulation experiments with sodium formate. A 96-well plate was 
seeded using 5000 cells (A2780, HOF or MRC5 cells of ovarian and lung origin) per 
well using 150 L, and incubated at 310 K for 48 h in drug-free medium. Solutions of 
osmium complexes 2 and 7 were freshly prepared in culture medium (containing 5% 
v/v DMSO) and exact Os concentrations were determined using ICP-OES (Chapter 2, 
section 2.2.8). After removal of the supernatant, cells were exposed to equipotent 
concentrations of either osmium complex, equal to 0.5 × IC50 concentration in A2780 
cancer cells (15.5 μM and 6.5 μM for 2 and 7, respectively), by dilution from stock 
solutions using culture medium. Sodium formate was independently added to the wells 
at three concentrations (final concentration: 0.5, 1.0 and 2.0 mM) within 5 min of drug 
exposure. Positive control cells were treated with cisplatin, and negative controls were 
established with 0-2 mM sodium formate. After 24 h drug exposure, cells were washed 
with PBS and further incubated for 72 h in drug-free cell culture medium. After this 
time, viability was determined using the SRB assay as described in Chapter 2 (page 
59). The experiment was carried out as duplicates of triplicates, as part of two 
independent experiments. The experiment was repeated using sodium acetate in place 
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of formate in all cell lines. Statistics were calculated using a two-tailed t-test with 
unequal variances (Welch’s t-test) at the 95% confidence level.  
 
Cell viability modulation experiments with N-formylmethionine. The above cell 
viability modulation experiments were repeated using PC3 prostate cancer cells. In 
this case, Os complexes 2 and 7 were co-administered with a non-toxic concentration 
of N-formylmethionine (fMet) or N-acetylmethionine at (0.25, 0.5 and 1 mM). PC3 
cancer cells are known to overexpress human peptide deformylase which is 
responsible for the cleavage of the formyl moiety from formylmethionine,15 hence 
fMet could be enzymatically converted into formate and act as an in situ-generated 
hydride source in the transfer hydrogenation process.  
 
Formate-dependent metal accumulation in cancer cells. Osmium accumulation 
was determined in A2780 human ovarian cancer cells as described in Chapter 2 (page 
61) using 4.0 × 106 cells seeded in P100 petri dishes using 10 ml culture medium, 24 
h pre-incubation, 24 h drug exposure and no recovery time in drug-free medium. The 
experiment was carried out with the following modifications: cells were exposed to 
equipotent concentrations of complexes (S,S)-2 or (S,S)-7 equal to 1/3 × IC50 (IC50 
concentration in A2780 cancer cells: 15.5 μM and 6.5 μM for 2 and 7, respectively) in 
the presence of sodium formate (2 mM). Data were obtained in triplicate, and 
compared to the Os-free negative control experiments (0 mM formate or 2 mM 
formate, respectively). These data followed the same experimental procedure as the 
cellular accumulation data presented in Chapter 4 (section 4.3.5; obtained at 1 × IC50 
concentration) and hence will be discussed together. 
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Cell cycle analysis. A 6-well plate was seeded using 1.0 × 106 A2780 cancer cells in 
2 ml of culture medium. After 24 h at 310K and in drug-free medium, the supernatant 
was removed and cells were exposed to complex 2 (1.0 × IC50 concentration in A2780: 
15.5 M) both in the presence and absence of sodium formate (2 mM) for 24 h (310 
K). After treatment, the drug solution was removed and cells were washed twice with 
PBS. Cell pellets were harvested using trypsin/EDTA (1 ml), washed and re-
suspended in PBS, then centrifuged (1000 rpm, 5 min, 277 K). Pellets were re- 
suspended in ice-cold ethanol to fix the cells (30 min, on ice). After this time, cells 
were washed again with PBS to remove ethanol, then stained using 500 μL of staining 
buffer in the dark for 30 min (staining buffer contains: 50 µgmL-1 of propidium iodide 
(PI) and 80 µgmL-1 of RNAse in phosphate-buffered saline). After centrifugation 
(1000 rpm, 5 min, 277 K) excess staining buffer was removed by suction and cells 
were re-suspended in PBS. A single cell solution was obtained in PBS, which was 
analysed by flow cytometry using a Becton Dickinson FACScan Flow Cytometer (PI 
red fluorescence detected using FL2 channel, λex/em = 535/617 nm). Samples were 
measured as instrumental triplicates and cell cycle parameters determined using the 
Watson (pragmatic) model in FlowJo V10 for Windows. Statistics were analysed 
using a two-tailed t-test with unequal variances (Welch’s t-test).  
 
Induction of Apoptosis.  A 6-well plate was seeded using 1.0 × 106 A2780 cancer 
cells. After 24 h, the supernatant was removed and cells were exposed to complex 2 
(1.0 × IC50, 15.5 M) both in the presence and absence of sodium formate (2 mM) for 
24 h (310 K). The drug solution was removed and cells were washed twice with PBS. 
Cells were harvested using trypsin/EDTA, re-suspended in PBS, then centrifuged 
(1000 rpm, 5 min, 277 K). Positive control samples were treated with staurosporine (1 
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μgml-1).16 Pellets were stained with 0.5% v/v Annexin V FITC conjugate and 0.5% 
v/v propidium iodide in PBS for 30 min in the dark, and then analysed by flow 
cytometry using a Becton Dickinson FACScan Flow Cytometer (Annexin V-FITC 
green fluorescence detected using FL1 channel, λex/em = 488/518 nm; PI red 
fluorescence detected using FL2 channel, λex/em = 535/617 nm). Data were processed 
using FlowJo V10 for Windows and reported as percentage populations and statistics 
calculated using a two-tailed t-test assuming unequal variances (Welch’s t-test). 
 
Membrane integrity. A 6 well-plate was seeded using 1.0 × 106 A2780 cancer cells. 
After 24 h, cells were exposed to complex 2 (1.0 × IC50, 15.5 M) both in the presence 
and absence of sodium formate (2 mM) for 24 h (310 K). After treatment, the drug 
solution was removed and cells were washed twice with PBS. Cell pellets were 
harvested using trypsin/EDTA (1 ml), re-suspended in PBS, then centrifuged (1000 
rpm, 5 min, 277 K). Pellets were stained (without fixation) using 500 μL of staining 
buffer in the dark for 30 min (containing 50 µgmL-1 of propidium iodide (PI) and 80 
µgmL-1 of RNAse), excess dye removed after centrifugation (1000 rpm, 5 min, 277 
K) and samples re-suspended in PBS for analysis by flow cytometry as instrumental 
triplicates using a Becton Dickinson FACScan Flow Cytometer. Data were processed 
using FlowJo V10 for windows and statistics calculated using a two-tailed t-test 
assuming unequal variances (Welch’s t-test).  
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5.2.4 In-cell reduction of pyruvate to lactate 
Briefly, 30 × 106 A2780 ovarian cancer cells were seeded using 15 ml culture medium 
in T75 flasks and incubated for 24 h (310 K). Separately, stock solutions of osmium 
complexes (R,R)-2 and (S,S)-2 were prepared in culture medium containing 5% v/v 
DMSO. The metal concentration in the stock solutions was determined and adjusted 
by ICP-OES prior to drug exposure to cells. In triplicate flasks, supernatant solutions 
were removed and cells were exposed to equipotent concentrations (1.0 × IC50 
concentration) of either complex (R,R)-2 or (S,S)-2, either in the presence and absence 
of sodium formate (2 mM). Control experiments were also obtained in triplicate (either 
treated with 2 mM formate, or untreated). After 24 h, the supernatant was collected 
for analysis of extracellular D-lactate, and cells were washed twice with PBS and 
harvested using trypsin/EDTA. Cells were counted, and equal sized cell pellets (40 × 
106 cells) were obtained by centrifugation (1000 rpm, 5 min, 277 K). Intracellular and 
extracellular D-lactate were determined using the D-lactate assay kit (Cayman 
Chemical) as described in the manufacturer’s instructions. Samples were 
deproteinated by addition of MPA reagent (0.25 M) with vortexing, then placed on ice 
(5 min). Proteins were pelleted by centrifugation (1000 rpm, 5 min, 277 K) and the 
supernatant neutralised with potassium carbonate (25 μL). Samples were re-
centrifuged to remove precipitated salts (1000 rpm, 5 min, 277 K) and the supernatant 
extracted (20 μL) for the final assay, which was carried out with a calibration range of 
D-lactate: 0, 25, 50, 100, 250, 500, 1000 μM (R2 =0.995). Fluorescence was measured 
using a Promega GloMax Multi+ microplate reader (λex: 530-540 nm, λem: 585-595 
nm). Data were normalised to the respective complex-free control, and averages and 
standard deviations were calculated. Statistics were calculated using a two-tailed t-test 
assuming unequal variances (Welch’s unpaired t-test) at the 95% confidence level. 
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5.3 Results 
 
5.3.1 Reduction of pyruvic acid using formic acid 
Pyruvate was selected as a target substrate for catalysis as the molecule is pro-chiral, 
is present at millimolar concentrations inside cells, and is a key metabolic intermediate 
in glycolysis. To initially confirm whether Os sulfonamide catalysts could reduce 
pyruvate, the reduction of pyruvic acid was studied using formic acid: triethylamine 
azeotrope, as described in Chapter 3 (section 3.2.5) for acetophenone-derived ketones. 
(5 µmol catalyst, 500 µL formic acid / triethylamine azeotrope, 100 µL d6-benzene, 1 
mmol pyruvate; 1:200 catalyst loading). Using either enantiomer of p-cymene 
complex 2 or biphenyl complex 7, rapid turnover (TOF ~ 300 h-1) was observed using 
time-dependent 1H-NMR spectroscopy to observe the conversion to lactic acid by the 
formation a new quartet at 4.17 ppm (Table 5.1), relative to the singlet CH3 signal 
from pyruvate (2.26 ppm). The experiment was monitored in triplicate for 1 h, with 
data acquired every 73 s. Due to the limitations of 1H-NMR, this technique could not 
resolve the enantioselectivity of the complexes. Furthermore, the enantiomeric excess 
(ee) could not be determined using chiral GC-FID due to the high chemical similarity 
of pyruvate, lactate and formate.  
 
Table 5.1. Reduction of pyruvic acid by Os complexes 2 or 7, or Ru complex 11 in formic acid : 
triethylamine azeotrope (5:2 mol ratio), studied by time-dependent 1H-NMR (C6D6, 310 K). Final 
concentration: Os catalyst, 6.9 mM; pyruvic acid, 1.4 M.  
 Complex (R,R) TOF / h-1 (S,S) TOF / h-1 
2 [Os(p-cymene)((R,R)-TsDPEN)] 303.2 ± 0.8 298 ± 2 
7 [Os(biphenyl)((S,S)-TsDPEN)] 103 ± 2 102 ± 1 
11 [RuCl(p-cymene)((S,S)-TsDPEN)] N.D. 132 ± 1 
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The rate of ketone reduction was equal between enantiomers. Similarly to data 
obtained in Chapter 3 (section 3.2.5), the initial rate of reduction (TOFmax) was 
significantly faster using Os catalyst 2 than Ru catalyst 11 (TOF = 132 h-1). However, 
the TOF obtained with Os catalyst 7 was significantly lower (TOF ~ 100 h-1). These 
data suggested that complex 2 was a worthy candidate for further exploration as a 
catalyst for pyruvate reduction in aqueous media and inside cells.  
 
5.3.2 Aqueous-phase reduction of pyruvate using sodium pyruvate 
The aqueous-phase reduction of sodium pyruvate was explored in phosphate-buffered 
saline (PBS) with 5% v/v DMSO to aid solubility, in which the Os catalysts are known 
to be stable (Chapter 3, section 3.3.4). Solutions of either (R,R)-2 or (S,S)-2 were 
prepared independently, and sodium formate was used as a biologically-compatible 
hydride source. 
Conversion of pyruvate to lactate was observed using time-dependent 1H-NMR (600 
MHz, 90% H2O / 10% D2O, 310 K) using 0.05 mol% catalyst and sodium formate 
(Table 5.2). Though less rapid than in formic acid : triethylamine azeotrope, the 
reduction was observed to occur in aqueous media (TOFmax = 16.4 h
-1), further 
confirming the potential for detecting in cell catalysis.  
 
Table 5.2. Reduction of sodium pyruvate to lactate by osmium sulfonamide catalyst (R,R)-2 (0.05 
mol%) using sodium formate (4 mM or 30 mM) as a hydride source, in PBS (10% D2O). Turnover 
number (TON) and turnover frequency (TOFmax, h-1) determined using time-dependent 1H-NMR (600 
MHz, 90% H2O / 10% D2O, 310 K) using water-suppression techniques.  
catalyst / mM pyruvate / mM formate / mM TON TOFmax / h-1 
0.01 2 4 21 (14 h) 1.5 ± 0.1 
0.01 2 30 65 (4 h) 16.4 ± 0.7 
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Figure 5.1. (a) Formate-dependence (2 or 15 mol equiv) for the reduction of pyruvate by osmium 
complex (R,R)-2 in PBS monitored by time-dependent 1H-NMR (600 MHz, 90% H2O / 10% D2O, 310 
K); (b) Enantioselectivity for the reduction of pyruvate to lactate by complex (R,R)-2 or (S,S)-2, 
determined using enantioselective enzymatic assay kits. Os complex, 15 µM; pyruvate, 1 mM; formate, 
2 mM (24 h, 310 K).  
 
The turnover frequency was found to be highly dependent on the concentration of 
formate, with 10× enhancement of turnover frequency upon increasing formate from 
2 equiv to 15 equiv with respect to pyruvate (Figure 5.1a). This explains the rapid rate 
observed in the formic acid azeotrope, whereby the hydride source (formic acid) is 
acting as a solvent for the reaction, and is therefore in the greatest possible excess. 
Reduction rate may also be influenced by the pH of the reaction, however this goes 
beyond the scope of this thesis, since in cell reductions must occur under 
physiologically-relevant conditions (pH = 7.4) which is why phosphate-buffered 
saline was chosen as the solvent. 
Similarly to reductions carried out in formic acid : triethylamine azeotrope, the 
enantioselectivity of the reduction could not be readily determined by chiral gas 
chromatography (as for acetophenone-derived ketones in Chapter 3, section 3.2.5, 
page 83) due to the high chemical similarity and subsequent similar retention times of 
the substrate and sodium formate. Instead, enantioselective enzymatic assay kits were 
used to evaluate independently the concentration of each enantiomer of lactate, taking 
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advantage of the high specificity of the enzyme for a particular enantiomer of lactate 
(which have also been shown to be specific for lactate, compared to other 
monocarboxylates, such as pyruvate and formate).  
Remarkably, the enantioselectivity of the catalysts is conserved for pyruvate 
reduction, achieving ~83% enantiomeric excess (ee) for the production of lactate in 
aqueous solution (Table 5.3 and Figure 5.1b). D-lactate was selectively obtained using 
catalyst (R,R)-2 (9.2 ± 0.6 µM D-lactate, compared to 1 ± 2 µM L-lactate; 83% ee), 
and L-lactate using catalyst (S,S)-2 (1.0 ± 0.6 µM D-lactate, compared to 12 ± 2 µM 
L-lactate; 84% ee).The selection for the Re-face reduction by (R,R)-2 (and Si-face 
reduction by catalyst (S,S)-2, respectively) is in agreement with reductions carried out 
using complex 2 for the ATH aromatic ketone substrates in formic acid (Chapter 3, 
section 3.3.5, page 95). These data demonstrate that, while pyruvate lacks the large 
aromatic substituent of acetophenone-type ketones studied in Chapter 3 (page 96), the 
methyl and carboxylate substituents of pyruvate sufficiently differ enough in their 
chemical structure (sterics) and electronic effects (anionic carboxylate, compared to 
neutral methyl moiety) to facilitate enantioselective reduction by the Os catalyst, 
depending on the chiral configuration of the diamine. Importantly, these experiments 
provide comparative data for in cell reductions carried out in section 5.3.4. 
 
Table 5.3. Determination of enantiomeric excess (ee) for the reduction of sodium pyruvate by osmium 
complex (R,R)-2 or (S,S)-2 in PBS, using enantioselective enzymatic assay kits for L-lactate and D-
lactate (Cayman Chemical). Os complex, 15 µM; pyruvate, 1 mM; formate, 2 mM (24 h, 310 K). 
Complex L-Lactate / μM D-Lactate / μM Major product ee / % 
(R,R)-2 1 ± 2 9.2 ± 0.6 D-lactate 83 
(S,S)-2 12 ± 2 1.0 ± 0.6 L-lactate 84 
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5.3.3 Transfer hydrogenation reactions in cancer cells 
To initially explore the potential for in cell catalytic activity, Os complexes were 
administered to A2780 cancer cells at 0.5 × IC50 concentration (determined in Chapter 
4, section 4.3.4. IC50 concentrations: 15.5 μM and 6.5 μM for 2 and 7, respectively) 
with co-administration of sodium formate (2 mM), in order to observe any increase in 
potency due to an in cell catalytic effect. For precise concentrations to be administered 
to cells, stock solutions of the complexes in culture medium (ca. 100 μM) were 
analysed by ICP-OES to determine the osmium concentration before addition. Sodium 
formate is known to be non-toxic to cells at concentrations up to 2 mM.10 Cells were 
treated with the osmium with independent co-administration of sodium formate, 
achieving final working concentrations of formate from 0-2 mM. Negative control 
samples were also treated with sodium formate in the same manner.  
Importantly, the proliferation of A2780 ovarian cancer cells was significantly 
decreased by treatment of cells with sodium formate in combination with an osmium 
complex; either (R,R)-2, (S,S)-2, (R,R)-7 or (S,S)-7 (P<0.001 when co-administered 
with 2 mM formate). Conversely, the proliferation of cells treated with sodium 
formate, but without an osmium catalyst, was not affected at the 95% confidence level 
(Welch’s t-test). These data suggest that the mechanism of cell death may involve a 
catalytic component with respect to the osmium catalyst and sodium formate (Figure 
5.2), utilising transfer hydrogenation chemistry to increase the potency of the catalyst 
towards cancer cells. Both enantiomers of p-cymene complex 2 displayed comparable 
potency enhancement (reducing the normalised cell proliferation to 20% of the 
catalyst-free control), suggesting that the mechanism of action does not depend on the 
enantioselectivity of the catalyst (i.e. neither enantiomer exhibited higher potency 
enhancement than the other). Interestingly, the potency of biphenyl catalyst (S,S)-7 
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was increased by over one order of magnitude (ca. 13×) compared to the formate-free 
experiment using complex 7 alone. Here, the nature of the arene appears to be an 
important factor in determining the catalytic properties of the complex in a biological 
system. This is in agreement with ATH reductions carried out in Chapter 3 (section 
3.3.5) whereby arene extension yielded higher turnover frequencies for the reduction 
of aromatic ketones (p-cymene < biphenyl < m-terphenyl).  
The experiment was repeated using HOF ovarian fibroblasts and MRC5 lung 
fibroblasts. Such primary cell lines are routinely used as models of non-cancerous 
proliferating cells, and provide an indication of drug and/or mechanism selectivity for 
cancer cells over healthy cells. In both cases, the proliferation of non-cancerous cells 
was not affected by co-administration of the osmium complex with sodium formate at 
the 95% confidence level (Welch’s t-test) relative to the catalyst-free negative control. 
These data provide evidence for a highly selective specific enhancement of potency 
against ovarian cancer cells, which is both selective between cells from different 
organs (ovarian cancer vs. lung fibroblasts) and between cells obtained from the same 
tissue (ovarian cancer vs. ovarian fibroblasts).  
In order to confirm the specific role of sodium formate for the modulation of 
antiproliferative activity, the experiments were all repeated using sodium acetate in 
place of sodium formate. Substitution of the formyl moiety prevents sodium acetate 
from acting as a hydride donor for transfer hydrogenation reactions,10 therefore no 
modulation of cellular proliferation should be observed in such cases if the mechanism 
is synergistic with respect to both the osmium complex and formate. The 
antiproliferative activities of complexes (R,R)-2, (S,S)-2 and (S,S)-7 were unaffected 
(P>0.05) by co-administration of acetate, indicating that transfer hydrogenation 
chemistry appeared to be occurring inside cells, resulting in cell death (Figure 5.3).   
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Normalised cellular proliferation 
 
(R,R)-2 (S,S)-2 (S,S)-7 No Os complex 
A
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0.0 1.00 ± 0.03 1.00 ± 0.04 1.00 ± 0.05 1.00 ± 0.09 
0.5 0.76 ± 0.05 0.90 ± 0.04 0.20 ± 0.06 1.00 ± 0.07 
1.0 0.3 ± 0.1 0.22 ± 0.06 0.2 ± 0.1 0.98 ± 0.07 
2.0 0.2 ± 0.1 0.17 ± 0.07 0.08 ± 0.09 0.99 ± 0.07 
H
O
F
 
0.0 1.00 ± 0.04 1.00 ± 0.03 1.00 ± 0.03 1.00 ± 0.02 
0.5 1.03 ± 0.04 0.94 ± 0.03 0.94 ± 0.02 0.99 ± 0.03 
1.0 1.00 ± 0.05 0.87± 0.03 0.87 ± 0.02 0.92 ± 0.02 
2.0 1.03 ± 0.03 0.94 ± 0.02 0.94 ± 0.02 0.90 ± 0.03 
M
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0.0 1.00 ± 0.03 1.00 ± 0.03 1.00 ± 0.03 1.00 ± 0.09 
0.5 0.99 ± 0.04 0.99 ± 0.04 0.98 ± 0.04 0.96 ± 0.07 
1.0 0.90 ± 0.06 0.95 ± 0.03 0.98 ± 0.05 0.93 ± 0.08 
2.0 0.72 ± 0.04 0.85 ± 0.06 0.88 ± 0.08 0.95 ± 0.08 
 
Figure 5.2. Normalised proliferation of: A2780 ovarian cancer cells, HOF ovarian fibroblasts and 
MRC5 lung fibroblasts, treated with catalyst 2 or 7 and sodium formate (0.5, 1.0, 2.0 mM) with 24 h 
drug exposure + 72 h recovery. Statistics using Welch’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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0.0 1.00 ± 0.06 1.00 ± 0.02 1.00 ± 0.04 1.00 ± 0.06 
0.5 1.00 ± 0.06 0.95 ± 0.03 1.04 ± 0.04 0.99 ± 0.06 
1.0 1.04 ± 0.08 1.04 ± 0.03 1.08 ± 0.05 0.99 ± 0.09 
2.0 1.02 ± 0.05 0.98 ± 0.03 1.11 ± 0.04 0.99 ± 0.08 
 
Figure 5.3. Normalised proliferation of A2780 human cancer cells treated with complex 2 or 7 with 
independent co-administration of with sodium acetate at various concentrations (0.5, 1.0 and 2.0 mM). 
Cells were treated for 24 h and allowed 72 h recovery time in drug-free culture medium. 
 
The cellular accumulation of osmium in A2780 cancer cells treated with osmium 
sulfonamide complexes 2 and 7 was studied in depth in Chapter 4 (section 4.3.5). To 
investigate whether sodium formate influenced the internalisation of osmium (i.e. 
potency increase due to increased drug accumulation, rather than transfer 
hydrogenation reactions) the metal accumulation experiments were repeated based on 
the experimental procedure used in Chapter 4 (section 4.3.5) using cells that were co-
treated with either complex 2 or 7 (1/3 × IC50 concentration, 5.2 µM and 2.2 µM for 
complexes 2 and 7, respectively) in the presence of 2 mM formate. Cell pellets were 
digested in concentrated nitric acid (72%) and the metal content in samples was 
quantified using ICP-MS as described in Chapter 2 (section 2.2.8, page 54). 
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Table 5.4. Osmium accumulation in A2780 ovarian cancer cells treated with osmium complex 2 or 7 
with co-administration of sodium formate (2 mM). Cells were treated for 24 h and allowed 72 h recovery 
time in drug-free culture medium. Osmium accumulation determined (after digesting cells) by ICP-MS. 
Internal metal concentration reported as ng Os × 106 cells.  
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Cellular metal accumulation (ng Os × 106 cells) 
 
(S,S)-2 (S,S)-7 No Os complex 
A
2
7
8
0
 
0.0 11 ± 2 7 ± 1 0.059 ± 0.003 
2.0 10 ± 2 8 ± 2 0.009 ± 0.009 
 
Importantly, after treatment with Os complexes at 1/3 IC50 concentration, the 
accumulation of metal into the cell was not affected by the formate concentration 
(P>0.77, Table 5.4) indicating that the potency increase was not caused by greater 
influx of metallodrug into the cell. Rather, the potency enhancement is dependent on 
both the osmium complex and sodium formate in combination, since the cellular 
osmium accumulation was unchanged (11 ± 2 ng compared to 10 ± 2 ng in the presence 
of sodium formate for (S,S)-2; 7 ± 1 ng compared to 8 ± 2 ng in the presence of sodium 
formate for (S,S)-7). Importantly, the presence of sodium formate did not reduce the 
internalisation of the complex, however successful internalisation of the osmium 
transfer hydrogenation catalyst provides further evidence for the likelihood of an in 
cell catalytic mechanism. 
Overall, to the best of our knowledge, these experiments provide the first example of 
osmium-catalysed transfer hydrogenation chemistry in cells. Treatment of cancer cells 
with an osmium transfer hydrogenation catalyst and a hydride source (sodium 
formate) can catalytically increase the potency of the Os complex to achieve decreased 
cellular proliferation via a mechanism that is likely to involve transfer hydrogenation 
chemistry, while also generating selectivity for cancer cells over healthy cells.  
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5.3.4 In-cell reduction of pyruvate to lactate 
In cells, pyruvate is either utilised for oxidative phosphorylation, or reduced to L-
lactate by lactate dehydrogenase, the major enantiomer in cells. On the contrary, the 
intracellular concentration of D-lactate inside cells is low,17 and so the generation of 
additional D-lactate by an external catalyst would be readily detectable. To observe 
the reduction of pyruvate in cells using the enantioselective osmium sulfonamide 
catalysts, cancer cells were treated with either enantiomer of complex 2 (1 × IC50) and 
sodium formate for 24 h. After drug exposure, excess drug and formate were removed 
with PBS washes, cell pellets obtained, and the intracellular D-lactate concentration 
was determined using an enantioselective enzymatic assay kit, according to the 
manufacturer’s instructions.  
Upon co-administration of either Os catalyst and sodium formate, the intracellular D-
lactate concentration was found to increase, relative to the catalyst-free control (79 ± 
10 μM and 51 ± 4 μM, for complex (R,R)-2 and (S,S)-2, respectively, Figure 5.4). In 
the absence of sodium formate, neither complex significantly increased the 
intracellular concentration of D-lactate at the 95% confidence level relative to the 
osmium-free untreated control. Furthermore, co-administration of formate alone did 
not affect D-lactate concentration in A2780 cancer cells (31 μM and 29 μM, 
respectively; P=0.7259) confirming the role of the catalyst in the modulation of D-
lactate concentration. The involvement of formate was confirmed by comparing D-
lactate levels in cells treated with (R,R)-2 alone, and (R,R)-2 with formate, which was 
found to be significantly greater (47.6 μM compared to 79 μM; P=0.0474).  
These data suggest that the transfer hydrogenation of pyruvate, catalysed by Os 
complexes, occurs inside cells, and represents the first example of Os-catalysed in-cell 
transfer hydrogenation. 
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Importantly, cells treated with (R,R)-2 and formate were found to have significantly 
greater levels of D-lactate than those treated with (S,S)-2 and formate (79 μM 
compared to 51 μM; P=0.0452) signifying that catalyst enantioselectivity is retained 
inside cells during pyruvate reduction. This process allows for selective generation of 
D-lactate inside cells depending on the chosen enantiomer of osmium catalyst 2 
(Figure 5.4). The antiproliferative activities of L-lactate and D-lactate were 
determined using the SRB assay as described in Chapter 2 (page 59).18 Both 
enantiomers were found to be non-toxic towards A2780 cancer cells up to 2 mM 
(highest concentration investigated), suggesting that the production of lactate is 
unlikely to be the direct cause of cell death. 
 
    
 
 Intracellular D-lactate / μM 
 (R,R)-2 (S,S)-2 No Os complex 
0.0 mM formate 47.6 ± 0.5 38 ± 10 31 ± 5 
2.0 mM formate 79 ± 10 * 51 ± 4 29 ± 2 
 
Figure 5.4. Intracellular D-lactate (μM) in A2780 ovarian cancer cells exposed to either complex (R,R)-
2 or (S,S)-2 for 24 h (1.0 × IC50, 310 K, no recovery time): (a) Os complex only; (b) Independent co-
adminstration of 2 mM sodium formate (within 5 min of drug addition). All statistics (*) were calculated 
using a two-tailed t-test assuming unequal variances between samples (Welch’s t-test). 
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To confirm that the reduction of pyruvate occurred inside cancer cells, and not in the 
culture medium, extracellular lactate concentrations were determined in the same 
manner, per the lactate detection kit manufacturer’s instructions. In this case, 
extracellular D-lactate levels were not statistically different (P > 0.1 using a two-tailed 
t-test assuming unequal variances) between the complex-free, or formate-free negative 
control experiments (Table 5.5). Since the culture medium used in the experiments did 
not contain pyruvate, these data suggest that pyruvate export from cells into the 
extracellular matrix is not significant, and reduction does not occur in the culture 
medium. Rather, the enantioselective reduction of pyruvate to D-lactate catalysed by 
complex (R,R)-2 only occurs inside cells. 
 
Table 5.5. Extracellular D-lactate (μM) in A2780 ovarian cancer cells exposed to either complex (R,R)-
2 or (S,S)-2 for 24 h (1.0 × IC50, 310 K, no recovery time). All statistics were calculated using a two-
tailed t-test assuming unequal variances between samples (Welch’s t-test). 
 
 Extracellular D-lactate / μM 
 (R,R)-2 (S,S)-2 No Os complex 
0.0 mM formate 32 ± 4 35 ± 5 38 ± 4 
2.0 mM formate 32 ± 4 36 ± 5 36 ± 6 
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5.3.5 Alternative in-cell hydrogenation using N-formylmethionine 
N-formylmethionine was explored as a formate precursor in PC3 prostate cancer cells, 
which are known to over-express the peptide deformylase enzyme. We hypothesised 
that this would result in the in situ generation of formate in PC3 cells after enzymatic 
cleavage from methionine.  
Co-administration of N-formylmethionine (fMet) with either osmium p-cymene 
complex 2 or biphenyl complex 7 decreased the normalised cellular proliferation of 
PC3 cancer cells (Table 5.6). Similarly to experiments using sodium formate as a 
hydride source in A2780 cells, the potency of biphenyl complex 7 was enhanced to a 
greater degree than p-cymene complex 2 (ca. 20% decrease in normalised proliferation 
by complex 7 and formate, compared to ca. 10% by complex 2 and formate).  
 
Table 5.6. Normalised cell proliferation for PC3 prostate cancer cells treated with osmium catalyst (2 
or 7; 0.5 × IC50) with co-administration of either N-formyl-methionine or N-acetyl-methionine (0.0, 
0.25, 0.5 and 1.0 mM). All experiments using 24 h drug exposure time +72 h recovery in drug-free 
medium (310 K). Statistics calculated using a two-tailed t-test assuming unequal variances (Welch’s t-
test). *P < 0.05, **P < 0.01. 
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 0.00 1.00 ± 0.09 1.00 ± 0.08 1.00 ± 0.07 
0.25 0.96 ± 0.07 0.98 ± 0.08 1.00 ± 0.08 
0.50 0.91 ± 0.10 0.88 ± 0.09 * 1.0 ± 0.1 
1.00 0.87 ± 0.06 ** 0.80 ± 0.06 ** 1.0 ± 0.1 
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 0.00 1.00 ± 0.02 1.00 ± 0.03 1.00 ± 0.07 
0.25 1.01 ± 0.06 1.01 ± 0.08 1.0 ± 0.2 
0.50 1.04 ± 0.07 1.03 ± 0.05 1.1 ± 0.2 
1.00 0.98 ± 0.02 0.96 ± 0.09 1.1 ± 0.1 
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The extent of potency increase was not as dramatic when using formylmethionine in 
PC3 prostate cancer cells, compared to co-administration of sodium formate in A2780 
cancer cells. Both the antiproliferative activities of 2 and 7 (IC50 in A2780: 15.5 ± 0.5 
µM and 6.5 ± 0.3 µM for 2 and 7, respectively; IC50 in PC3: 12.0 ± 0.3 µM and 9.9 ± 
0.2 µM for 2 and 7, respectively) and the cellular accumulation of 2 (30 ± 2 ng × 106 
cells in A2780; 32 ± 2 ng × 106 cells in PC3) were found to be similar between the 
cell lines (Chapter 4, sections 4.3.4 and 4.3.5). It is therefore likely that the lesser 
increase in potency, compared to those observed upon co-administration of sodium 
formate (achieving over one order of magnitude greater potency in the case of complex 
7 in combination with formate), is related to the efficiency of either (a) 
formylmethionine accumulation, and/or (b) formyl cleavage by the peptide 
deformylase enzyme.  
Similarly to studies for the co-administration of sodium acetate in A2780 cancer cells 
to confirm the specific role of formate, the ability of N-formylmethionine to provide a 
source of formate was confirmed by co-administration of N-acetylmethionine in place 
of formylmethionine. N-acetylmethionine cannot release formate, and therefore 
cannot act as a hydride donor (even if the acetyl residue was cleaved, this cannot act 
to donate hydride).  
No significant change in the normalised cellular proliferation of PC3 cancer cells was 
observed upon treatment of cells with N-acetylmethionine in combination with either 
p-cymene osmium complex 2 or biphenyl complex 7. These data confirm that (a) N-
formylmethionine is internalised by PC3 cells, whereby the peptide deformylase can 
cleave the formyl residue; (b) N-formylmethionine was able to provide an alternative 
source of formate, and therefore act as an alternative hydride source for in cell transfer 
hydrogenation reactions. 
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5.3.6 Mechanism of action for formate-activated catalysis 
To investigate the impact of formate-modulated anticancer activity, mechanistic 
studies of the cell cycle, induction of apoptosis and the integrity of the cell membrane 
were undertaken for cells treated with osmium complex (R,R)-2 in both the presence 
and absence of sodium formate (2 mM). Additionally, experiments were repeated to 
include recovery time in drug-free culture medium to observe any late-onset effects 
(such as late-onset apoptosis).  
 
Cell cycle arrest in A2780 cancer cells 
A2780 cancer cells were treated with Os complex (R,R)-2 in both the presence and 
absence of sodium formate (2 mM) for 24 h. The cell cycle analysis was conducted by 
fixing the cells using ethanol (making the cells permeable, thereby allowing the dye 
to cross the cell membrane) and staining with propidium iodide (PI, a DNA 
intercalating agent). Treated samples were analysed using flow cytometry using the 
FL2 (red) channel to detect propidium iodide fluorescence, which is greatly enhanced 
upon DNA intercalation (Figure 5.5). The G1, G2/M and S-phase populations were 
fitted to experimental data using FlowJo V10. The experiment was repeated allowing 
72 h recovery time in complex and formate-free culture medium to observe any late-
onset cell cycle arrest.  
Cells treated with 2 showed slight G1 phase arrest relative to the untreated control 
immediately after drug exposure time (66.0 % in Os-treated cells compared to 52 % 
in the untreated control). While sodium formate was not found to greatly modify the 
cell cycle, co-administration of the hydride source did statistically enhance G1 arrest 
after 72 h recovery time, from 66 % to 71.4 %, respectively (P=0.0046). 
Chapter 5. Osmium(II)-catalysed in cell asymmetric transfer hydrogenation 
189 
                            Complex 2             Complex 2 + formate 
N
o
 r
e
c
o
v
e
ry
 
  
7
2
 h
 r
e
c
o
v
e
ry
 
  
   
 
Normalised population / % 
 
Untreated 
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G1 phase 52 ± 2 66.0 ± 0.9 63 ± 3 
S phase 24 ± 1 18.1 ± 0.3 17 ± 1 
G2/M phase 24.3 ± 0.5 16.0 ± 0.6 20 ± 2 
7
2
 h
 
G1 phase 62 ± 1 66 ± 1 71.4 ± 0.7 
S phase 30.0 ± 0.8 22.3 ± 0.4 20.4 ± 0.4 
G2/M phase 5.0 ± 0.6 5 ± 1 6.3 ± 0.7 
 
Figure 5.5. Cell cycle analysis for A2780 cancer cells treated with complex 2 (1.0 × IC50 concentration, 
310 K, 24 h drug exposure) in the presence / absence of sodium formate (2 mM). The experiment was 
repeated with 72 h recovery time in drug-free medium. Data fitted using Watson (pragmatic) model (●) 
in FlowJo V10. Representative data shown from instrumental triplicates for complex (R,R)-2 in the 
presence and absence of sodium formate. G1 phase population (●); S phase population (●); G2M phase 
population (●). Statistical analysis were carried out using a two-tailed t-test assuming unequal variances 
in the sample populations (Welch’s t-test). 
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Induction of apoptosis in A2780 cancer cells 
Treated cells were stained using a solution of propidium iodide (PI, a red DNA 
intercalating agent) and Annexin V-FITC (phosphatidylserine-binding protein, 
conjugated to the green FITC fluorophore) to allow for two-colour detection. Since 
cells were not fixed in this experiment, propidium iodide only permeates late-apoptotic 
(FL1+, FL2+) and non-viable (FL1-, FL2+) cells, resulting in the intercalation of 
DNA, enhancing the PI fluorescence. On the other hand, early-apoptotic cells (FL1+, 
FL2-) undergo membrane-flip, translocating phosphatidylserine to the exterior of the 
cell membrane, where it may be bound by Annexin V. Late-apoptotic cells are both 
permeable to propidium iodide, and have undergone membrane-flip, facilitating the 
binding of both dyes (FL1+, FL2+).  
After 24 h exposure to complex (R,R)-2, no early/late-stage apoptotic cells were 
detectable, irrespective of the formate concentration (early/late-apoptotic populations 
for treated cells < 0.4 %) relative to the untreated control. The populations of 
early/late-stage apoptotic cells were re-determined after 72 h recovery time in drug 
and formate-free culture medium. Interestingly, while the non-viable cell population 
was significantly increased (P=0.0057), the early/late-stage apoptotic populations (< 
0.03%) were statistically similar to the untreated control population (0.01% and 0.02% 
for early- and late-stage apoptotic populations, respectively). 
In all cases, apoptotic cells were not detected, irrespective of the formate concentration 
or recovery time. These data suggest that cell death resulting from treatment with 
complex 2 may have occurred via a non-apoptotic alternative mechanism (Figure 5.6). 
Furthermore, the increase in the non-viable population after 72 h recovery time in 
drug-free culture medium may be due to over-confluency of cells. 
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Early-apoptotic 0.03 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 
Late-apoptotic 1.1 ± 0.2 0.2 ± 0.1 0.4 ± 0.2 
Non-viable 2.6 ± 0.1 3.3 ± 0.2 3.5 ± 0.2 
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Viable 93.2 ± 0.3 92.6 ± 0.5 94.2 ± 0.5 
Early-apoptotic 0.01 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 
Late-apoptotic 0.02 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 
Non-viable 6.8 ± 0.2 7.4 ± 0.5 5.8 ± 0.5 
 
Figure 5.6. Detection of apoptosis by dual staining of A2780 cells using Annexin V-FITC (FL1) and 
propidium iodide (FL2). Cells were treated with complex (R,R)-2 (1.0 × IC50) for 24 h in the presence 
and absence of sodium formate (2 mM). The experiment was repeated with 72 h recovery time in drug-
free medium. Data were gated and processed using FlowJo V10 for Windows: viable (FL1-Fl2-), early-
apoptotic (FL1+FL2-), late-apoptotic (FL1+FL2+) and non-viable (FL1-FL2+) cells. 
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Membrane integrity of A2780 cancer cells 
The cellular membrane integrity was determined for A2780 cancer cells treated with 
complex 2 in the presence and absence of sodium formate (2 mM). Cells were stained 
using propidium iodide, without fixation. In this experiment, A2780 cells with a 
compromised cell membrane would allow propidium iodide to permeate into the cell, 
intercalate into DNA, resulting in increased fluorescence. Stained cells were analysed 
using flow cytometry (FL2 channel) to detect PI fluorescence. Data were gated using 
FlowJo V10 into two populations, FL2- and FL2+, representing non-compromised and 
compromised cell membranes, respectively.  
The membrane integrity of cancer cells exposed to complex 2 was not significantly 
affected after 24 h drug exposure (P>0.05) relative to the untreated control (97.4 ± 0.2 
% viable cell membrane population). Furthermore, co-administration of sodium 
formate did not affect the membrane integrity (97.8 ± 0.1 % and 98.4 ± 0.1 % viable 
cell membrane population, for cells treated with complex 2 in the absence and 
presence of formate, respectively).  
While loss of integrity was observed in Os-treated cells after 72 h recovery time in 
drug-free medium when compared to those determined without recovery time 
(P<0.001), the effect was also apparent in the negative control sample (untreated cells: 
94.4 ± 0.5 %; complex 2 only: 95.6 ± 0.4 %; complex 2 with formate: 93.1 ± 0.2 %). 
This effect was also observed in the above study for the induction of apoptosis, and is 
likely a result of cells becoming over-confluent during the recovery time, resulting in 
a greater number of non-viable cells. These data suggest that complex 2, regardless of 
the concentration of sodium formate or recovery time in drug-free medium, does not 
affect the viability of the cell membrane in A2780 cancer cells. 
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Membrane integrity of A2780 cancer cells 
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Non-viable 5.6 ± 0.4 4.4 ± 0.3 6.9 ± 0.2 
 
Figure 5.7. The membrane integrity of A2780 ovarian cancer cells was determined by staining with 
propidium iodide (FL2). Cells were treated with complex (R,R)-2 (1.0 × IC50) in the presence and 
absence of sodium formate (2 mM) for 24 h. The experiment was repeated with 72 h recovery time in 
drug-free medium. Data were gated (viable membrane, FL2-; non-viable membrane, FL2+) and 
processed using FlowJo V10 for Windows. Statistical analysis was carried out using a two-tailed t-test 
assuming unequal variances (Welch’s t-test).  
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5.4 Discussion 
 
5.4.1 Transfer hydrogenation as a novel approach to achieving cell death 
A series of Os complexes were explored for activity as transfer hydrogenation 
catalysts (Chapter 3, section 3.3.5, page 95) and for antiproliferative activity against 
A2780 cancer cells (Chapter 4, section 4.3.4). Sulfonamide substitution was not 
beneficial to the catalytic activity of complexes 3-6 for the reduction of acetophenone 
(TOF ranging from 40-61.4 h-1, compared to 63.9 h-1 using complex 2). While arene 
extension increased the activity of complex 8 (4.4 μM in A2780), a useful catalyst for 
in cell reactions should be minimally potent before activation.  
Co-administration of an osmium complex with sodium formate significantly 
decreased the proliferation of A2780 cancer cells (Figure 5.2), to ca. 20% of the 
formate-free proliferation for cells treated with 2, and reduced to 8% for cells treated 
with 7. Comparing the results to Os-free experiments (100% normalised proliferation 
in the presence of 2 mM formate) and those using sodium acetate (100% normalised 
proliferation in the presence of 2 mM acetate, with or without Os complex), the effect 
is dependent on both formate and the osmium catalyst (Figure 5.3, section 5.3.3). For 
cells treated with complex 2, normalised proliferation decreased to 76% at 0.5 mM 
formate (which is in excess of the catalyst concentration) however potency was further 
enhanced at 1.0 and 2.0 mM formate, achieving a decrease to 30% and 20% of the 
original formate-free proliferation, respectively. This is suggestive of the fact that the 
mechanism is likely to be catalytic. Cellular Os accumulation experiments 
demonstrated that the potency increase is not due to a formate-enhanced drug 
accumulation (10 ± 2 and 11 ± 2 ng Os × 106 cells for cells treated with complex 2 in 
the presence and absence of formate, respectively; Table 5.4).  
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This mechanism generated high selectivity for cancer cells, achieving up to 83% 
decrease in normalised proliferation for cells treated with complex (R,R)-2, compared 
to only a small decrease in healthy ovarian (6%) and lung (15%) cells in the presence 
of formate. The origin of this selectivity is likely due to the heightened redox stress in 
cancer cells, resulting from the high metabolic rate required to maintain rapid 
proliferation.19 Conversely, non-cancerous cells are known to not only readily recover 
from redox stress,20 but also possess functional mitochondria which can generate ATP 
by oxidative phosphorylation, a more efficient process than glycolysis alone, on which 
cancer cells are reliant as a result of commonly dysfunctional mitochondria.13 
 
5.4.2 Asymmetric reduction of pyruvate in cells 
The in cell reduction of NAD+ to NADH has been comprehensively studied using  
ruthenium(II) complexes,10 however the lack of a stereogenic centre would not allow 
for the investigation of any in cell enantioselectivity that may occur when using chiral 
Os catalysts. Pyruvate, the simplest of the alpha-keto acids, is a vital pro-chiral 
molecule in cellular metabolism, is present at millimolar concentrations in the 
cytoplasm, and was selected as a target compound.  
Transfer hydrogenation of acetophenone-derived ketones by Os complexes using 
formic acid as a hydride source was studied in Chapter 3 (section 3.4.3, page 95). The 
reduction of pyruvate to lactate was studied in the same manner (5:2 mol ratio formic 
acid : triethylamine azeotrope, 310 K), achieving rapid turnover (TOF ~300 h-1) when 
using complex 2 (Table 5.1). This is, to the best of our knowledge, the first example 
of the production of lactate by a Noyori-type ATH catalyst (Figure 5.8). Interestingly, 
the reduction using catalyst 7 proceeded at a slower rate (TOF ~102 h-1) while the 
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Noyori Ru(II) catalyst proceeded with TOF=132 h-1. Reduction of pyruvate in aqueous 
solution, using sodium formate as an alternative hydride source to formic acid, 
proceeded at a slower rate than in the organic solvent system (1.5-16.4 h-1), however 
lactate formation was readily identified by 1H-NMR (Figure 5.1). Using an 
enantioselective assay kit, the aqueous reduction of pyruvate by either enantiomer of 
complex 2 was found to proceed with high enantioselectivity (83% ee). The rate of 
catalysis was found to be highly dependent on the concentration of sodium formate 
(Table 5.2), with an order of magnitude rate enhancement observed upon increasing 
the formate concentration from 4 mM (TOF = 1.5 h-1) to 30 mM  (TOF = 16.4 h-1). 
 
 
Figure 5.8. Reduction of pyruvate to L / D lactate by Os complex 2 or 7 
 
Though no direct evidence for the proposed transition state was obtained in this study, 
the substrate carboxylate group may interact with the catalyst arene (p-cymene or 
biphenyl for complex 2 or 7, respectively) in an electrostatic manner, to orientate 
pyruvate for subsequent enantioselective reduction to lactate (Figure 5.9).21 This 
hypothesised transition state is based on previous mechanistic and computational 
studies undertaken for the transfer hydrogenation of aromatic ketones, where the 
transition state is determined by a C-H--π interaction between the catalyst arene and 
the aromatic group of the substrate. However, it is unclear whether the transfer of 
hydride occurs via a concerted 6-membered transition state, or in a step-wise fashion 
involving solvent participation.22, 23 
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Figure 5.9. Proposed transition state for the reduction of pyruvate to D-lactate by complex R,R-2. 
 
The enantioselectivity for the reduction of pyruvate likely occurs in the same manner 
as the original Noyori asymmetric transfer hydrogenation transition state, which is 
governed by steric effects involving the pendent phenyl groups of the chirally-pure 
diamine.24, 25  This favours carbonyl reduction on a specific face; in the case of the 
(R,R) configured catalyst, reduction occurs on the Re face, yielding D-lactate (and Si 
face reduction to yield L-lactate for the (S,S) configured catalyst). In addition to steric 
effects and arene interaction between the catalyst and the substrate, the less-favoured 
transition state may be further destabilised by unfavourable interactions between the 
substrate and the sulfonyl group on the catalyst.22, 23, 26  
 
Generation of lactate in cells using osmium sulfonamide complexes 
In cells, the conversion of pyruvate to L-lactate is catalysed by lactate dehydrogenase 
(LDH).27 This process is particularly prevalent in cancer cells, which up-regulate 
glycolysis to meet the metabolic demands of rapid growth and proliferation, as 
described by the Warburg Effect.28 The exclusivity of this process to cancer cells 
makes depletion of pyruvate (and other glycolytic pathway-targeting methods) an 
attractive strategy for the development of novel anti-cancer therapies. 
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The significantly greater production of D-lactate by the chiral (R,R) osmium complex, 
compared to the (S,S) complex (79 μM compared to 51 μM, Figure 5.4), offers the 
first example of in cell enantioselective reduction by a synthetic catalyst. Though the 
apparent in cell turnover frequency (TOF) is low, lactate and pyruvate homeostasis is 
tightly regulated in cells by monocarboxylate transporters (MCT1-4),27, 29 and 
therefore the concentration of lactate determined after 24 h drug exposure is likely not 
to reflect the true extent of conversion. Furthermore, though cells were treated using 
15 μM of complex 2, the concentration of active catalyst in the cytoplasm is likely to 
be significantly lower. In fact, compartmentalisation studies using complex 2 in 
Chapter 4 (section 4.3.6) showed that only ca. 50% of the total metal accumulated 
remains in the cytoplasmic fraction. Though ICP-MS was used to investigate osmium 
accumulation in treated cells, the technique does not distinguish between active and 
deactivated catalyst. Small molecules have been shown to deactivate metal complexes 
inside cells.30 Co-administration of complex 2 with a glutathione synthetase inhibitor 
(L-BSO) was found to increase the activity of the complex (from IC50 = 15.5 μM, to 
IC50 = 10.0 μM in the presence of 5 μM L-BSO; Figure 4.11), and therefore it is likely 
that glutathione may deactivate the catalyst (Chapter 4, section 4.3.8).  
In addition to the availability of active catalyst inside the cell, the intracellular formate 
concentration may be limited by homeostatic feedback mechanisms involving the 
same monocarboxylate transporters described above.27, 29 In addition, formate has 
been linked to the activity of mitochondrial electron transport chain Complex I.31 
Exploration of Complex I inhibitors may therefore be beneficial in order to modulate 
intracellular formate levels. Overall, the depletion of formate is expected to reduce the 
turnover frequency, as demonstrated in aqueous model system experiments. Strategies 
to counteract homeostatic mechanisms may improve in cell catalytic activities.   
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5.4.3 Enzymatic activation of N-formylmethionine 
The first amino acid of newly synthesised polypeptide chains is commonly formylated 
methionine (N-formyl-methionine, fMet). After assembly, the formyl residue is 
usually cleaved as part of post-translational modification. The enzyme responsible for 
catalysing the hydrolysis, peptide deformylase (PDF) has been identified in human 
cells, and is known to be over-expressed in some cancer cell lines, including PC3 
prostate cancer cells.15 Though many studies have explored the inhibition of human 
peptide deformylase, resulting in the inhibition of mitochondrial function and the 
induction of apoptosis,32-34 few have explored the potential of utilising its over-
expression, and none have used the enzyme for in cell hydrogenation. By co-
administration of additional N-formylmethionine, it was hoped that formate could be 
generated in situ inside cells that are prone to deformylase over-expression.  
Co-administration of either complex 2 or 7 with fMet in PC3 cells resulted in a 
significant reduction (20% reduction, P=0.003) in normalised proliferation relative to 
the Os-free control (Table 5.6, section 5.3.5). Conversely, co-administration of N-
acetyl-methionine did not affect the cellular proliferation (~2% decrease normalised 
proliferation), as was similarly observed in experiments conducted using A2780 
cancer cells co-treated with an Os complex and sodium acetate. Though the decrease 
in proliferation was not as prominent as in A2780 cancer cells treated with sodium 
formate, the maximum dose of fMet was only 1 mM (compared to 2 mM formate) and 
the formate availability was likely further limited by the rate of hydrolysis by peptide 
deformylase. Considering that the rate of catalysis was shown to be highly dependent 
on the formate concentration, the results obtained by co-administration of N-formyl-
methionine demonstrate that formate precursors may warrant further exploration for 
in cell reductions.  
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5.5 Conclusions 
Osmium complexes 2 [Os(p-cymene)(TsDPEN)] and 7 [Os(biphenyl)(TsDPEN)] 
have been shown to reduce pyruvate to lactate in both in vitro and in cell experiments. 
The reduction was found to be dependent on the concentration of sodium formate 
available, and was found to proceed with high enantioselectivity (~83% ee) in the 
aqueous model system. Selective treatment of cancer cells with a particular enantiomer 
of catalyst 2 allowed for the specific production of un-natural D-lactate; providing the 
first example of an asymmetric in cell transformation catalysed by a synthetic 
compound.  
N-formyl-methionine was explored as an alternative hydride source to sodium 
formate, and when co-administered to PC3 cancer cells alongside an osmium complex 
led to a ~20% reduction in normalised cell proliferation. PC3 cancer cells are known 
to over-express the peptide deformylase enzyme,15 and the process appears to generate 
formate in situ. While further work is required to determine the precise mechanism of 
action, these preliminary data are promising. We hypothesise that exploration of 
alternative hydride sources may further increase the selectivity between cancer cells 
and healthy cells, based on cell phenotypes (e.g. enzyme over-expression). 
While it is unlikely that the generation of lactate causes cell death (since neither D-
lactate or L-lactate were found to be toxic towards A2780 cancer cells up to 2 mM), 
the Os(II) catalysts demonstrate manipulation of key metabolic components while 
retaining enantioselectivity. The interactions between chiral biomolecules and chiral 
active sites in enzymes are crucial to the maintenance of cell proliferation, and may 
present a novel target for future drug design for many diseases beyond the treatment 
of cancer.  
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In contrast to cisplatin, which damages DNA by the formation of inter- and intra-
strand adducts leading to G2/M cell cycle arrest,
7, 35 treatment of A2780 cancer cells 
with osmium complex 2 induced G1 cell cycle arrest with no significant sub-G1 
population. Cellular distribution studies found low nucleic Os accumulation (1.6% of 
total accumulated Os, see Chapter 4, section 4.3.6), and in combination with the cell 
cycle analysis, we conclude that complex 2 is unlikely to target DNA. Co-
administration of formate enlarged the G1 population after 72 h recovery (66% to 
71.4%, Figure 5.5, section 5.3.6), suggesting that the mechanism of action may be 
enhanced, rather than altered. Treated cells were also not found to be apoptotic (early 
/ late apoptotic populations <1%, Figure 5.6, section 5.3.6). In the absence of 
apoptosis, G1 arrest has been linked to a cellular response to metabolic stress,
36 which 
is consistent with the postulate that the osmium complexes are targeting pyruvate, a 
key metabolic intermediate in the glycolytic pathway. Interestingly, a half-sandwich 
rhodium(III) sulfonamide complex has also been shown to induce G0/G1 arrest without 
induction of apoptosis.37 The apparent cytostatic nature of osmium complex 2 may 
result from pyruvate depletion. In addition, the observation of G1 arrest without a 
significant population of non-viable cells (by dual FITC-Annexin V / PI staining) is 
suggestive of a highly cytostatic component of the mechanism of action, which has 
previously been observed for other osmium(II) half-sandwich complexes.38 
Relative to the untreated control, no significant membrane disruption (P>0.05) was 
observed upon treatment with 2 and formate, excluding membrane-targeting as a 
potential mechanism of action (Figure 5.7). Though the population of cells with non-
viable membranes was increased after 72 h, this was also observed in untreated cells 
(Figure 5.7, section 5.3.6).  
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6. In vivo studies of organo-Os and organo-Ir complexes 
 
6.1 Introduction 
Cell-based assays facilitate high-throughput phenotypic screening for novel 
compounds. In Chapters 4 and 5, cell assays were used to explore the antiproliferative 
activity (section 4.3.4, page 125), cellular accumulation and distribution (sections 
4.3.5 and 4.3.6, pages 131 and 138), generation of reactive oxygen species (section 
4.3.8, page 141), redox modulation (section 4.3.8, page 141) and catalytic activity 
(section 5.3.3, page 180) of Os(II) and Ir(III) complexes. However, in vivo studies are 
more complex. Administered compounds must be internalised by the host, transported 
to target sites (e.g. tumours), with consideration given to their metabolism, excretion, 
and toxicity to various organs.  
Zebrafish provide a rapidly-developing vertebrate model  for observation of drug 
toxicity over a short time period.1 The similarities between zebrafish and human 
genomes has been studied in great depth.2, 3 Despite clear physiological difference 
between zebrafish and humans, almost three-quarters of human genes have at least one 
orthologue in zebrafish.4 Though some prominent human genes (such as BRCA1) do 
not have a direct zebrafish orthologue, zebrafish often possess genes which encode 
functionally similar proteins (e.g. BARD1).4  
Many small molecules show conserved biological activities in zebrafish and humans,5 
and studies suggest that zebrafish assays can be used successfully and reliably to 
predict drug toxicity in humans.6 Cardio-, hepato- and nephrotoxicity have been 
shown to correlate closely between zebrafish, preclinical mammalian models (rodents) 
and humans, owing to genetic similarities and common biochemical pathways.7, 8 Both 
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toxicological endpoints (LC50) and mechanisms of toxicity may be readily studied in 
vivo, by both qualitative and quantitative assessments.9 As well as toxicology assays, 
zebrafish have been used to observe the teratogenic effects of small molecules,10 as 
hosts for cancer cell xenografts11 as well as primary human fibroblasts,12 and both 
cancer mutant and transgenic oncogene lines have been investigated.13 Interestingly, 
novel cell cycle inhibitors have been identified in zebrafish, which were not detected 
in mammalian cell experiments.14 Another study comparing MCF7 human breast 
cancer cells and zebrafish successfully identified compounds which activated P53 in 
zebrafish, which was shown to translate to human cells in vitro.15  
Primary cell lines are frequently used in drug development as a measure of drug 
selectivity for target cells (e.g. cancer) over normal proliferating cells.16-18 However, 
the life-span of non-immortalised cells is finite, and most enter senescence within 5-
10 passages. In contrast, the zebrafish model offers a high-throughput and cost-
effective in vivo solution to acute toxicity testing of novel pharmaceuticals.19, 20 
Zebrafish are also transparent, allowing for visualisation of many phenotypes in real-
time using light microscopy.19, 21 Furthermore, zebrafish share developmental 
phenotypes with mammalian species, which is particularly important when studying 
the embryonic organism.22 
The study of organometallic compounds (particularly ruthenium complexes) in vivo 
using the zebrafish embryo acute toxicity test has attracted interest over recent years, 
likely due to the ease of embryo handling, breeding and drug administration. 
Ruthenium(II) N-heterocyclic carbene (NHC) anti-cancer complexes were found to 
impart only low toxicity in zebrafish embryos,23 while ruthenium(II) bipyridine 
complexes showed a wide range of zebrafish toxicities (9-170 mg L-1) along with high 
selectivity for cancer cells over MRC5 fibroblasts.24 A phosphorescent Ru(II) complex 
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(designed for imaging cell nuclei) exhibited low toxicity in zebrafish, and only slightly 
inhibited growth of human breast cancer cells (MDA-MB-231) and epidermal 
(HaCaT) cells.25  
More recently, complexes of iridium have also been studied using zebrafish. Making 
use of the transparent properties of the embryos, phosphorescent iridium(III)-
ethylenediamine complexes have been visualised in fish.26 Other chemo-sensing 
iridium(III) complexes have been used to track zinc(II) ions27 and hypochlorous acid28 
in vivo. Photoactivatable iridium(III)-PEG complexes showed the absence of toxicity 
in the dark, and their potential for in vivo imaging.29  
However, organometallic studies are not limited to ruthenium and iridium complexes. 
In fact, copper complexes of alkyl substituted-malonic acids with higher 
hydrophobicity (determined by octanol-water partition coefficients) were found to 
delay embryo hatching relative to those with lower hydrophobicity.30 Toxicities of 
antimicrobial Au(III)31 and Ag(I)32 complexes have been evaluated in MRC5 cells and 
zebrafish, however no clear trend was identified in either case between mammalian 
and fish models. Induction of apoptosis in cancer cells by the platinum anti-cancer 
drug cisplatin is known to occur in human cancer cells,33 and has also been observed 
in zebrafish using immuno-staining methods.34 Cisplatin was also found to cause hair 
cell loss in lateral line neuromasts of zebrafish, which correlated with Pt 
accumulation.35 In summary, the comprehensive use of the zebrafish embryo acute 
toxicity test to investigate potential organometallic compounds in vivo demonstrates 
the clear advantages the organism presents to identify potential lead compounds.  
For the purposes of this work, zebrafish embryos were explored as a tool for 
investigating drug toxicity in a healthy model organism. To the best of my knowledge, 
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this is the first example of toxicity and mechanistic studies of osmium(II) complexes 
in zebrafish (Os complexes 2-8, and 18-23; Table 6.1). The findings are compared to 
structurally similar iridium complexes, first explored in Chapter 4 (Ir complexes 12-
14, see Chapter 4, section 4.3.1; and Table 6.1), and current platinum drugs, cisplatin 
and carboplatin. In this chapter, trends are identified between in vitro human cell 
culture experiments and current in vivo zebrafish research.  
 
 arene R1 
 
 
2 p-cymene 4-tolyl  
3 p-cymene methyl  
4 p-cymene 4-nitrophenyl  
5 p-cymene 4-fluorophenyl 
6 p-cymene phenyl 
7 biphenyl 4-tolyl    R1 (arene) R2 R3 X 
8 m-terphenyl 4-tolyl  19 p-cymene H NMe2 Cl 
12 Cp* 4-tolyl   20 p-cymene H NMe2 I 
13 CpxPh 4-tolyl   21 biphenyl H NMe2 Cl 
14 CpxBip 4-tolyl   22 biphenyl H NMe2 I 
18 p-cymene SRB [a]  23 biphenyl H OH I 
 
Table 6.1: Os complexes 2-8 and Ir complexes 12-14 were described previously (sections 3.3.1 and 
4.3.1). Chapter 6 introduces fluorescent complex 18 [Os(p-cymene)(SRB-DPEN)] and Os azopyridine 
complexes 19-23.36-38 [a] SRB = 2-(3-diethylamino-6-diethylazaniumylidene-xanthen-9-yl)-5-sulfo-
benzenesulfonyl. 
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6.2 Experimental 
  
6.2.1 Materials 
Os complexes 2-8 were introduced in Chapter 3 (section 3.3.1, page 79). Ir complexes 
12-14 and corresponding antiproliferative activities (IC50) were described in Chapter 
4 (sections 4.3.1 and 4.3.3, respectively). Osmium complexes 19-23 were kindly 
synthesised by Dr. Russell Needham (University of Warwick, UK). L-Ascorbic acid 
(≥99%), cis-diaminedichloroplatinum(II) (CDDP, cisplatin, ≥99%), carboplatin 
(≥99%), DMSO (> 99%, molecular biology grade), tricaine (98%, ethyl 3-
aminobenzoate methanesulfonate) and thiourea (≥99%) were purchased from Sigma 
Aldrich and used as received. Ultrapure grade nitric acid (72% v/v) was freshly 
distilled before use. Hanks Balanced Salt Solutions (without phenol red), 0.05% 
trypsin/EDTA. ROS/superoxide detection kit was purchased from Enzo Life Sciences 
(UK). Three strains (AB, Singapore and TU) of wild-type zebrafish (Danio rerio) were 
maintained in reverse-osmosis water supplemented with Aquavitro salt (pH 7.5; 
hereon described as “egg water”). Powder food (GEMMA micro) was purchased from 
Skretting, and live food (Artemia salina) from ZM Fish Food. 
 
Tricaine solution was prepared using 4 mg mL-1 tricaine powder: 400 mg (1.53 
mmol) ethyl 3-aminobenzoate methanesulfonate in 97.9 mL doubly-deionised water 
with ca. 2.1 mL 1M Tris (pH 9) to adjust pH = 7. The solution was stored at 277 K 
and used within one month of preparation.39 For embryo euthanisation, the tricaine 
stock solution was used directly. For anesthetisation, the stock solution was diluted 
1:24 to achieve a final working concentration of 0.17 mg mL-1. 
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6.2.2 Synthesis of rhodamine-tagged ligand L18 and osmium complex 18 
 
 
Ligand L18 (SrbDPEN) 
 
2-(3-diethylamino-6-diethylazaniumylidene-xanthen-9-yl)-5-(N-(2-amino-1,2-
diphenyl-ethyl)sulfonoyl)-benzenesulfonate (Ligand L18). (1R,2R)-1,2-
diphenylethylenediamine (112 mg, 0.58 mmol) and triethylamine (117 mg, 160 µL, 
1.16 mmol) were dissolved in dichloromethane (2 ml) at 273 K. Sulforhodamine B 
acid chloride (400 mg, 0.69 mmol) in dichloromethane (2 ml) was added dropwise 
over 3 h. The solution was washed with water (10 × 25 ml) and aqueous fractions 
extracted with dichloromethane (3 × 10 ml). Organic fractions were dried over 
magnesium sulphate and the solvent removed to yield a dark purple amorphous solid. 
(78.6 mg, 0.104 mmol, 18%). 1H NMR (500 MHz, CD3CN, 25°C, TMS): δ=8.43 (s, 
1H, ArH), 7.49 (m, 1H, ArH), 7.38 (m, 1H, ArH), 6.88-7.35 (m, 14H, ArH), 6.81 (m, 
2H, ArH), 4.55 (d, 3J(H,H)=7.4 Hz, 1H, CHNH), 4.15 (d, 3J(H,H)=7.4 Hz, 1H, 
CHNH), 3.58-3.73 (m, 8H, CH2), 1.24-1.33 (m, 12H, CH3); 
13C NMR (125 MHz, 
CD3CN, 25°C, TMS) δ 158.8, 158.2, 156.0, 148.4, 143.0, 142.6, 139.6, 133.5, 133.4, 
130.0, 128.6, 128.5, 128.3, 128.2, 127.8, 127.6, 127.5, 127.4, 127.4, 127.3, 127.0, 
126.8, 113.6, 95.9, 65.1, 61.2, 60.2, 59.8, 50.0, 12.2; UV/Vis: λmax 557, 399, 353, 307, 
281, 258 nm; HRMS (m/z): [M+H]+ calcd. for C41H45N4O6S2, 753.2775; found, 
753.2769; analysis: (calcd. for C41H44N4O6S2, found): C (65.40, 65.05), H (5.89, 6.04), 
N (7.44, 7.62).  
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(R,R)-18 
 
[Os(η6-p-cymene)(SrbDPEN)] (18). This complex was synthesised following the 
method described for 2,40 using osmium p-cymene dimer [Os(η6-biphenyl)Cl2]2 (15.7 
mg, 0.02 mmol) and ligand L18 (1R,2R)-SrbDPEN (30 mg, 0.04 mmol). The organic 
layer was washed with water and concentrated in vacuo to yield a purple oil, which 
was precipitated as a dark purple solid by addition of n-pentane. (13 mg, 0.012 mmol, 
61%). 1H NMR (500 MHz, CD3CN, 25°C, TMS): δ=6.70-8.64 (m, 19H, ArH), 6.14 
(d, 3J(H,H)=5.5 Hz, 1H, Os-ArH), 6.03 (d, 3J(H,H)=5.5 Hz, 1H, Os-ArH), 5.90 (m, 
2H, Os-ArH), 4.40 (s, 1H, CHNTs), 3.96 (d, 3J(H,H)=4.4 Hz, 1H, CHNH), 3.55-3.74 
(m, 8H, CH2), 2.90 (sept, 
3J(H,H)=7.0 Hz, 1H, CH(CH3)2), 2.31 (s, 3H, CH3), 1.25-
1.35 (m, 12H, CH3), 1.23 (d, 
3J(H,H)=7.0 Hz, 6H, CH(CH3)2); 
13C NMR (125 MHz, 
CD3CN, 25°C, TMS) δ 159.7, 158.2, 156.0, 133.9, 133.7, 133.5, 129.5, 129.3, 128.9, 
128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.7, 127.5, 127.2, 126.9, 126.7, 
126.6, 126.1, 113.6, 113.5, 113.4, 95.8, 91.6, 83.6, 81.0, 77.0, 74.1, 73.1, 69.7, 71.2, 
68.2, 63.8, 63.2, 58.7, 58.5, 46.0, 45.9, 33.9, 33.0, 31.2, 23.8, 23.3, 23.2, 20.6, 18.6, 
12.3; UV/Vis: λmax 555, 398, 352, 281, 258 nm; HRMS (m/z): [M+H]+ calcd. for 
C51H57N4O6OsS2, 1077.3329; found, 1077.3337. 
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6.2.3 In vivo studies and husbandry of zebrafish (Danio rerio) 
Experiments were carried out using three strains of wild-type zebrafish embryos (AB, 
Singapore and Tubingen) in collaboration with Dr. Karuna Sampath (Warwick 
Medical School) under project AWERB.10/16-17. Warwick University are members 
of the Institute of Animal Technology and the Laboratory Animal Science 
Association. Zebrafish were maintained in accordance with ASPA 1986 by Mr. Ian 
Bagley, using 3.5 L tanks (checked daily for water quality) in a 14 h light cycle, and 
provided with food (live and powder) four times a day during the week and twice a 
day during weekends. Fish were mated in breeding tanks fitted with a divider. Two 
mating pairs were used per breeding tank, and the divider was removed at dawn.  
 
6.2.4 Acute toxicity assessment in zebrafish (Danio rerio) 
Twenty-four-well plates were prepared with solutions of test compounds (20 wells per 
plate per concentration using 1 ml per well, 4 negative control wells per plate, Figure 
6.1). DMSO did not exceed 1% v/v. Plates were seeded using at least one (and a 
maximum of 3) embryos per well, and incubated at 301.5 K for 96 h. Mortality was 
assessed by (a) embryo coagulation, (b) somite formation, (c) tail detachment, (d) 
heartbeat.41 Dose-response curves were obtained by plotting % survival against the 
logarithm of the drug concentration, and were fitted using Origin 9.1 for Windows. 
LC50 values were determined from two independent experiments and standard 
deviations calculated. 
      
Figure 6.1. Typical 24-well plate experiment for LC50 determination of a compound in zebrafish (Danio 
rerio). Six concentrations (low to high, 0.01-100 μM) with four untreated controls per plate.  
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6.2.5 Fluorescence imaging in zebrafish (Danio rerio)39 
This method was adapted from an existing literature procedure.39, 42 Approximately 
10-20 zebrafish embryos were seeded in a P100 petri dish containing ca. 30 mL of 
either complex 1, 18 or 20 (at concentrations equal to either 1× or 2× LC50) for 96 h 
at 301.5 K. Untreated embryos were also incubated for 96 h for use as either negative 
or positive control samples.  
Low-melting point agarose was prepared (1% w/v) using HBSS, and tricaine was 
diluted to anaesthetising concentrations (0.2 mg mL-1) using egg water. After drug 
exposure, embryos were collected and washed with HBSS three times to remove the 
metal complex. Additionally, 20 untreated embryos were exposed to rotenone 
(positive control: 50 μM, 2 min) then washed three times with HBSS to remove the 
rotenone.42 Embryos were then stained using an ROS Detection Kit (Enzo Life 
Sciences) using 500 μL of stain solution in the dark for 20 min (20 μM ROS reagent). 
Embryos were washed three times using HBSS to remove the stain, then anaesthetised 
using tricaine (0.2 mg mL-1) for 5-10 min at 298 K.  
Approximately three viable anesthetised embryos were transferred individually to a 
glass-bottom slide and mounted laterally using ca. 200 μL of 1% agarose, which was 
covered with approximately 200 μL egg water. Embryos were analysed by confocal 
microscopy using a LSM880 confocal microscope (Argon laser; excitation: 458, 488, 
561 nm; green emission for ROS: 493-550 nm; red emission for complex 18: 568-750 
nm). Data were obtained and processed using Zen 2.3 for Windows. 
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6.3 Results 
 
6.3.1 Acute toxicity in zebrafish embryos (LC50) 
The in vivo toxicity (LC50, μM) of Os and Ir complexes (sections 3.3.1 and 4.3.1), 
cisplatin, carboplatin and previously reported highly potent Os azopyridine 
complexes37, 38 were evaluated using zebrafish embryos. Three wild-type strains (SG, 
AB and TU) were studied to evaluate continuity between wild-type strains. The 
zebrafish embryo acute toxicity test is a live/dead assay, reliant on four observable 
parameters: (a) embryo coagulation, (b) lack of somite formation, (c) tail detachment, 
(d) lack of heartbeat. If any one of the four observations are made, the fish is recorded 
as dead. Viable embryos are required to not exhibit any of the four aforementioned 
developmental phenotypes.  
Cisplatin was found to exhibit the highest toxicity (LC50 0.6 ± 0.2 μM) of all 
compounds investigated (Figure 6.2), whilst carboplatin was found to have ca. ten-
fold less toxicity (LC50 5.7 ± 0.9 μM) than cisplatin. The toxicity of Os compounds 
was not significantly affected by variation of the sulfonamide substituent (Table 6.1) 
in compounds 3-6 relative to complex 2. Arene extension in both Os (2, 7-8) and Ir 
complexes (12-14) increased toxicity (LC50 Os: 2.4, 2.2, 0.7 μM; Ir: 1.8, 1.6, 0.71 μM, 
respectively). Ir complexes were found to exhibit higher toxicities than structurally-
similar Os analogues (Ir-CpxPh > Os-biphenyl). Interestingly, Os azopyridine 
complexes 19-23 showed remarkably low toxicities (LC50 6.6-24.3 μM) compared to 
both Os / Ir sulfonamides (LC50 0.7-3.5 μM) and Pt agents (LC50 0.6-5.7 μM). 
Furthermore, all trends in toxicity between series of compounds were found to be 
conserved in all three wild-type zebrafish strains investigated.  
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    LC50 / μM 
Metal Arene Ligand SG-WT AB-WT TU-WT 
2 Os p-cym TsDPEN 2.4 ± 0.4 4.3 ± 0.7 2.6 ± 0.3 
3 Os p-cym MsDPEN 3.5 ± 0.4 2.8 ± 0.6 2.8 ± 0.5 
4 Os p-cym NsDPEN 1.9 ± 0.3 3.9 ± 0.3 2.2 ± 0.3 
5 Os p-cym FbDPEN 0.7 ± 0.2 3.0 ± 0.5 1.5 ± 0.3 
6 Os p-cym BsDPEN 0.8 ± 0.2 3.1 ± 0.3 1.5 ± 0.3 
7 Os biphenyl TsDPEN 2.2 ± 0.2 3.5 ± 0.8 3.3 ± 0.4 
8 Os m-terphenyl TsDPEN 0.7 ± 0.2 N.D.[d] N.D.[d] 
12 Ir Cp* TsDPEN 1.8 ± 0.1 6.4 ± 0.3 6.5 ± 0.6 
13 Ir CpxPh TsDPEN 1.6 ± 0.3 5.5 ± 0.7 1.9 ± 0.3 
14 Ir CpxBip TsDPEN 0.71 ± 0.07 3.8 ± 0.1 1.3 ± 0.2 
18 Os p-cym SrbDPEN 2.2 ± 0.1 4.0 ± 0.1 3.1 ± 0.1 
19 Os p-cym AzPy-NMe2 13.61 ± 0.09 14 ± 2 12 ± 1 
20 Os p-cym AzPy-NMe2 24.3 ± 0.4 16.8 ± 0.8 17 ± 1 
21 Os biphenyl AzPy-NMe2 16.8 ± 0.8 12 ± 1 15.8 ± 0.9 
22 Os biphenyl AzPy-NMe2 6.6 ± 0.4 7.7 ± 0.1 6.5 ± 0.8 
23 Os biphenyl AzPy-OH 8.0 ± 0.1 7.4 ± 0.2 7.2 ± 0.2 
CDDP Pt - - 0.6 ± 0.2 1.02 ± 0.03 0.94 ± 0.05 
CBP Pt - - 5.7 ± 0.9 10 ± 1 7.1 ± 0.7 
 
Figure 6.2. LC50 concentrations (μM) determined for Os / Ir sulfonamide complexes (Chapters 3 and 
4), and previously reported Os azopyridine complexes37, 38 in three wild-type (WT) zebrafish embryo 
stains: SG (Singapore), AB and TU. (96 h exposure, with no recovery time in drug-free solution). All 
trends in toxicity are conserved in all three embryonic strains investigated. CDDP = cisplatin; CBP = 
carboplatin. R2 = 0.81 (SG-WT / AB-WT). R2 = 0.94 (SG-WT / TU-WT). N.D. = not determined. 
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6.3.2 ROS induction in whole-mount zebrafish 
Chapter 4 demonstrated that the generation of reactive oxygen species (ROS) 
generation likely contributes to the in vitro mechanism of action of sulfonamide 
complexes in cancer cells (section 4.3.7, page 139). In this Chapter, a method to 
visualise in vivo ROS generation in zebrafish was adapted and optimised in 
collaboration with Mrs Hannah Bridgewater, based on an adapted literature 
procedure.39 Zebrafish embryos were treated with a known zebrafish ROS-inducer 
(rotenone, 96 hpf embryos exposed to 50 M for 2 min), after which time, embryos 
(treated and untreated) were stained using the ROS Detection Kit (Enzo Life 
Sciences). Comparison between rotenone-treated and untreated embryos (which 
exhibit low fluorescence due to basal signalling levels of ROS) confirmed the efficacy 
of the dye for ROS detection in anesthetised whole-mount embryos.  
To explore ROS production by Os complexes in vivo, newly fertilised embryos were 
treated with equipotent concentrations of Os sulfonamide complex 2 or Os azopyridine 
complex 20 (1 or 2 LC50 concentration) for 96 hours to replicate experiments for 
LC50 determination. Both complex 2 and 20 induced the generation of ROS in whole-
mount zebrafish embryos. In both cases, the generation of reactive oxygen species 
appears to be proportional to the concentration of drug administered (Figure 6.3), 
however those treated with sulfonamide complex 2 exhibit tightly localised ROS 
(likely to be the swim bladder) whereas ROS in samples treated with azopyridine 
complex 20 display broader ROS production throughout the organism. Furthermore, 
levels of in vivo ROS appear to be greater in embryos treated with sulfonamide 
complex 2, compared to azopyridine complex 20, based on evidence from confocal 
microscopy.  
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Figure 6.3. Whole-mount SG-WT zebrafish treated with Os complex 2 or 20 for 96 h (1 or 2× LC50), 
stained using ROS detection kit (Enzo life science). Data acquired using a Zeiss LSM880 confocal 
microscope. Fluorescence for ROS (green) shown superimposed onto transmitted light images. 
Excitation: 458, 488 nm; Emission: 493-550 nm. Rotenone (positive control; 50 μM, 2 min). 
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6.3.3 Synthesis and biological properties of a fluorescent osmium complex 
To confirm that the location of in vivo ROS correlated with the distribution of the 
complex inside the zebrafish, a red-fluorescent derivative of complex 2 was designed. 
Previous ligand substitutions at the sulfonamide did not significantly impact either the 
catalytic (Chapter 3, section 3.3.5, page 88) or biological (Chapter 4, section 4.3.4, 
page 125) properties. Substitution of the tosyl moiety for a sulforhodamine (SRB) 
group, which is known to be highly fluorescent,43 was readily achieved using the same 
synthetic procedure described in Chapter 3 (section 3.3.1, page 79) for other 
sulfonamide ligands studied in this thesis. Addition of the corresponding sulfonyl 
chloride to a solution of an enantio-pure diamine in basic solution afforded the highly 
fluorescent ligand L18, which was reacted with Os p-cymene dimer to obtain 18 
[Os(p-cymene)(SrbDPEN)] as a purple solid (Figure 6.4). 
 
 
 
Figure 6.4. Two-step synthesis using sulforhodamine acid chloride and diphenylethylenediamine 
(forming intermediate L18) which was reacted with Os p-cymene chlorido dimer to obtain 18. 
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The 1H-NMR spectrum of complex 18 in d6-DMSO was acquired after 24 incubation 
at 310 K, and no change was observed. Complex 18 was also studied in aqueous 
solution (95% PBS / 5% DMSO) by UV-visible spectroscopy for 24 h (spectra 
acquired at 1 h intervals) and no change in the spectrum was observed. These data 
suggest that 18 remains highly stable in both DMSO and in aqueous solution, similarly 
to findings using complex 2 (Chapter 3, section 3.3.4, page 86), from which 18 is 
derived. 
Os(II) sulfonamide complex 18 was characterised using 3D fluorescence mapping. 
Complex 18 exhibited an optimal excitation at 560 nm, with red light emission at 580 
nm (Figure 6.5). Unlike many metal complexes,44 fluorescence of ligand L18 (Ex / 
Em = 560 / 580 nm) was not quenched upon coordination to the osmium metal centre. 
Complex 18 was found to be highly fluorescent in both organic solvents 
(dichloromethane and acetonitrile) but importantly also retained fluorescence in 
phosphate-buffered saline solution.  
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Figure 6.5. Representative three-dimensional (peak excitation / emission) fluorescence spectra for 
complex 18 (~0.01 mM) in acetonitrile acquired using a Jasco FP-6500 Fluorimeter. Ex / Em = 560 / 
580 nm. Ligand L18 retains fluorescence upon coordination to osmium.  
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To evaluate the impact of rhodamine substitution, the antiproliferative activity of 
complex 18 was assessed towards A2780 cancer cells (Figure 6.6). Interestingly, the 
complex displayed highly similar antiproliferative activity (18 ± 3 μM) as parent tosyl 
compound 2 [Os(p-cymene)(TsDPEN)] in A2780 cancer cells (15.5 ± 0.5 μM).  
Zebrafish embryos allow the facile study of highly coloured or fluorescent compounds 
in vivo due to the transparency of the zebrafish in the early stages of development, 
before pigment formation. Complex 18 was observed to retain fluorescence in aqueous 
media and therefore studies were continued in the animal model. The LC50 of osmium 
SRB complex 18 (2.2 ± 0.1 μM) was found to be similar to that of parent osmium tosyl 
complex 2 (2.4 ± 0.4 μM), suggesting that the rhodamine substituent, while sterically 
demanding and highly lipophilic, did not significantly affect the acute toxicity of 18 
compared to 2 (Figure 6.6). 
 
 
                                                                 X = 4-tolyl                          X = SRB 
 
 X A2780 cells IC50 / μM SG-WT zebrafish LC50 / μM 
2 4-tolyl 15.5 ± 0.5 2.4 ± 0.4 
18 SRB 18 ± 3 2.2 ± 0.1 
 
Figure 6.6. Comparison between the antiproliferative activity (IC50 / μM) of 2 and 18 in A2780 cancer 
cells (24 h drug exposure, 72 h recovery time in drug-free medium) and acute toxicity (LC50 / μM) in 
Singapore wild-type (SG-WT) zebrafish embryos. Modification of the sulfonamide group does not 
significantly impact the biological properties.  
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Investigation of in vivo ROS generation by complex 18 was carried out as previously 
described for studies with complex 2. The difference between the emission 
wavelengths of fluorescence for 18 and the ROS dye allowed for dual imaging of 
reactive oxygen species (green) and the fluorescent osmium complex (red). By 
superimposing green and red fluorescence, the merged image (co-localisation in 
yellow) shows high similarity in the position of metal complex and ROS localisation 
(Figure 6.7). Reactive oxygen species were confined to a small area, likely to be the 
swim bladder, as was also found for embryos treated with complex 2 (Figure 6.3).  
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Figure 6.7. Dual-colour confocal microscopy of Singapore wild-type zebrafish treated with 18 (96 h 
drug exposure, 1 or 2× LC50 concentration) and stained using ROS detection kit (Enzo life sciences). 
Data acquired using a Zeiss LSM880 confocal microscope. Fluorescence for ROS (green) and complex 
18 (red) shown superimposed onto transmitted light images; co-localisation shown in overlay (yellow). 
Excitation: 458, 488, 561 nm; Green emission: 493-550 nm; Red emission: 568-750 nm. 
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6.4 Discussion 
6.4.1 Acute aquatic toxicity of osmium complexes 
All Os and Ir complexes investigated were found to be less toxic than the well-
established platinum anticancer complex, cisplatin. Clinical studies in humans have 
previously demonstrated the lower toxicity of carboplatin, compared to cisplatin,45 
which was also observed in zebrafish (5.7 µM compared to 0.6 µM, respectively). 
While no significant trends in toxicity were observed upon substitution on the 
sulfonamide, arene extension was found to increase toxicity (2 < 7 < 8), in agreement 
with higher antiproliferative activities observed for arene-extended complexes in 
Chapter 4 (15.5 µM, 6.5 µM and 4.4 µM against A2780 cancer cells, respectively). 
Toxicity trends (arene extension, Os complexes less toxic than Ir complexes) were 
maintained in all three wild-type strains investigated, showing that no given phenotype 
presents significantly advantageous properties when compared to the other wild-type 
strains. For this reason, further studies were pursued using only Singapore (SG) wild-
type embryos. 
Os complexes typically exhibited less toxicity than their Ir counterparts, but were more 
active against cancer cells (Chapter 4, section 4.3.4, page 125), which may encourage 
future development of novel Os therapies. While previously reported Ru(II) arene 
complexes bearing N,O-bidentate ligands have been found to be less toxic under the 
same experimental conditions (LC50 = 20.0 ± 1.8 μM) whilst achieving similar 
antiproliferative activities against A2780 cancer cells (IC50 = 13 ± 1 μM) compared to 
Os complex 2 (LC50 = 2.4 ± 0.4 μM; IC50 = 15.5 ± 0.5 μM), the Ru complex was not 
shown to act catalytically (e.g. to carry out the oxidation of NADH). Therefore, though 
more toxic than the Ru-arene complex, the catalytic nature of Os complex 2 may 
facilitate dose minimisation, circumventing potential toxicity to the host organism. 
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While Os-azopyridine complexes are known to be highly potent towards cancer cells, 
achieving nanomolar potencies,36-38 the acute toxicities of 19-23 were generally an 
order of magnitude less than those of Os-sulfonamide complexes. In agreement with 
the low acute aquatic toxicity against zebrafish embryos, complex 20 has previously 
been shown to delay the growth of colorectal cancer xenografts in mice, with 
negligible toxicity to the host.46 Comparison of the sulfonamide and azopyridine series 
demonstrates that the N,N-chelating ligand is crucial not only to 20 achieving potent 
antiproliferative activity towards mammalian cancer cells, but also to the low aquatic 
toxicity, upon comparison to 2 (Figure 6.2).  
 
6.4.2 In vivo generation of reactive oxygen species 
Detection of reactive oxygen species in vivo using the ROS detection kit (Enzo Life 
Sciences) was validated using a known ROS inducer, rotenone (inhibitor of complex 
I in mitochondria). The positive control experiment showed even distribution of ROS 
over the entire organism, suggesting that the dye was able to permeate the embryo and 
was evenly dispersed in the zebrafish. The ROS dye detects a range of reactive species, 
including hydroxyl radicals, peroxynitrite, and hydrogen peroxide.  
Internalisation of the osmium complex was confirmed by administering a highly 
fluorescent derivative of complex 2; complex 18. Complex 18 is red-fluorescent, and 
was readily prepared using Sulforhodamine B acid chloride in combination with 
diphenylethylenediamine in the presence of a base (TEA), as previously described for 
the synthesis of structurally similar ligands in Chapter 3 (section 3.2.2, page 61). The 
intense fluorescence in water allows for the dual-imaging of red-fluorescence from the 
Os complex, and the green ROS probe. The internalisation of 18 was readily observed 
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(Figure 6.7) and the localisation appeared to coincide with the generation of ROS in 
vivo. Structurally similar phosphorescent iridium(III) diamine complexes have also 
been used in zebrafish,26 however this work appears to be the first example of a 
fluorescent osmium(II) complex studied using zebrafish. 
Interestingly, the generation of ROS by 2 [Os(p-cymene)(TsDPEN)] was greater than 
that generated by osmium azopyridine complex 20 [Os(p-cymene)(4-(2-pyridylazo)-
N,N-dimethylaniline)I]PF6, despite the administered dose of 2 being an order of 
magnitude less than that administered of 20 (LC50 concentration administered: 2.4 µM 
compared to 24.3 µM, respectively). This observation may be rationalised by the 
structure and properties of the complexes. Osmium sulfonamide complex 2 is a 
transfer hydrogenation catalyst, and both oxidises NADH to NAD+ (Chapter 4, section 
4.3.2, page 122) and reduces pyruvate to lactate when co-administered with a hydride 
source (Chapter 5, section 5.3.4, page 185). Conversely, the generation of ROS in vitro 
by azopyridine complex 20 is not catalytic.36 It is likely that the generation of ROS by 
2 in vivo is catalytic, which may involve the oxidation of NADH to NAD+ (by hydride 
transfer from NADH to the catalyst; described in section 4.3.2, page 122), which has 
previously been linked to the generation of reactive oxygen species in cells.47, 48 The 
catalytic nature of the sulfonamide complexes would allow lower doses to be 
administered in order to achieve the same effect (to achieve the same level of ROS). 
These data suggest that the zebrafish are a useful tool for translating mechanistic 
experiments from in vitro to in vivo. Live whole-organism imaging make zebrafish 
particularly suited to such an application, providing further mechanistic evidence for 
new compounds. 
Chapter 6. In vivo studies of organo-osmium and organo-iridium complexes 
226 
6.5 Conclusions 
While Ir(III) complexes have been previously studied in zebrafish,27-29 to the best of 
my knowledge, this work presents the first example of toxicity studies using 
osmium(II) complexes in zebrafish. While toxicities of Os sulfonamide complexes did 
not significantly differ despite sulfonamide substitution, Os azopyridine complexes 
displayed low toxicities in zebrafish, in contrast to their potency towards human cancer 
cell lines.36 This chapter highlights the importance of the N,N-chelating ligand, which 
appears crucial to the aquatic toxicity of osmium(II) and iridium(III) complexes. 
Furthermore, Os complexes are shown to accumulate in zebrafish, using fluorescent 
Os complex 18, imaged using confocal microscopy. Complex 18 was further utilised 
to generate ROS in zebrafish, allowing for the dual imaging of the red-fluorescent 
complex and green ROS-detection probe. 
The ease of throughput, handling and drug administration make the zebrafish a useful 
experimental tool for toxicity screening of lead compounds. It is envisaged that the 
methods established in this Chapter: (i) determination of the acute aquatic toxicities, 
and (ii) detection of ROS in treated embryos; may be readily adopted to become a 
common experimental step as part of future metallodrug development, before 
considering translation to mammalian models (e.g. rodents).  
Additionally, future research may employ genetic manipulation techniques (e.g. 
CRISPR) to develop transgenic zebrafish strains to study to the mechanism of 
organometallic complexes in greater depth in vivo. Such work may include knocking-
out genes which have been associated with the antiproliferative activity in vitro (for 
example, P21 and P53) in order to examine whether experimental observations 
translate to an in vivo model.    
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7. Conclusions and future work 
 
7.1 Conclusions 
Catalytic pharmaceuticals would allow for dose-minimisation, with a view to 
decreasing the number of off-target effects in the patient, as well as reducing the cost 
of medication. Catalysts that are activated by co-administration of a second compound 
(such is the case for transfer hydrogenation catalysts, which require a hydride source) 
may gain additional selectivity for diseased cells over healthy cells through dual-
targeting methods. This thesis focusses on the potential medicinal applications of 
chiral half-sandwich osmium catalysts. While Sadler et al. have previously reported a 
series of similar osmium complexes that generate reactive oxygen species in cancer 
cells, the mechanism was not catalytic.1 In fact, few other examples of osmium 
bioorthogonal catalysts exist. In this work, novel osmium(II) 16-electron complexes 
of the general formula [Os(arene)(diamine)] have been described. They are 
structurally-related to a non-chiral Ru(II) complex which was previously explored as 
a catalytic metallodrug. By co-administration of the Ru(II) complex with sodium 
formate, the NAD+/NADH ratio was catalytically modulated in cancer cells.2 Here, 
new Os(II) catalysts are shown, in an analogous way, to carry out asymmetric transfer 
hydrogenation reactions in cancer cells as a new strategy for selectively targeting 
cancer cells.  
In Chapter 3, a series of novel osmium(II) 16-electron complexes, analogous to the 
well-established ruthenium(II) Noyori active catalyst, were synthesised and fully 
characterised. The complexes were found to be highly stable in atmospheric air, and 
in aqueous solution.3 Additional methoxy-substituted derivatives were synthesised 
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with the aim of increasing the water solubility (which was investigated further in later 
chapters). The transfer hydrogenation of acetophenone-derived ketones was readily 
catalysed by the osmium complexes using formic acid as a hydride source, achieving 
high conversions and enantioselectivities (>99%).3 The synthesis proceeded via a 
novel di-chlorido intermediate complex, which was also found to be active for transfer 
hydrogenation catalysis.3 Importantly, the turnover frequency (TOF) for acetophenone 
reduction by Os(II) catalysis was significantly higher than that achieved by the 
analogous Ru(II) catalyst under identical conditions (63.9 h-1 and 23 h-1, respectively). 
The nature of the η6-arene was found to considerably modulate the rate of catalysis. 
Substituting p-cymene (2) for biphenyl (7) increased the catalytic rate from 63.9 h-1 to 
78 h-1, whereas m-terphenyl substitution caused rate reduction (43 h-1), likely due to 
steric hindrance in the transition state. In contrast, variation of the sulfonamide 
substituent of the diamine in complexes 3-6 [Os(p-cymene)(diamine)] did not enhance 
the rate of catalysis, which was confirmed by the similarity between the calculated 
electrostatic potential surfaces using DFT, as charge effects were localised only at the 
site of substitution. Osmium is a third-row transition metal, and its ligand exchange 
kinetics are typically slower than second-row ruthenium, perhaps accounting for the 
lack of development of osmium catalysts. These data, however, suggest that 
osmium(II) catalysts may provide a useful alternative to ruthenium(II) complexes.3  
Chapter 4 explored the biological properties of the arene osmium(II) complexes in 
cancer cells. For comparison between metal centres, a series of Cp* iridium(III) 
sulfonamide complexes were synthesised by the similar method as described for the 
osmium complexes in Chapter 3, and were readily isolated as dark purple solids which 
were fully characterised using NMR, mass spectrometry, UV-visible spectroscopy and 
elemental analysis. Antiproliferative activities (half-maximal inhibitory 
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concentration, IC50) towards a series of human cancer cell lines were determined for 
both Os(II) and Ir(III) complexes. It was found that the lipophilicity of the complexes 
(determined by the octanol / water partition coefficient, Log P) correlated well with 
antiproliferative activities, and that osmium(II) complexes were typically more potent 
than their iridium counterparts. Antiproliferative activities ranged from moderate to 
good (IC50 4-30 μM), however none of the catalysts were highly potent (i.e. nanomolar 
potency) when administered to cells alone, which may be advantageous for the 
development of catalytic therapies (Chapter 5). Osmium complexes showed better 
selectivity for cancerous ovarian cells over healthy ovarian fibroblasts, while the 
selectivity of iridium was much lower. However, iridium complexes did not display 
evidence of cross-resistance when antiproliferative activities were evaluated in 
cisplatin-resistant A2780cis cancer cells. Cellular accumulation of osmium / iridium 
in cancer cells exposed to equipotent concentrations of the complexes were 
determined in all cell lines using 1 × IC50 concentration and 24 h exposure. The cellular 
accumulation in A2780 cells did not correlate with either drug lipophilicity or 
antiproliferative activity. However when the accumulation of complex 2 [Os(p-
cymene)(TsDPEN)] or 12 [Ir(Cp*)(TsDPEN)] was examined across a range of cell 
lines, a clear trend between antiproliferative activity and metal accumulation was 
observed; higher antiproliferative activities (lower IC50 concentrations) were 
determined for cells in which a greater amount of drug (metal) accumulated.  
Representative compounds from each series (Os complex 2 and Ir complex 12) were 
further investigated for the time, temperature and concentration dependence of cell 
accumulation, as well as cellular compartmentalisation. The accumulation profiles for 
2 [Os(p-cymene)(TsDPEN)] and 12 [Ir(Cp*)(TsDPEN)] significantly differed, with 
rapid accumulation and efflux of the iridium complex compared to the osmium 
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counterpart, for which detoxification from the cell was significantly more gradual. The 
compartmentalisation of metal in the cell was also different, with a greater amount of 
osmium from complex 2 localising in the membrane / particulate fraction, compared 
to iridium from complex 12 which mainly located in the cytoplasmic fraction.  
Reactive oxygen species (ROS) are known to be produced in cells by Os and Ir 
complexes,1, 4, 5 and so the induction of oxidative stress was assessed in cells treated 
with 2 [Os(p-cymene)(TsDPEN)] or 12 [Ir(Cp*)(TsDPEN)], which both produced a 
large burst of ROS after drug exposure, which remained prevalent in cells even after 
72 h recovery in drug-free medium. Furthermore, the tripeptide glutathione (GSH) is 
an important antioxidant in cells, and co-administration of osmium complex 2 with a 
non-toxic concentration of a glutathione synthetase inhibitor (L-BSO) was found to 
enhance the potency of the compound. Overall, Chapter 4 highlights that the role of 
the metal centre is not purely structural. Rather, the biological properties of the 
complexes may be greatly altered by exchange of osmium for iridium (and p-cymene 
for Cp* to still obtain neutral complexes), consequently affecting the oxidation state 
of the metal centre. 
Chapter 5 examines the potential for osmium complexes to carry out transfer 
hydrogenation chemistry inside cancer cells. By co-administration of a non-toxic 
concentration of sodium formate (as an alternative hydride source to formic acid) cell 
proliferation was decreased catalytically with respect to both formate and the osmium 
catalyst. The effects were found to be more prominent in A2780 ovarian cancer cells 
than in healthy HOF (fibroblast) and MRC5 (lung) cells, enhancing the selectivity of 
the complexes for cancerous cells. N-formyl-methionine was explored as an 
alternative hydrogen source, and formate precursor, for use in cells that over-express 
for deformylase enzyme, thereby selectively generating formate in situ in cancer cells. 
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Most importantly, it was shown that both aqueous and in cell reductions proceeded 
with high enantioselectivity (83% ee). This was demonstrated for the reduction of 
pyruvate (a key metabolic intermediate) to D-lactate, which is normally only present 
at very low concentrations in eukaryotic cells.6 The catalytic rate (TOF) was found to 
be highly dependent on the concentration of formate, using a model aqueous system 
which was studied using time-dependent 1H-NMR. Mechanistic studies showed that 
the complex caused G1 cell cycle arrest but did not induce apoptosis which, in 
combination, has previously been associated with metabolic interference.7 
Furthermore, the cell membrane viability was not affected by treatment of cancer cells 
with the complex (nor by the complex in combination with sodium formate). Chiral 
recognition between biological components (enzymes, substrates, DNA helical 
chirality) are crucial to cellular proliferation and therefore the manipulation of 
enantiomeric ratios of important molecules (such as lactate) in the cell are anticipated 
to play a vital role in the development of future catalytically-targeting therapies. 
In Chapter 6, in vivo experiments were undertaken using the zebrafish (Danio rerio) 
model. Osmium and iridium sulfonamide catalysts from previous chapters were 
compared to highly potent osmium azopyridine drug candidates and existing platinum-
based drugs, cisplatin and carboplatin. This work presents the first example of osmium 
complexes investigated using the zebrafish model. While the sulfonamide complexes 
showed a broad activity range against A2780 cancer cell proliferation (IC50 4-30 μM), 
the toxicity range in zebrafish was particularly narrow (LC50 0.7-3.5 μM), though all 
complexes investigated were found to be either equally or less toxic than cisplatin 
(LC50 0.7 μM). Interestingly, while osmium(II) azopyridine complexes are highly 
potent towards human cancer cells in vitro,4 they displayed negligible toxicity in 
zebrafish (notably for Os complex 20 [Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-
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dimethylaniline)I]PF6, LC50 24.3 μM). The simple screening process allows for rapid 
identification of compounds which possess low toxicity and is promising for further 
study and development. Confocal microscopy was used to visualise the internalisation 
of a fluorescent derivative of complex 2, which was synthesised using methods 
described in Chapter 3. The antiproliferative activity and toxicity of fluorescent 
complex 18 [Os(p-cymene)(SrbDPEN)] were not statistically different from those of 
2 [Os(p-cymene)(TsDPEN)] (IC50 18 μM, LC50 2.2 μM), suggesting that the probe did 
not significantly affect the biological properties of the complex. Complex 18 was 
found to internalise in zebrafish, and appeared to concentrate in the swim bladder. 
Following ROS detection in vitro (Chapter 4), the generation of ROS in vivo was 
observed using a commercially-available green fluorescent probe for oxidative stress. 
Dual-colour imaging of fluorescent osmium complex 18 and the green oxidative stress 
probe confirmed high co-localisation of the signals, indicative of direct ROS 
generation by the osmium complex.   
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7.2 Future work 
The work in this thesis describes the progress achieved in osmium-catalysed 
asymmetric transfer hydrogenation reactions, including those carried out inside living 
cells. 16-electron osmium complexes [Os(η6-arene)(diamine)] are highly stable and 
reductions proceed with high enantioselectivity, yet the complexes are very poorly 
water soluble, and the pharmacokinetics, pharmacodynamics and further in vivo 
studies are still to be explored. 
 
7.2.1 Increasing the water-solubility of sulfonamide catalysts 
In Chapter 4, substitution of methoxy-groups onto the phenyl backbone of the 
sulfonamide ligand greatly improved the hydrophilicity of the Os and Ir sulfonamide 
series (lower octanol / water partition coefficients). Introduction of additional polar 
substituents may further increase the water solubility of the complexes. Surface-active 
ruthenium(II) and rhodium(III) sulfonamide catalysts have been reported which were 
found to form micelles in aqueous solution, achieved by functionalization with trialkyl 
ammonium side groups.8 Imidazolium-functionalised TsDPEN catalysts of rhodium 
have been shown to achieve up to 98% ee for the transfer hydrogenation of various 
ketones in water, using sodium formate as a hydride source (Figure 7.1).9  
 
 
 
Surface-active Ru(II) catalysts8 Imidazolium-functionalised ligand9 
Figure 7.1. Surface-active Ru(II) catalysts (Peruzzini et al.)8 and imidazolium-tethered catalysts (Ni et 
al.)9 have been developed to increase the water solubility of transfer hydrogenation catalysts. 
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7.2.2 Enhancement of anti-cancer efficacy and in cell catalysis 
The circadian rhythm, and other rhythmic cycles, have been shown to be important for 
the time-dependent efficacy and toxicity of drugs.10 Particularly, the liver has been 
shown to possess its own regulatory clock, and the disruption of which has been shown 
to modulate the rate of xenobiotic detoxification in mice.11 Future in vivo investigation 
of osmium and iridium sulfonamide complexes, and indeed other anti-cancer metal 
complexes, may greatly benefit from such an approach to further reduce off-target 
effects and lower toxicity. Similarly, studies of the time-dependence of in cell catalytic 
reductions may prove advantageous to improve potency. For example, by 
administering the hydride source at a given time-period before exposure to the catalyst 
(e.g. treatment with formate 24 h prior to drug introduction), the intracellular formate 
concentration may be increased, subsequently increasing the rate of catalysis. 
Combination therapy is a well-known strategy to improve drug efficacy and potency. 
In Chapter 5, complex 2 [Os(p-cymene)(TsDPEN)] was shown to catalyse the 
conversion of pyruvate to lactate with high enantioselectivity inside cells by co-
administration of the Os catalyst with a hydride source. This approach may be further 
enhanced as part of a combination therapy with an inhibitor of lactate transport. 
AZD3965 is a novel inhibitor of the monocarboxylate transporter protein MCT1, 
which acts by blocking lactate transport, and is currently undergoing clinical trials for 
the treatment of solid cancers.12 A multi-drug combination therapy of Os catalyst 2, a 
source of hydride and AZD3965 would be expected to increase the lactate 
concentration by way of Os(II)-catalysed transfer hydrogenation of pyruvate, raising 
the intracellular concentration beyond the tolerance threshold, leading to cell death. 
Since Os(II)-catalysed ATH in cells was shown to be selective for cancer cells over 
healthy cells, this approach may also increase the efficacy of AZD3965.  
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7.2.3 Sulfonamide ligand modification 
The apparent inert site of substitution on the sulfonamide ligand was identified in 
Chapters 3 and 4, whereby catalytic activities and antiproliferative activities towards 
cancer cells were relatively unchanged, compared to parent osmium complex 2 [Os(p-
cymene)(TsDPEN)]. A modification was utilised in Chapter 6 to track a fluorescent-
derivative of 2 bearing a sulforhodamine-based fluorophore in transparent zebrafish 
embryos. Further work could be carried out to explore additional functionalization at 
this position, including the introduction of an atom (such as bromine) that is readily 
detected by ICP-MS, or synchrotron x-ray fluorescence spectroscopy,13 to observe the 
co-localisation of the osmium metal centre and the ligand (Figure 7.2).  
The site of substitution could also be explored for conjugation of the sulfonamide 
complex to existing pharmaceuticals (similarly to Ferroquine, and osmium-derivatives 
of Tamoxifen)14-16 or to polymeric supports for either increased solubility, drug 
delivery17 or for the development of heterogeneous asymmetric reduction systems 
(which have been extensively studied for ruthenium(II) Noyori-type catalysts).18-20 
 
 
 
Figure 7.2. Functionalisation of the sulfonamide ligand (•) by substitution of a hydrogen atom by 
bromine would facilitate dual tracking of Os and Br in the final complex by ICP-MS.  
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7.2.4 Further utilisation of the zebrafish (Danio rerio) model 
In vitro and in vivo screening assays provide complementary approaches to examining 
large chemical libraries which, in combination, provide a robust method of identifying 
lead compounds,21 and zebrafish in particular facilitate high-throughput, low-cost in 
vivo testing.  In this thesis, acute toxicities were determined for Os(II), Ir(III) and Pt(II) 
complexes. While this work focussed on early-stage embryo toxicity, future work may 
investigate toxicity in adult zebrafish, with a view to develop a better understanding 
of the efficacy of lead compounds before undertaking further in vivo studies.  
Chapter 6 investigated the in vivo generation of reactive oxygen species (ROS), after 
previously observing their generation in vitro in cells treated with Os(II) complexes. 
Future work using zebrafish may examine whether other mechanistic observations 
from in vitro cell culture studies also translate to the animal model. This may include 
the activity-dependence of Os(II) complexes on key genes such as P21 and P53 using 
zebrafish with knockout-mutation(s). In fact, the wild-type zebrafish p53 protein is 
48% identical to human p53, and is highly expressed in the early developmental stages 
of zebrafish growth (< 48 hours post-fertilisation).22 Apoptotic cell death has also been 
observed in zebrafish using immuno-staining methods, and so such an experiment may 
be adapted to explore the in vivo induction of apoptosis by novel anti-cancer 
complexes that have been previously shown activity in vitro.23 More advanced 
screenings have identified behavioural changes after exposure to neuro-active 
compounds,24 as well as specific organ toxicities (liver, heart and kidney).25, 26 More 
recently, zebrafish bearing green-fluorescent protein (GFP) have been developed to 
aid the prediction of organ toxicities.27 Such an approach could be complemented by 
visualising both GFP and a fluorescent complex (such as 18, described in Chapter 6).  
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7.2.5 Involvement of the mitochondrial electron transport chain 
Osmium azopyridine complex 20 [Os(p-cymene)(AzPy-NMe2)]PF6 (investigated for 
acute toxicity and ROS generation in zebrafish in Chapter 6) has been previously 
shown to shift cellular metabolism from oxidative phosphorylation to glycolysis.4 
Complex 20 increases in the production of mitochondrial ROS, causes the up-
regulation of p21 and p53, and does not induce apoptosis.4 Such mechanistic 
observations were similarly recorded for cells treated with Os sulfonamide complex 2 
[Os(p-cymene)(TsDPEN)] in Chapter 4, suggesting that the two complexes may share 
a similar mechanism of action. Complex I of the electron transport chain (ETC) was 
implicated as a potential target of complex 20 in cancer cells.4 Preliminary 
experiments have attempted to determine the involvement of ETC complexes in the 
mechanism of 2 by determining its antiproliferative activity as previously described, 
with co-administration of known inhibitors at a non-lethal concentrations, including: 
rotenone (complex I),28 2-thenoyltrifluoroacetone (complex II),29 Antimycin A 
(complex III),30 potassium cyanide (complex IV)31 and CCCP (p-trichloromethoxy 
carbonyl cyanide phenyl hydrazine, a mitochondrial uncoupling agent).32  
Preliminary data appear to show that both ETC complexes I and II are affected by 
exposure of cells to complex 2. While complex I was also identified as a potential 
target for osmium azopyridine complex 20,4 complex II (succinate dehydrogenase) is 
redox-active, catalysing the oxidation of succinate to fumarate and concurrent 
reduction of ubiquinone to ubiquinol.33 Since complex 2 was shown to carry out 
transfer hydrogenation reactions in cells, if 2 can catalyse succinate oxidation and/or 
ubiquinone reduction in a model system, such redox chemistry may be involved in its 
mechanism of action. In fact, complex II has been associated with the generation of 
ROS, and has been implicated as a potential target for future anticancer therapies.33, 34 
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Table A1. Fractional atomic coordinates (×104) for the crystallographic structure of (R,R)-2 
         
Atom x y z  Atom x y z 
Os 1 4210(2) 5956.4(2) 2857.9(2)  C 17 9333(10) 4526(7) 3934(6) 
S 8 5744(2) 7762.1(1) 3559.2(9)  C 18 8782(8) 4936(6) 3345(5) 
O 8A 4682(5) 8375(4) 3388(3)  C 19 7041(7) 7040(5) 2018(4) 
O 8B 6978(5) 8202(4) 3523(3)  C 20 6037(8) 7443(5) 1650(4) 
N 9 5748(6) 6781(4) 3104(3)  C 21 6196(9) 7803(6) 974(4) 
N 12 5562(6) 5176(4) 2507(4)  C 22 7368(10) 7812(6) 670(4) 
C 1 5074(9) 6600(9) 6631(5)  C 23 8393(9) 7457(7) 1041(5) 
C 2 5239(8) 6890(7) 5862(4)  C 24 8210(8) 7074(6) 1703(5) 
C 3 6015(8) 6358(6) 5413(5)  C 25 2633(8) 6789(6) 3353(5) 
C 4 6163(8) 6607(6) 4709(4)  C 26 2624(9) 6915(5) 2615(5) 
C 5 5500(7) 7408(5) 4447(4)  C 27 2638(7) 6095(5) 2151(4) 
C 6 4739(8) 7951(6) 4887(5)  C 28 2590(8) 5152(6) 2447(4) 
C 7 4606(9) 7671(7) 5590(5)  C 29 2661(8) 5040(6) 3179(5) 
C 10 6913(7) 6550(5) 2721(4)  C 30 2688(7) 5864(5) 3649(4) 
C 11 6868(7) 5434(5) 2623(4)  C 31 2783(8) 5718(7) 4436(4) 
C 13 7477(7) 4912(5) 3255(4)  C 32 2656(8) 6248(6) 1357(4) 
C 14 6767(8) 4461(6) 3768(5)  C 33 1327(9) 6040(15) 1079(6) 
C 15 7322(8) 4047(7) 4352(5)  C 34 3634(8) 5656(6) 979(4) 
C 16 8608(9) 4090(7) 4448(5)      
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Table A2. Fractional atomic coordinates (×104) for the crystallographic structure of (R,R)-7 
         
Atom x y z  Atom x y z 
C 1 -2944(7) 3136(3) 1517.6(2)  C 13 3075(4) 1880(2) 3233.0(2) 
C 01 6872(4) 4775(3) 5151.9(2)  C 14 3168(5) 1461(2) 2781.6(2) 
Cl 1 4716(1) 4711.1(8) 5018.3(5)  C 15 2619(5) 1828(2) 2349.9(1) 
Os 1 2290(1) 4905.5(7) 3644.9(5)  C 16 1951(4) 2609(2) 2369.2(1) 
C 02 3059(6) 6835(3) 5707.0(2)  C 17 1869(4) 3024(2) 2818.6(1) 
C 2 -2678(5) 3440(2) 2040.3(2)  C 18 511(4) 3282(2) 4497.1(1) 
Cl 2 7734(2) 5663.3(7) 4900.5(4)  C 19 371(5) 2518(3) 4720.2(2) 
C 3 -1812(5) 4166(2) 2127.7(2)  C 20 504(6) 2426(3) 5229.2(2) 
Cl 3 7170(2) 4744.2(9) 5801.1(4)  C 21 784(5) 3099(3) 5526.1(2) 
C 4 -1558(5) 4451(2) 2604.2(1)  C 22 859(5) 3864(3) 5311.0(2) 
Cl 4 1398(2) 6256.8(7) 5458.5(5)  C 23 733(5) 3950(3) 4799.7(1) 
C 5 -2121(4) 4002(2) 3010.3(1)  C 24 3375(4) 4893(3) 2275.0(1) 
Cl 5 4406(2) 7170.0(1) 5238.0(7)  C 25 3224(5) 4724(3) 1773.6(2) 
C 6 -2972(4) 3274(2) 2929.7(2)  C 26 2236(5) 5210(3) 1470.0(1) 
Cl 6 2278(2) 7678.2(8) 6034.1(5)  C 27 1405(5) 5872(3) 1672.9(2) 
C 7 -3239(5) 3001(3) 2448.6(2)  C 28 1552(5) 6045(3) 2173.2(2) 
O 8A -2796(3) 3906.9(2) 3949.8(9)  C 29 2533(4) 5556.8(2) 2484.3(1) 
O 8B -1918(3) 5235.5(1) 3597.4(1)  C 30 2678(4) 5742.1(2) 3024.4(1) 
S 8 -1706(1) 4364.3(5) 3619.6(4)  C 31 1255(4) 6040(2) 3295.6(1) 
N 9 219(3) 4159.8(2) 3736.1(1)  C 32 1340(5) 6155(3) 3816.0(1) 
C 10 570(4) 3334(2) 3930.7(1)  C 33 2854(5) 5994(2) 4069.1(1) 
C 11 2356(4) 3103.1(2) 3753.3(1)  C 34 4319(5) 5753(2) 3803.5(1) 
N 11 3311(3) 3867.5(2) 3740.4(1)  C 35 4225(4) 5620(2) 3288.3(1) 
C 12 2423(4) 2665.1(2) 3257.1(1)      
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Table A3. Cartesian coordinates calculated for (R,R)-2 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
Os 1 -0.6332 -0.8017 -0.6446  C 37 -1.8447 2.2681 1.0238 
S 2 0.6975 0.3027 2.1219  C 38 -2.6245 1.2853 1.6346 
O 3 0.0166 -0.7797 2.8536  H 39 -2.2325 0.2758 1.7116 
O 4 0.8776 1.5738 2.8500  C 40 -3.8819 1.5930 2.1544 
N 5 0.0026 0.6088 0.6836  H 41 -4.4757 0.8106 2.6260 
N 6 -0.9153 0.8162 -1.6189  C 42 -4.3753 2.8926 2.0783 
C 7 6.3369 -1.6442 0.9417  H 43 -5.3555 3.1344 2.4868 
H 8 6.3201 -2.5678 0.3509  C 44 -3.5970 3.8867 1.4845 
H 9 6.8768 -1.8655 1.8677  H 45 -3.9647 4.9108 1.4309 
H 10 6.9085 -0.9016 0.3788  C 46 -2.3440 3.5744 0.9647 
C 11 4.9415 -1.1656 1.2244  H 47 -1.7448 4.3645 0.5119 
C 12 4.3812 -0.1072 0.5000  C 48 0.0124 -2.7517 0.3346 
H 13 4.9723 0.3883 -0.2681  H 49 0.6462 -2.8294 1.2110 
C 14 3.0813 0.3226 0.7445  C 50 -1.3758 -2.5599 0.5089 
H 15 2.6487 1.1272 0.1584  H 51 -1.7862 -2.5172 1.5142 
C 16 2.3236 -0.3151 1.7240  C 52 -2.2233 -2.2730 -0.6141 
C 17 2.8598 -1.3674 2.4638  C 53 -1.6507 -2.2886 -1.9254 
H 18 2.2592 -1.8542 3.2297  H 54 -2.2595 -2.0415 -2.7917 
C 19 4.1622 -1.7863 2.2082  C 55 -0.2475 -2.3888 -2.0802 
H 20 4.5806 -2.6104 2.7861  H 56 0.1956 -2.2487 -3.0649 
H 21 -1.2312 0.8592 -2.5898  C 57 0.6136 -2.6025 -0.9426 
C 22 -0.4724 1.9729 0.4301  C 58 2.0946 -2.7114 -1.1303 
H 23 0.2345 2.6964 0.8500  H 59 2.4408 -2.0272 -1.9094 
C 24 -0.4775 2.0997 -1.1070  H 60 2.3559 -3.7317 -1.4374 
H 25 -1.2104 2.8743 -1.3799  H 61 2.6291 -2.4810 -0.2067 
C 26 0.8730 2.5477 -1.6588  C 62 -3.6990 -2.0348 -0.3836 
C 27 1.7221 1.6819 -2.3499  H 63 -3.7906 -1.6612 0.6448 
H 28 1.4083 0.6540 -2.5076  C 64 -4.4483 -3.3686 -0.4750 
C 29 2.9590 2.1224 -2.8233  H 65 -4.3869 -3.7803 -1.4888 
H 30 3.6093 1.4307 -3.3578  H 66 -5.5067 -3.2282 -0.2328 
C 31 3.3613 3.4391 -2.6163  H 67 -4.0367 -4.1099 0.2174 
H 32 4.3257 3.7841 -2.9864  C 68 -4.3037 -0.9870 -1.3137 
C 33 2.5150 4.3163 -1.9370  H 69 -3.7256 -0.0584 -1.2773 
H 34 2.8147 5.3513 -1.7766  H 70 -5.3324 -0.7698 -1.0095 
C 35 1.2821 3.8729 -1.4687  H 71 -4.3390 -1.3371 -2.3514 
H 36 0.6267 4.5715 -0.9481      
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Table A4. Cartesian coordinates calculated for (R,R)-3 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
Os 1 -0.6396 -0.8226 -0.2781  C 32 1.1231 3.7959 -0.4462 
S 2 0.6574 0.2446 2.5389  H 33 2.1553 3.7296 -0.7861 
O 3 -0.6506 -0.1115 3.0990  C 34 -1.6969 -2.1749 1.1961 
O 4 1.3472 1.4392 3.0244  H 35 -1.3931 -2.3033 2.2284 
N 5 0.5624 0.2989 0.8967  C 36 -2.5311 -1.0805 0.8759 
N 6 0.5256 -0.0107 -1.5620  H 37 -2.8387 -0.4118 1.6709 
H 7 0.5237 -0.2204 -2.5532  C 38 -2.8040 -0.7427 -0.4880 
C 8 1.2969 1.3747 0.2292  C 39 -2.2929 -1.5961 -1.5181 
H 9 2.2196 1.5961 0.7771  H 40 -2.4477 -1.3326 -2.5580 
C 10 1.6521 0.8126 -1.1622  C 41 -1.4027 -2.6490 -1.1983 
H 11 1.7488 1.6620 -1.8519  H 42 -0.9142 -3.2038 -1.9927 
C 12 2.9809 0.0700 -1.1710  C 43 -1.0667 -2.9332 0.1739 
C 13 3.0700 -1.2996 -0.9162  C 44 -0.1226 -4.0506 0.4972 
H 14 2.1541 -1.8601 -0.7503  H 45 0.6778 -4.1222 -0.2444 
C 15 4.3084 -1.9370 -0.8862  H 46 -0.6629 -5.0048 0.5028 
H 16 4.3613 -3.0041 -0.6859  H 47 0.3295 -3.9188 1.4829 
C 17 5.4762 -1.2157 -1.1182  C 48 -3.6634 0.4622 -0.7998 
H 18 6.4410 -1.7147 -1.0998  H 49 -3.5228 1.1612 0.0347 
C 19 5.3979 0.1497 -1.3827  C 50 -5.1364 0.0399 -0.8281 
H 20 6.3021 0.7210 -1.5740  H 51 -5.3230 -0.6687 -1.6428 
C 21 4.1596 0.7828 -1.4097  H 52 -5.7796 0.9111 -0.9874 
H 22 4.1053 1.8493 -1.6212  H 53 -5.4366 -0.4378 0.1094 
C 23 0.5086 2.6752 0.1213  C 54 -3.2646 1.1897 -2.0805 
C 24 -0.7997 2.7987 0.5865  H 55 -2.1985 1.4354 -2.0746 
H 25 -1.2713 1.9443 1.0620  H 56 -3.8309 2.1214 -2.1702 
C 26 -1.4858 4.0057 0.4641  H 57 -3.4847 0.5930 -2.9732 
H 27 -2.5032 4.0852 0.8382  C 58 1.7403 -1.1430 2.8622 
C 28 -0.8717 5.1094 -0.1185  H 59 1.8454 -1.2357 3.9449 
H 29 -1.4060 6.0510 -0.2092  H 60 1.2959 -2.0460 2.4424 
C 30 0.4422 5.0019 -0.5695  H 61 2.7075 -0.9470 2.3975 
H 31 0.9403 5.8614 -1.0098      
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Table A5. Cartesian coordinates calculated for (R,R)-4 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
Os 1 -0.8711 -0.8049 -0.6773  C 36 -4.1888 1.3267 2.2969 
S 2 0.4431 0.3458 2.0815  H 37 -4.6786 0.5242 2.8422 
O 3 -0.0688 -0.8608 2.7393  C 38 -4.8173 2.5598 2.1609 
O 4 0.5076 1.5983 2.8338  H 39 -5.8014 2.7251 2.5900 
N 5 -0.3171 0.6128 0.6571  C 40 -4.1654 3.5882 1.4836 
N 6 -1.2942 0.8116 -1.6140  H 41 -4.6372 4.5621 1.3857 
C 7 4.7528 -0.6040 1.0239  C 42 -2.9038 3.3735 0.9401 
C 8 4.1160 0.4330 0.3501  H 43 -2.4000 4.1912 0.4274 
H 9 4.6575 1.0007 -0.3971  C 44 -0.0208 -2.7072 0.2179 
C 10 2.7906 0.7110 0.6545  H 45 0.6760 -2.7374 1.0473 
H 11 2.2667 1.5047 0.1326  C 46 -1.4023 -2.6209 0.4975 
C 12 2.1310 -0.0572 1.6128  H 47 -1.7273 -2.5961 1.5310 
C 13 2.7834 -1.0873 2.2880  C 48 -2.3498 -2.3859 -0.5536 
H 14 2.2418 -1.6576 3.0357  C 49 -1.8745 -2.3446 -1.9027 
C 15 4.1123 -1.3686 1.9916  H 50 -2.5655 -2.1275 -2.7092 
H 16 4.6568 -2.1615 2.4906  C 51 -0.4843 -2.3470 -2.1664 
H 17 -1.6465 0.8531 -2.5630  H 52 -0.1266 -2.1705 -3.1757 
C 18 -0.8871 1.9481 0.4434  C 53 0.4713 -2.5009 -1.0975 
H 19 -0.2279 2.7029 0.8854  C 54 1.9401 -2.4938 -1.3904 
C 20 -0.9129 2.1083 -1.0876  H 55 2.1785 -1.7922 -2.1941 
H 21 -1.6862 2.8478 -1.3371  H 56 2.2620 -3.4931 -1.7074 
C 22 0.4111 2.6274 -1.6398  H 57 2.5188 -2.2140 -0.5076 
C 23 1.2443 1.8441 -2.4384  C 58 -3.8178 -2.2523 -0.2144 
H 24 0.9356 0.8309 -2.6782  H 59 -3.8588 -1.8672 0.8128 
C 25 2.4590 2.3443 -2.9072  C 60 -4.4709 -3.6386 -0.2352 
H 26 3.0958 1.7194 -3.5280  H 61 -4.4460 -4.0659 -1.2438 
C 27 2.8570 3.6374 -2.5836  H 62 -5.5185 -3.5711 0.0746 
H 28 3.8038 4.0271 -2.9464  H 63 -3.9613 -4.3345 0.4381 
C 29 2.0270 4.4330 -1.7946  C 64 -4.5676 -1.2648 -1.1039 
H 30 2.3250 5.4461 -1.5396  H 65 -4.0593 -0.2961 -1.1258 
C 31 0.8147 3.9324 -1.3338  H 66 -5.5801 -1.1126 -0.7185 
H 32 0.1739 4.5631 -0.7203  H 67 -4.6677 -1.6355 -2.1305 
C 33 -2.2713 2.1312 1.0544  O 68 6.6830 -0.2311 -0.1670 
C 34 -2.9242 1.1146 1.7501  O 69 6.6863 -1.8141 1.3100 
H 35 -2.4260 0.1593 1.8817  N 70 6.1485 -0.9055 0.6980 
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Table A6. Cartesian coordinates calculated for (R,R)-5 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
Os 1 -0.6540 -0.7843 -0.6626  H 35 -2.1229 0.3546 1.8677 
S 2 0.7115 0.2380 2.1218  C 36 -3.7600 1.7012 2.2537 
O 3 0.0200 -0.8779 2.7792  H 37 -4.3343 0.9584 2.8013 
O 4 0.8909 1.4910 2.8562  C 38 -4.2570 2.9913 2.1021 
N 5 0.0344 0.5768 0.6629  H 39 -5.2224 3.2611 2.5208 
N 6 -0.8765 0.8563 -1.6271  C 40 -3.4964 3.9406 1.4228 
C 7 4.8976 -1.2587 1.2232  H 41 -3.8640 4.9572 1.3122 
C 8 4.4061 -0.1790 0.4999  C 42 -2.2585 3.5918 0.8940 
H 9 5.0303 0.2991 -0.2473  H 43 -1.6680 4.3487 0.3805 
C 10 3.1141 0.2636 0.7541  C 44 -0.1004 -2.7557 0.3184 
H 11 2.7022 1.0948 0.1913  H 45 0.5294 -2.8456 1.1955 
C 12 2.3380 -0.3848 1.7132  C 46 -1.4752 -2.4890 0.4993 
C 13 2.8472 -1.4611 2.4362  H 47 -1.8639 -2.4001 1.5071 
H 14 2.2233 -1.9400 3.1843  C 48 -2.3165 -2.1701 -0.6209 
C 15 4.1416 -1.9094 2.1885  C 49 -1.7516 -2.2266 -1.9334 
H 16 4.5695 -2.7456 2.7310  H 50 -2.3546 -1.9494 -2.7905 
H 17 -1.1952 0.9232 -2.5864  C 51 -0.3561 -2.3953 -2.0967 
C 18 -0.3919 1.9608 0.4335  H 52 0.0872 -2.2852 -3.0813 
H 19 0.3366 2.6472 0.8788  C 53 0.5010 -2.6387 -0.9616 
C 20 -0.3833 2.1137 -1.0993  C 54 1.9775 -2.8007 -1.1502 
H 21 -1.0820 2.9207 -1.3600  H 55 2.3403 -2.1619 -1.9598 
C 22 0.9861 2.5123 -1.6403  H 56 2.2123 -3.8407 -1.4071 
C 23 1.7889 1.6338 -2.3681  H 57 2.5203 -2.5390 -0.2399 
H 24 1.4249 0.6281 -2.5578  C 58 -3.7743 -1.8475 -0.3796 
C 25 3.0415 2.0334 -2.8340  H 59 -3.8208 -1.3884 0.6164 
H 26 3.6528 1.3355 -3.4005  C 60 -4.5851 -3.1478 -0.3515 
C 27 3.5084 3.3188 -2.5793  H 61 -4.5564 -3.6450 -1.3274 
H 28 4.4833 3.6308 -2.9431  H 62 -5.6324 -2.9395 -0.1113 
C 29 2.7117 4.2068 -1.8579  H 63 -4.1980 -3.8484 0.3946 
H 30 3.0639 5.2145 -1.6556  C 64 -4.3567 -0.8449 -1.3709 
C 31 1.4624 3.8058 -1.3989  H 65 -3.7412 0.0586 -1.4177 
H 32 0.8466 4.5074 -0.8390  H 66 -5.3648 -0.5568 -1.0586 
C 33 -1.7578 2.2925 1.0247  H 67 -4.4417 -1.2685 -2.3783 
C 34 -2.5191 1.3547 1.7215  F 68 6.1412 -1.6882 0.9780 
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Table A7. Cartesian coordinates calculated for (R,R)-6 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
Os 1 -0.5964 -0.7581 -0.6495  H 35 -2.0268 0.7210 1.7628 
S 2 0.7414 0.1293 2.1898  C 36 -3.4347 2.3367 1.9838 
O 3 -0.1521 -0.8503 2.8213  H 37 -4.1594 1.7257 2.5155 
O 4 1.0677 1.3606 2.9105  C 38 -3.6974 3.6824 1.7512 
N 5 0.2068 0.5261 0.6870  H 39 -4.6288 4.1272 2.0900 
N 6 -0.4932 0.8615 -1.6694  C 40 -2.7463 4.4601 1.0941 
C 7 4.7129 -2.0340 1.5799  H 41 -2.9299 5.5171 0.9215 
C 8 4.4190 -0.9015 0.8213  C 42 -1.5541 3.8867 0.6665 
H 9 5.1372 -0.5229 0.0998  H 43 -0.8135 4.5108 0.1692 
C 10 3.2009 -0.2488 0.9801  C 44 -0.3412 -2.7568 0.3790 
H 11 2.9589 0.6223 0.3802  H 45 0.2599 -2.9109 1.2669 
C 12 2.2781 -0.7450 1.8980  C 46 -1.6724 -2.3093 0.5298 
C 13 2.5637 -1.8706 2.6672  H 47 -2.0560 -2.1386 1.5288 
H 14 1.8260 -2.2251 3.3804  C 48 -2.4413 -1.8986 -0.6094 
C 15 3.7871 -2.5166 2.5023  C 49 -1.8686 -2.0538 -1.9115 
H 16 4.0168 -3.3961 3.0969  H 50 -2.4142 -1.7097 -2.7828 
H 17 -0.7276 0.9406 -2.6519  C 51 -0.5105 -2.4260 -2.0498 
C 18 0.0358 1.9507 0.3900  H 52 -0.0421 -2.4027 -3.0287 
H 19 0.8408 2.5239 0.8630  C 53 0.2875 -2.7544 -0.8944 
C 20 0.1603 2.0439 -1.1432  C 54 1.7295 -3.1268 -1.0518 
H 21 -0.3861 2.9399 -1.4686  H 55 2.1905 -2.5698 -1.8719 
C 22 1.6030 2.2035 -1.6122  H 56 1.8168 -4.1966 -1.2773 
C 23 2.2935 1.1819 -2.2646  H 57 2.2927 -2.9200 -0.1396 
H 24 1.7854 0.2388 -2.4428  C 58 -3.8473 -1.3788 -0.4089 
C 25 3.6150 1.3622 -2.6721  H 59 -3.8717 -0.9499 0.6009 
H 26 4.1367 0.5549 -3.1798  C 60 -4.8329 -2.5515 -0.4560 
C 27 4.2645 2.5692 -2.4347  H 61 -4.8360 -3.0179 -1.4475 
H 28 5.2933 2.7111 -2.7535  H 62 -5.8494 -2.2047 -0.2451 
C 29 3.5818 3.5994 -1.7895  H 63 -4.5771 -3.3219 0.2777 
H 30 4.0771 4.5481 -1.6022  C 64 -4.2416 -0.2746 -1.3854 
C 31 2.2637 3.4165 -1.3876  H 65 -3.5010 0.5308 -1.3820 
H 32 1.7384 4.2284 -0.8877  H 66 -5.2097 0.1469 -1.0990 
C 33 -1.2883 2.5297 0.8773  H 67 -4.3468 -0.6537 -2.4085 
C 34 -2.2384 1.7648 1.5531  H 68 5.6656 -2.5401 1.4526 
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Table A8. Cartesian coordinates calculated for (R,R)-7 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
C 1 -4.5564 3.7862 -1.5444  C 36 3.2416 1.2128 -0.0665 
H 2 -4.7751 3.9225 -0.4783  C 37 4.0178 2.2562 0.4483 
H 3 -5.4151 3.2743 -1.9891  H 38 3.5289 3.0956 0.9403 
H 4 -4.4831 4.7807 -1.9925  C 39 5.4031 2.2429 0.3298 
Os 5 0.6971 -1.5221 0.3491  H 40 5.9881 3.0663 0.7305 
C 6 -3.2888 3.0021 -1.7351  C 41 6.0370 1.1803 -0.3106 
C 7 -3.2898 1.6057 -1.6252  H 42 7.1189 1.1675 -0.4087 
H 8 -4.2213 1.0814 -1.4249  C 43 5.2718 0.1440 -0.8358 
C 9 -2.1189 0.8744 -1.7713  H 44 5.7563 -0.6811 -1.3512 
H 10 -2.1356 -0.2070 -1.6884  C 45 3.8836 0.1623 -0.7180 
C 11 -0.9213 1.5408 -2.0282  H 46 3.2837 -0.6335 -1.1467 
C 12 -0.8977 2.9258 -2.1552  C 47 -2.8909 -1.5040 1.4117 
H 13 0.0402 3.4199 -2.3873  H 48 -2.1314 -1.1276 2.0920 
C 14 -2.0802 3.6454 -2.0088  C 49 -4.2179 -1.1211 1.5661 
H 15 -2.0629 4.7274 -2.1128  H 50 -4.4961 -0.4713 2.3908 
O 16 1.5918 1.5597 -2.7050  C 51 -5.1832 -1.5546 0.6585 
O 17 0.2982 -0.6115 -2.8901  H 52 -6.2199 -1.2540 0.7794 
S 18 0.6051 0.6241 -2.1681  C 53 -4.8124 -2.3732 -0.4047 
N 19 1.0056 0.2289 -0.6185  H 54 -5.5588 -2.7180 -1.1144 
C 20 1.7309 1.2650 0.1239  C 55 -3.4835 -2.7595 -0.5596 
H 21 1.3934 2.2604 -0.1904  H 56 -3.1998 -3.4114 -1.3812 
C 22 1.3643 1.0745 1.6139  C 57 -2.5096 -2.3283 0.3465 
H 23 2.2475 1.3530 2.2049  C 58 -1.1002 -2.7562 0.1783 
N 24 1.0981 -0.3437 1.7950  C 59 -0.4905 -2.7673 -1.1119 
C 25 0.2140 1.9403 2.0965  H 60 -1.0155 -2.3472 -1.9603 
C 26 0.4499 2.9609 3.0195  C 61 0.8768 -3.0948 -1.2659 
H 27 1.4598 3.1195 3.3932  H 62 1.3518 -2.9181 -2.2221 
C 28 -0.5889 3.7741 3.4681  C 63 1.6513 -3.4304 -0.1254 
H 29 -0.3873 4.5603 4.1904  H 64 2.7218 -3.5744 -0.2192 
C 30 -1.8816 3.5753 2.9931  C 65 1.0351 -3.5322 1.1615 
H 31 -2.6939 4.2076 3.3406  H 66 1.6414 -3.7482 2.0339 
C 32 -2.1269 2.5602 2.0695  C 67 -0.3300 -3.1884 1.3175 
H 33 -3.1306 2.3999 1.6846  H 68 -0.7831 -3.1792 2.3025 
C 34 -1.0891 1.7460 1.6291  H 69 1.0364 -0.6001 2.7737 
H 35 -1.2847 0.9594 0.9075      
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Table A9. Cartesian coordinates calculated for (R,R)-8 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
C 1 -6.5773 -0.4502 1.2249  C 41 1.9186 5.6683 -1.2013 
H 2 -6.3303 -0.5441 2.2895  H 42 2.4833 6.5336 -1.5368 
H 3 -6.9660 -1.4168 0.8924  C 43 2.0468 4.4481 -1.8579 
H 4 -7.3809 0.2871 1.1426  H 44 2.7117 4.3597 -2.7130 
Os 5 1.0600 -0.2980 -0.5498  C 45 1.3181 3.3389 -1.4350 
C 6 -5.3695 -0.0389 0.4312  H 46 1.4019 2.3929 -1.9603 
C 7 -4.5215 -0.9983 -0.1334  C 47 -1.1288 -3.3103 0.4457 
H 8 -4.7568 -2.0543 -0.0261  H 48 -0.6594 -2.7494 1.2493 
C 9 -3.3827 -0.6277 -0.8385  C 49 -2.2484 -4.0897 0.7103 
H 10 -2.7401 -1.3799 -1.2843  H 50 -2.6253 -4.1595 1.7268 
C 11 -3.0831 0.7249 -0.9856  C 51 -2.8936 -4.7672 -0.3233 
C 12 -3.9230 1.6994 -0.4527  H 52 -3.7691 -5.3757 -0.1159 
H 13 -3.6936 2.7470 -0.6200  C 53 -2.4073 -4.6599 -1.6231 
C 14 -5.0572 1.3114 0.2526  H 54 -2.9002 -5.1860 -2.4355 
H 15 -5.7156 2.0717 0.6654  C 55 -1.2809 -3.8863 -1.8881 
O 16 -1.7904 2.6337 -2.1890  H 56 -0.8952 -3.8249 -2.9016 
O 17 -1.3568 0.2433 -2.8975  C 57 -0.6295 -3.1984 -0.8584 
S 18 -1.6003 1.2264 -1.8427  C 58 0.5768 -2.3919 -1.1509 
N 19 -0.3997 1.0931 -0.7113  C 59 0.7045 -1.6712 -2.3649 
C 20 -0.3152 2.2411 0.2068  H 60 -0.1517 -1.5817 -3.0193 
H 21 -1.3231 2.5871 0.4697  C 61 1.8128 -0.8297 -2.5836 
C 22 0.3647 1.7211 1.4895  H 62 1.8195 -0.1597 -3.4344 
H 23 0.9267 2.5568 1.9271  C 63 2.8682 -0.7742 -1.6140 
N 24 1.2967 0.6912 1.0587  H 64 3.6790 -0.0664 -1.7469 
C 25 -0.5908 1.2161 2.5575  C 65 2.8591 -1.6170 -0.4596 
C 26 -0.5800 1.7936 3.8281  C 66 1.6638 -2.3444 -0.1995 
H 27 0.1139 2.6050 4.0392  H 67 1.5781 -2.9151 0.7180 
C 28 -1.4440 1.3458 4.8262  H 68 1.9967 0.4724 1.7594 
H 29 -1.4175 1.8050 5.8107  C 69 3.9573 -1.5702 0.5303 
C 30 -2.3387 0.3148 4.5595  C 70 5.2828 -1.4550 0.0976 
H 31 -3.0162 -0.0345 5.3338  C 71 3.7066 -1.6627 1.9060 
C 32 -2.3616 -0.2654 3.2914  C 72 6.3293 -1.4273 1.0137 
H 33 -3.0654 -1.0628 3.0672  H 73 5.4961 -1.4084 -0.9668 
C 34 -1.4909 0.1758 2.3015  C 74 4.7534 -1.6356 2.8206 
H 35 -1.5150 -0.2757 1.3145  H 75 2.6826 -1.7399 2.2623 
C 36 0.4545 3.4328 -0.3457  C 76 6.0687 -1.5166 2.3781 
C 37 0.3256 4.6643 0.3031  H 77 7.3521 -1.3420 0.6584 
H 38 -0.3574 4.7559 1.1462  H 78 4.5397 -1.7016 3.8835 
C 39 1.0496 5.7744 -0.1179  H 79 6.8857 -1.4947 3.0931 
H 40 0.9294 6.7249 0.3949      
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Table A10. Cartesian coordinates calculated for (R,R)-9 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
Os 1 -0.4996 -1.0063 -0.8531  C 41 -4.4714 2.8596 1.2366 
S 2 0.2103 -0.2307 2.2332  C 42 -3.5186 3.7858 0.7985 
O 3 -0.6906 -1.3160 2.6433  H 43 -3.8224 4.8196 0.6674 
O 4 0.3005 0.9657 3.0721  C 44 -2.2178 3.3784 0.5562 
N 5 -0.0932 0.2338 0.6861  H 45 -1.4907 4.1219 0.2340 
N 6 -0.4028 0.6934 -1.7307  C 46 -0.2707 -3.0617 0.0862 
C 7 5.8069 -2.6240 2.2081  H 47 0.1363 -3.2411 1.0745 
H 8 5.8499 -3.5393 1.6061  C 48 -1.6381 -2.7310 -0.0347 
H 9 6.1184 -2.8912 3.2228  H 49 -2.2462 -2.6786 0.8609 
H 10 6.5424 -1.9255 1.8009  C 50 -2.1806 -2.2975 -1.2921 
C 11 4.4249 -2.0334 2.1993  C 51 -1.3289 -2.3057 -2.4410 
C 12 4.1414 -0.8701 1.4765  H 52 -1.7040 -1.9435 -3.3914 
H 13 4.9348 -0.3772 0.9198  C 53 0.0582 -2.5420 -2.2916 
C 14 2.8608 -0.3287 1.4541  H 54 0.7237 -2.3973 -3.1368 
H 15 2.6525 0.5682 0.8798  C 55 0.6158 -2.9029 -1.0107 
C 16 1.8401 -0.9622 2.1562  C 56 2.0856 -3.1536 -0.8726 
C 17 2.0978 -2.1165 2.8923  H 57 2.6603 -2.4834 -1.5174 
H 18 1.2881 -2.5848 3.4435  H 58 2.3154 -4.1851 -1.1668 
C 19 3.3844 -2.6451 2.9072  H 59 2.4191 -3.0062 0.1565 
H 20 3.5856 -3.5459 3.4825  C 60 -3.6416 -1.9163 -1.3774 
H 21 -0.4655 0.8276 -2.7330  H 61 -3.9201 -1.5576 -0.3783 
C 22 -0.3748 1.6541 0.4552  C 62 -4.4747 -3.1638 -1.6913 
H 23 0.2659 2.2624 1.1033  H 63 -4.2215 -3.5611 -2.6805 
C 24 0.0078 1.8889 -1.0191  H 64 -5.5421 -2.9211 -1.6903 
H 25 -0.5752 2.7470 -1.3814  H 65 -4.3052 -3.9569 -0.9567 
C 26 1.4812 2.2301 -1.2068  C 66 -3.9271 -0.7883 -2.3644 
C 27 2.4001 1.3325 -1.7578  H 67 -3.2888 0.0765 -2.1605 
H 28 2.0514 0.3527 -2.0710  H 68 -4.9714 -0.4735 -2.2787 
C 29 3.7395 1.6689 -1.8995  H 69 -3.7718 -1.1049 -3.4023 
H 30 4.4541 0.9728 -2.3284  C 70 -6.6975 2.4569 1.9247 
C 31 4.1982 2.9246 -1.4923  H 71 -6.8771 1.6355 1.2178 
C 32 3.2937 3.8396 -0.9475  H 72 -6.4210 2.0318 2.8986 
H 33 3.6171 4.8233 -0.6263  H 73 -7.6146 3.0376 2.0361 
C 34 1.9539 3.4833 -0.8166  C 74 6.0243 4.4135 -1.2667 
H 35 1.2621 4.2083 -0.3910  H 75 5.8813 4.5832 -0.1915 
C 36 -1.8214 2.0454 0.7289  H 76 7.0930 4.3988 -1.4862 
C 37 -2.7765 1.1411 1.1804  H 77 5.5559 5.2363 -1.8226 
H 38 -2.4867 0.1113 1.3644  O 78 5.5234 3.1606 -1.6683 
C 39 -4.0928 1.5329 1.4330  O 79 -5.7208 3.3502 1.4492 
H 40 -4.8020 0.7972 1.7965      
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Table A11. Cartesian coordinates calculated for (R,R)-10 at the PBE0/Lanl2DZ/6-31+G** level. 
         
Atom x y z  Atom x y z 
C 1 4.9268 2.4211 2.8020  C 40 -5.7056 1.7550 -0.0127 
H 2 5.3488 2.6279 1.8107  C 41 -5.1543 0.5430 0.3998 
H 3 5.6122 1.7322 3.3055  H 42 -5.7871 -0.2785 0.7171 
H 4 4.9213 3.3619 3.3585  C 43 -3.7678 0.3842 0.4244 
Os 5 -0.6993 -1.5607 -0.6114  H 44 -3.3435 -0.5536 0.7683 
C 6 3.5459 1.8384 2.6907  C 45 2.9465 -1.8923 -1.3309 
C 7 3.3663 0.4978 2.3260  H 46 2.3214 -1.2764 -1.9719 
H 8 4.2337 -0.1311 2.1388  C 47 4.3227 -1.6999 -1.2993 
C 9 2.0955 -0.0474 2.2056  H 48 4.7743 -0.9527 -1.9457 
H 10 1.9703 -1.0889 1.9307  C 49 5.1162 -2.4490 -0.4316 
C 11 0.9788 0.7523 2.4472  H 50 6.1915 -2.2973 -0.4069 
C 12 1.1326 2.0835 2.8193  C 51 4.5244 -3.3914 0.4048 
H 13 0.2509 2.6790 3.0336  H 52 5.1358 -3.9811 1.0816 
C 14 2.4135 2.6163 2.9380  C 53 3.1462 -3.5868 0.3729 
H 15 2.5333 3.6551 3.2353  H 54 2.6879 -4.3333 1.0159 
O 16 -1.5723 1.0488 2.8663  C 55 2.3442 -2.8392 -0.4950 
O 17 -0.6176 -1.2965 2.7633  C 56 0.8792 -3.0665 -0.5259 
S 18 -0.6649 0.0772 2.2586  C 57 0.1404 -3.1974 0.6894 
N 19 -0.9207 0.0209 0.6329  H 58 0.6278 -3.0164 1.6388 
C 20 -1.3973 1.2682 0.0242  C 59 -1.2671 -3.3372 0.6723 
H 21 -0.9782 2.1306 0.5575  H 60 -1.8106 -3.2482 1.6039 
C 22 -0.8550 1.2859 -1.4249  C 61 -1.9552 -3.3519 -0.5665 
H 23 -1.6135 1.7801 -2.0476  H 62 -3.0391 -3.3426 -0.5868 
N 24 -0.7361 -0.1039 -1.8396  C 63 -1.2252 -3.3252 -1.7982 
C 25 0.4410 2.0502 -1.6143  H 64 -1.7606 -3.2934 -2.7404 
C 26 0.4588 3.2353 -2.3572  C 65 0.1841 -3.1836 -1.7820 
H 27 -0.4638 3.5993 -2.8054  H 66 0.7355 -3.0779 -2.7097 
C 28 1.6289 3.9575 -2.5383  H 67 -0.5661 -0.1909 -2.8354 
H 29 1.6454 4.8747 -3.1184  C 68 -7.9225 1.0082 0.3372 
C 30 2.8230 3.5049 -1.9699  H 69 -7.7630 0.7281 1.3868 
C 31 2.8256 2.3239 -1.2235  H 70 -8.9279 1.4179 0.2262 
H 32 3.7329 1.9515 -0.7606  H 71 -7.8313 0.1095 -0.2876 
C 33 1.6413 1.6103 -1.0573  C 72 5.1381 3.8634 -1.6361 
H 34 1.6555 0.6960 -0.4722  H 73 5.0871 3.8299 -0.5394 
C 35 -2.9129 1.4087 0.0382  H 74 5.4488 2.8774 -2.0071 
C 36 -3.4848 2.6233 -0.3628  H 75 5.8791 4.6061 -1.9358 
H 37 -2.8399 3.4527 -0.6486  O 76 -7.0372 2.0212 -0.0724 
C 38 -4.8574 2.8010 -0.3926  O 77 3.9181 4.2742 -2.2018 
H 39 -5.3008 3.7443 -0.6957      
 
